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ABSTRACT 
Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic virus, the 
etiological agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL). 
One of the key viral proteins that contribute to tumorigenesis is vFLIP, a viral 
homolog of the FLICE inhibitory protein. This KSHV protein interacts with the NFκB 
pathway to trigger the expression of antiapoptotic and proinflammatory genes and 
ultimately leads to tumor formation. The expression of vFLIP is regulated at the 
translational level by an internal ribosomal entry site (IRES) element. However, the 
precise mechanism by which ribosomes are recruited internally and the exact 
location of the IRES has remained elusive. The aims of this study were to confirm 
the previously identified 252-nt fragment directly upstream of vFLIP as the location of 
the vFLIP IRES in cellulo and to determine the structure and mechanism of action of 
the vFLIP IRES. Here we show that a 252-nt, within a coding region, directs 
translation in HEK293 cells. We have also established its RNA structure using 
chemical and enzymatic probing of RNA structure in solution and mutational analysis 
studies revealed that the domain If of the vFLIP IRES is crucial for its activity. Also, 
we demonstrate that IRES activity requires the presence of eIF4A and the eIF4E-
eIF4G interaction. These interactions may define a new paradigm for IRES-mediated 
translation. Finally, we attempted to identify cellular proteins that may interact with 
the vFLIP IRES using several types of protein affinity chromatography, but we could 
detect a protein interacting with vFLIP IRES but yet to be confirmed. 
 
 
u 
u [Type text] [Type text] 
4 
 
Acknowledgements 
Firstly all thanks to almighty Allah (SWT), the most gracious and the most merciful 
who bestowed upon me the blessings of life and sound health to enable complete 
this thesis.   
I would like to express my sincere thanks to my supervisor Dr. Nicolas Locker for the 
guidance, support, patience, and motivation he has shown me all through my Ph.D. I 
would also like to express my heartfelt thanks to Dr. Margaret Carter for her constant 
technical support, answering questions and giving me advice. I would also like to 
thank Prof Lisa Roberts, and Dr. Elizabeth Royall, Dr. Belinda Hall for their guidance 
throughout my time at the University of Surrey. 
To my fellow Ph.D. researchers and friends in the lab, Melvin, David, Majid, Nargs, 
and Nicole I really appreciated your friendship, assistance, and advice. I am also 
thankful to the Tertiary Education Trust Fund   and the University of Ilorin for funding 
my research. 
Importantly, I would like to thank my parents for the amazing support they have 
shown me throughout my Ph.D. Thank you for your prayers and motivational talks. 
My special thanks to my husband and son Amadu and Ziyad Dainkeh for the support 
and understanding, thank you for your love and patience. 
Finally, I would like to thank my brothers and sisters for their love, support, and 
assistance shown to me throughout my Ph.D. I could not wish for a better family. 
 
 
 
u 
u [Type text] [Type text] 
5 
 
Publications arising from this thesis 
Othman, Z., Sulaiman, M. K., Willcocks, M. M., Ulryck, N., Blackbourn, D. J., 
Sargueil, B., Roberts, L.O., & Locker, N. (2014). Functional analysis of Kaposi’s 
sarcoma–associated herpesvirus vFLIP expression reveals a new mode of IRES-
mediated translation. RNA, 20(11), 1803–1814.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
u 
u [Type text] [Type text] 
i 
 
Table of Contents 
     Chapter 1: Introduction………………………………………………………..………1 
1.1. Overview .......................................................................................................... 1 
1.2. Viruses and Cancer ......................................................................................... 2 
1.3. KSHV ............................................................................................................... 3 
1.3.1 Taxonomy and classification ....................................................................... 3 
1.3.2 Historical overview……………………………………………………………….5 
1.3.3 Mode of transmission of KSHV…………………………………………………5 
1.4. Clinical diseases associated with KSHV………………………………….……….6 
1.4.1. Kaposi's sarcoma (KS)………………………………………………………….6 
1.4.2. Primary effusion lyphoma (PEL)……………………………………………….7 
1.4.3. Multicentric Castleman's disease (MCD)……………………………………..8 
1.4.4. KSHV Induced Cytokine Syndrome (KICS)………………………………….8 
1.5. Virion structure of KSHV…………………………………………………………..10 
1.6. KSHV GENOME ............................................................................................ 13 
1.7. REPLICATION STRATEGIES OF KSHV ....................................................... 15 
1.7.1. Lytic life cycle ........................................................................................... 15 
1.7.2 Latent life cycle ............................................................................................ 17 
1.8. Latently expressed genes of KSHV ............................................................... 20 
1.8.1. Latency associated nuclear antigen (LANA) ............................................ 20 
1.8.2. v-Cyclin (vCYC) ....................................................................................... 20 
1.8.3. Kaposins (ORFK12) ................................................................................. 21 
1.8.4. Viral microRNAs (miRNAs) ...................................................................... 21 
1.8.5. v-FLIP ...................................................................................................... 22 
1.9. Overview of translation initiation ........................................................................ 25 
1.9.1 Components of translation initiation .......................................................... 25 
1.10 Eukaryotic initiation factors ........................................................................... 31 
1.10.1 Initiation factor 4F complex ..................................................................... 31 
         1.10.1.1 Initiation factor 4A…………………………………………………………31 
      1.10.1.2 Initiation factor 4E………………………………………………………….31 
      1.10.1.1 Initiation factor 4G………………………………………………………....32 
1.11 Mechanisms of translation initiation .............................................................. 34 
u [Type text] [Type text] 
ii 
 
1.11.1 Cap-dependent translation initiation ....................................................... 34 
     1.11.1.1 Ribosomal dissociation……………………………………………………...34 
   1.11.1.2 Formation of the 40Spreinitiation complex (PIC)…………………………..35 
   1.11.1.3 Preinitiation complex assembly onto mRNA………………………………..35 
   1.11.1.4 Ribosome scanning of mRNA 5'UTR………………………………………..36 
1.12 Alternative Mechanisms of translation initiation ............................................ 40 
1.12.1 Leaky scanning ....................................................................................... 40 
1.12.2 Reinitiation .............................................................................................. 40 
1.12.3 Ribosome shunting ................................................................................. 41 
1.12.4 Ribosomal frameshifting ......................................................................... 41 
1.12.5 Cap-independent translation initiation ..................................................... 41 
1.13. Internal ribosome entry site (IRES) elements ............................................... 44 
1.13.1 Type I IRES elements ............................................................................. 45 
1.13.2. Type II IRES elements ........................................................................... 46 
1.13.3. Type III IRES elements (HCV-like IRES) ............................................... 47 
1.13.4. Type IV IRES elements.......................................................................... 48 
1.13.5. IRES of Lentiviruses .............................................................................. 49 
1.13.6 Cellular IRES .......................................................................................... 49 
1.13.7. DNA virus IRESs ................................................................................... 50 
1.14. Role of IRES trans-acting Factors (ITAFs) in IRES-mediated initiation ........ 52 
1.15. KSHV IRES .................................................................................................. 54 
1.16. Relevance of RNA structures for IRES function ........................................... 56 
1.17. Project aims ................................................................................................. 57 
 
     Chapter 2: Materials and methods……………………………………..................58  
2.1. Transformation with competent E.coli DH5α .................................................. 58 
2.2. Plasmid DNA Minipreparation (QIAGEN KIT) ................................................ 58 
2.3. Plasmid DNA Midipreparation (QIAGEN KIT) ................................................ 58 
2.4. Agarose gel electrophoresis ........................................................................... 59 
2.5. Gel extraction of DNA .................................................................................... 59 
2.6. Cloning KSHV IRES into pRF vector ............................................................. 59 
2.7. Blunt ending restriction digested DNA ........................................................... 60 
u [Type text] [Type text] 
iii 
 
 2.8. Self-ligation of DNA fragments ...................................................................... 60 
 2.9. Polymerase chain reaction (PCR) ................................................................. 60 
  2.10. Restriction enzyme digestion ..................................................................... 61 
   2.11. In vitro production of RNA transcripts ........................................................ 61 
2.11.1. Production of uncapped RNA transcripts in vitro ................................... 61 
2.11.2. Production of Capped RNA transcripts .................................................. 61 
   2.12. Phenol/chloroform purification of RNA ...................................................... 61 
   2.13. SDS-Polyacrylamide Gel electrophoresis (PAGE) .................................... 62 
   2.14 Tissue culture methods .............................................................................. 63 
2.14.1 Cell Lines ................................................................................................ 64 
2.14.2. Cell counting .......................................................................................... 65 
2.14.3. Cryopreservation of cell lines ................................................................. 65 
2.14.4. Recovery of cryopreserved cells ............................................................ 66 
2.14.5. Growth of BCBL-1 cells.......................................................................... 66 
2.14.6. Growth of Sofia Levinton-Kriss (SLK) cells ............................................ 66 
2.14.7. Growth of HEK293 cells ......................................................................... 67 
    2.15. Transfection of plasmid DNA into mammalian cells (Transient expression  
system .................................................................................................................. 67 
2.15.1. Transfection into BCBL-1 cells ............................................................... 67 
2.15.2. Transfection into SLK cells .................................................................... 68 
2.15.3 Transfection into HEK293 cells ............................................................... 68 
2.16. Assaying luciferase activity of IRES reporters .............................................. 69 
2.17. Identifying RNA Interacting Partners Using RNA affinity chromatograghy ... 69 
 
     Chapter 3 : Analysis of vFLIP IRES sufficient sequence activity in cells…70 
3.1 Introduction to chapter 3 ................................................................................. 70 
3.2 Chapter aims ................................................................................................... 71 
3.3 Materials and Methods .................................................................................... 72 
      3.3.1 Cell lines ..................................................................................................... 72 
      3.3.1.1 SLK cells………………………………………………………………………..72 
     3.3.1.1 HEK cells……………………………………………………………………….72 
        3.3.2 Construction of plasmids ........................................................................... 73 
        3.3.2.1 Bicistronic plasmid………………………………………………..…………73 
u [Type text] [Type text] 
iv 
 
      3.3.2.2 Monocistronic plasmid………………………………………………………73 
3.3.3 Transfection of plasmid DNA into mammalian cells .................................. 75 
3.3.3.1 Transfection into SLK cells………………………………………………….75 
3.3.3.1 Transfection into HEK cells………………………………………………….76 
3.3.3.3 Assaying luciferase activity of IRES reporters…………………………….76 
3.3.4 Cell viability assay .................................................................................... 76 
   3.4 Results ......................................................................................................... 77 
3.4.1 Analysing 252-nt sufficient IRES domain in cells ...................................... 77 
3.4.1.1 Analysis of bicistronic construct…………………………………………….77 
3.4.1.2 Analysis of monocistronic construct………………………………………..81 
3.4.2 vFLIP IRES requirement for eukaryotic initiation factors ........................... 83 
3.4.2.1 vFLIP IRES requirement for eIF4A…………………………………………86 
3.4.2.2 vFLIP IRES requirement for eIF4E/eIF4G interaction……………………88 
3.5 Discussion ....................................................................................................... 91 
 
Chapter 4: Structural and mutational analysis of vFLIP IRES……….….……94 
   4.1 Introduction to chapter 4 ............................................................................... 94 
   4.2 Chapter aims ................................................................................................ 96 
   4.3 Materials and methods ................................................................................. 97 
4.3.1 Plasmid construct ..................................................................................... 97 
4.3.2 Transcription ............................................................................................. 98 
4.3.3 Modification of RNA .................................................................................. 98 
4.3.3.1 Modification of RNA with CMCT……………………………………………98 
4.3.3.2 Modification of RNA with DMS…………………………………………….100 
4.3.3.3 Hydolysis of RNA with RNase V1…………………………………………100 
4.3.3.4 SHAPE……………………………………………………………………….102 
4.3.4 32-P Labelling…………………………………………………………………..102 
4.3.5 Primer extension………………………………………………………………104 
4.3.6 Sequencing ladder preparation ............................................................... 104 
u [Type text] [Type text] 
v 
 
4.3.7 Sequencing gel ....................................................................................... 106 
4.3.8 RNA structure prediction ......................................................................... 106 
     4.3.9 Mutational analysis .................................................................................... 107 
4.3.9.1 Overlapping PCR……………………………………………………………...107 
 4.3.9.2 Preparation of IRES pseudoknot mutants…………………………………111 
  4.3.9.3 Translation of mRNA transcripts in Flexi RRL……………………………113 
   4.4 Results ....................................................................................................... 114 
4.4.1 RNA structure probing ............................................................................ 114 
4.4.2 Deletion analysis of the vFLIP IRES ....................................................... 121 
4.4.3 vFLIP IRES putative Pseudoknot mutagenesis ...................................... 123 
4.5 Discussion ..................................................................................................... 126 
 
Chapter 5: Identification of vFLIP IRES transacting proteins………………..127 
5.1 Introduction to chapter 5 ............................................................................... 131 
5.2 Materials and methods .................................................................................. 132 
5.2.1 Plasmid constructs .................................................................................. 132 
5.2.1.1 Cloning of 252-nt fragment into pSP64poly(A) vector………………….132 
5.2.1.2 Cloning of 252-nt vFLIP IRES fragment into pUC18 vector……………132 
5.2.2 Preparation of HEK293 cytoplasmic cell lysates ..................................... 133 
5.2.3 Preparation of BCBL-1 cytoplasmic cell lysates ...................................... 133 
5.2.4 Protein Assay .......................................................................................... 133 
5.2.5 Labelling of RNA ..................................................................................... 134 
5.2.5.1 Periodate oxidation of RNA………………………………………………..134 
5.2.5.2 Biotinylation of RNA………………………………………………………..135 
5.2.6 RNA-protein binding assay ..................................................................... 136 
5.2.6.1 Binding experiment using Oligo(dT)25 Dynabeads………………..…….136 
5.2.6.2 Using Streptavidin M280 Dynabeads…………………………………….137 
5.3 Results .......................................................................................................... 141 
5.4 Discussion ..................................................................................................... 150 
 
u [Type text] [Type text] 
vi 
 
Chapter 6: General discussion……………………………………………….146 
             General discussion……………………………………………………………………….146 
 
References……………………………………………...………………….…….159 
Appendix I (Solutions)……………………………………………….………...203 
Appendix II (Publication arising from thesis)……………………….…….206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
u [Type text] [Type text] 
vii 
 
LIST OF FIGURES 
Chapter 1 
Figure 1.1: A brief overview of where KSHV fits into the Herpesvirale order………………..4 
Figure 1.2 Kaposi’s sarcoma on the skin and mouth of AIDS patients……………………….9 
Figure 1.3. Morphology of the KSHV virion…………………………………………..…12 
Figure1.4: The genome organisation of KSHV…………………….……………….….14 
Figure 1.5: Schematic representation of KSHV major latency locus……………..….19 
Figure 1.6: Model of vFLIP mediated tumorigenesis……………………………..……24 
Figure 1.7 Model a typical eukaryotic mRNA……………………………………..……28 
Figure 1.8 Model of the 80S eukaryotic ribosome……………………………………29 
Figure 1.9 Schematic representation of eIF4G…………………………………….…33 
Figure 1.10 Mechanism of mRNA circularization…………………………………….33 
Figure 1.11 Cap-dependent Translation initiation pathway in eukaryotes……..….39 
Figure 1.12 Schematic representation of Alternative mechanism of initiation…….43 
Figure 1.13 Structures and Mechanism of IRES elements………………………….51 
Figure 1.14 Schematic representation of the vCyclin-vFLIP fragment……………..55 
Chapter 3 
Figure 3.1 Previously identified sufficient sequence required for IREs activity….….67 
Figure 3.2 Schematic representation of plasmids………………………………….…75  
Figure 3.3 Assay of IRES activity in SLK cells…………………….…………….……79 
Figure 3.4 Assay of IRES activity in HEK293 cells…………………….…………..…80 
Figure 3.5 Assay of monocistronic reporter IRES activity……………….………..…82 
Figure 3.6 Cell viability assay in HEK293 cells………………………………………..85 
u [Type text] [Type text] 
viii 
 
Figure 3.7 Assay of IRES activity with or without hippuristanol…………………..….87 
Figure 3.8 Assay of IRES activity with or without 4E2Rcat……………………..…….90 
Chapter 4 
Figure 4.1 Predicted vFLIP IRES secondary structure………………………………...95 
Figure 4.2 Schematic representation of the dicistronic plasmid used in the cloning of 
KSHV IRES……………………………………………………………………..……….….97  
Figure 4.3 The 252-nt fragment sequence of the vFLIP IRES……………..…….….103 
Figure 4.4 Sequencing gel analysis showing RNAse V1 
modifications………………………………………………………………………..…….115 
Figure 4.5 Sequencing gel analysis showing RNAse V1 and CMCT 
modifications………………………………………………………………………….......116 
Figure 4.6 Sequencing gel analysis showing CMCT and DMS 
modifications………………………………………………………………………………117 
Figure 4.7 Map of 252-nt sequence highlighting the locations of the modified 
nucleotides……………………………………………………………………………..…118 
Figure 4.8 Secondary structure of the vFLIP IRES……………………………….….120 
Figure 4.9 Comparison of vFLIP IRES activity wild-type and mutant RNAs in 
dicistronic translation assay……………………………….…………………….……...122  
Figure 4.10 Comparison of IRES activity of vFLIP IRES wild-type and mutant RNAs 
in dicistronic translation assay………………………………………..…..……….……125 
 
 
 
 
 
u [Type text] [Type text] 
ix 
 
Chapter 5 
Figure 5.1 3′-End labelling of RNA……………………………………….……..…….138 
Figure 5.2 Strategy for terminally biotinylated tagged mRNA-based isolation of the 
binding proteins…………………………………………………………………..….….141 
Figure 5.3 Strategy for internally biotinylated tagged mRNA-based isolation of the 
binding proteins……………………………………………………………….……...…142 
Figure 5.4 Strategy for poly(A) tagged mRNA-based isolation of the binding 
proteins………………………………………………………..………………….…...…143 
Figure 5.5 Bead binding assay using Oligo(dT)25 Dynabeads………………..…...146 
Figure 5.6 Bead binding assay using terminal biotinylated RNA and Streptavidin 
M280 Dynabeads…………………………………………………………………...….147 
Figure 5.7 Identification of cellular proteins interacting with KSHV IRES……......149 
Chapter 6 
Figure 6.1 Schematic representation of the vFLIP IRES proposed structure with the 
eIFs required show………………………………………………………………….….158 
 
 
   
 
 
 
 
 
u [Type text] [Type text] 
x 
 
LIST OF TABLES 
Chapter 1 
Table 1.1. Summary of the known human oncogenic viruses and their associated 
malignancies…………………………………………………………………….………..….2 
Table 1.2.  Summary of eukaryotic initiation factors of the translation initiation 
pathway and their respective roles in initiation……………………………………….…30 
Table 1.3 IRES-trans-acting factors and the corresponding IRESs with which they 
interact………………………………………………………………………………………53 
Chapter 2 
Table 2.1 Composition of the 10% SDS gels used in the study…………………...….63 
Table 2.2 Tissue culture media and supplements………………………………….…..64 
Table 2.3 Summary of cell lines used in this study……………………………….……65 
Chapter 3 
Table 3.1 Assembly of blunt ending reaction using T4 DNA polymerase……………74 
Table 3.2 Assembly of self-ligation reaction………………………………………….....74 
Chapter 4 
Table 4.1 Assembly and process of the CMCT RNA modification reaction………….….…...99 
Table 4.2 Assembly and process of the DMS RNA modification reactions……………..…..101 
Table 4.3 Assembly and process of the RNase V1 RNA modification reactions….101 
Table 4.4 Primer sequences used for vFLIP IRES structure probing………….…...103 
Table 4.5 Preparation of sequencing ladder reaction…………………………..…….105 
Table 4.6 Preparation of nucleotide mix……………………………………….………105 
u [Type text] [Type text] 
xi 
 
Table 4.7 Sequences of primers designed for PCR reactions to delete domains 1c to 
1f IRES loop of the predicted KSHV IRES structure…………………………..……..108 
Table 4.8 Assembly of left hand and right hand PCR reactions…………………….109 
Table 4.9 PCR cycle details for left and right hand PCR…………………………….109 
Table 4.10 Assembly of the overlapping PCR reactions……………………..……...110 
Table 4.11 PCR cycle for the overlapping PCR reactions…………………….……..110 
Table 4.12 Sequences of primers designed to mutate five bases in domains II and IV 
of the predicted KSHV IRES structure………………………………………….….…..111 
Table 4.13 PCR cycle for D II and IV mutation PCR reactions…………………..….112 
Table 4.14 Assembly of Flexi RRL reactions…………………………………..…..….113 
Chapter 5 
Table 5.1 Assembly of periodate oxidation reaction…………………………….....…134 
 
 
 
 
 
 
 
 
 
 
 
 
 
u [Type text] [Type text] 
xii 
 
ABBREVIATIONS 
Apaf     Apoptotic protease activating factor  
ATP     Adenosine triphosphate 
BiP     Binding immunoglobulin protein  
CAT     Chloraphenicol acetyltransferase 
CHX    Cycloheximide 
CITEs    Cap-independent translation elements 
CMCT    1-cyclohexyl-(2-morpholinoethyl)carbodiimide metho-p-
toluene  
CrPV     Cricket paralysis virus  
DMS     Dimethyl sulphate  
DMSO    Dimethyl sulfoxide  
EBV     Epstein-Barr virus 
eIF     Eukaryotic translation initiation factor  
EMCV    Encephalomyocarditis virus  
EMSA    Electrophoretic mobility shift assay  
EV71     Enterovirus 71  
FADD    Fas-associated death domain 
FLICE    FADD interleukin -1β-converting enzyme 
fLUC     Firefly luciferase 
FMDV    Foot-and-mouth disease virus  
GDP     Guanosine diphosphate 
GTP     Guanosine triphosphate  
HAV     Hepatitis A virus  
HBV     Hepatitis B virus 
u [Type text] [Type text] 
xiii 
 
HCV     Hepatitis C virus 
hnRNPs    Heterogeneous nuclear ribonucleoproteins 
HIV     Human immunodeficiency virus 
HPV     Human papilloma virus  
IGR     Intergenic region  
IRES     Internal ribosomal entry site  
ITAF     IRES trans acting factors  
kDa     kilo Daltons 
KICS     KSHV induced cytokine syndrome 
KS     Kaposi’s Sarcoma 
KSHV    Kaposi’s sarcoma associated herpesvirus  
La     Lupus autoantigen 
LANA     Latency associated nuclear antigen 
LUC     Luciferase 
m7GpppG   7-methyl guanosine cap structure of RNA  
MCD     Multicentric Castleman’s disease 
MCV     Merkel cell polyomavirus 
mRNA    Messenger RNA 
NHL     Non-Hodgkins lymphoma 
ORF    Open reading frame  
PEL     Primary effusion lymphoma 
 
u [Type text] [Type text] 
xiv 
 
PCBP2     Poly(rC)-binding protein 2  
PCR      Polymerase chain reaction  
PIC      Pre initiation complex  
poly(A)     Polyadenylation tail  
PTB     Polypyrimidine tract-binding protein  
PV      Poliovirus 
RRL      Rabbit Reticulocyte Lysate 
ROS     Reactive oxygen species 
Rpm      revolutions per minute 
rRNA      Ribosomal RNA 
tRNA      Transfer RNA 
SDS-PAGE     Sodium dodecyl sulphate Polyacrylamide gel 
electrophoresis  
SHAPE     Selective 2′-hydroxyl acylation analysed by primer 
extension 
TNF      Tumor necrosis factor 
TR      Terminal repeat 
UTR      Untranslated region 
vFLIP      Viral FLICE inhibitory protein   
WT      Wild type  
Xiap      X-linked inhibitor of apoptosis protein  
 
 
 
 Chapter 1                                                                                         Introduction 
0 | P a g e  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
u 
 Chapter 1                                                                                         Introduction 
1 | P a g e  
  
1.1. Overview  
This thesis aims at analyzing the structure and function of the Kaposi’s sarcoma 
associated herpes virus (KSHV) viral FLICE-like inhibitory protein (vFLIP) internal 
ribosome entry site (IRES). This chapter will discuss the importance of KSHV, and 
the role of vFLIP during infection. The components of the translational initiation 
machinery and the key steps involved in translation initiation in eukaryotes will also 
be discussed. Alternate mechanisms of translation initiation used by cellular and viral 
mRNAs will be reviewed with emphasis on IRES-mediated translation. Finally, 
current knowledge on the KSHV vFLIP IRES will be reviewed. 
1.2. Viruses and Cancer 
Approximately 10-15% of human cancers worldwide have been attributed to viral 
infections (reviewed in Moore and Chang 2010). Both DNA and RNA viruses have 
been implicated in the development of human cancers (Liao 2006). Epstein-Barr 
virus (EBV) was the first human oncogenic virus to be discovered in 1964 (Epstein et 
al. 1964). In addition to EBV and KSHV, there are five other human oncogenic 
viruses currently known.  
KSHV induces cancer through its expression of several oncogenes that interact with 
cellular proteins to interrupt cell cycle checkpoints, inhibit apoptosis and induce cell 
immortalization and transformation (Chen et al. 2014). The tumorigenesis mediated 
by KSHV will be discussed in more details in a subsequent section. Table 1.1 
summarises the seven known human oncogenic viruses and their associated 
malignancies.   
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 Virus  Malignancy 
Epstein-Barr virus (EBV) Burkitt’s lymphoma, Nasopharyngeal 
carcinoma, Hodgkin’s lymphoma (Epstein et 
al. 1964) 
Hepatitis B virus (HBV) Liver carcinoma (Blumberg et al. 1965) 
Human T-lymphotropic virus-I (HTLV-I) 
Adult T-cell leukaemia (Poiesz et al. 1980) 
Human papillomavirus (HPV) Cervical cancer (Durst et al. 1983) 
Hepatitis C virus (HCV) Liver carcinoma (Choo et al. 1989) 
Kaposi’s sarcoma-associated 
herpesvirus 
Kaposi’s sarcoma, primary effusion lymphoma 
(Chang et al. 1994) 
Merkel cell polyomavirus (MCV) Merkel cell carcinoma (Feng et al. 2008) 
 
 
 
 
 
 
 
Table 1.1. Summary of the known human oncogenic viruses and their associated 
malignancies. 
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1.3. KSHV 
This section of the introduction presents general background on the life cycle, 
discovery, and diseases associated with KSHV. 
1.3.1 Taxonomy and classification 
KSHV, also known as human herpes virus 8 (HHV), belongs to a family of viruses 
known as herpesviridae.The herpesviridae family belongs to the order Herpesvirales 
which consists of three families namely Malacoherpesviridae, Alloherpesviridae as 
well as the herpesviridae family (reviewed in Davison et al. (2009). The 
herpesviridae family is divided into three subfamilies: alpha (α), beta (β) and gamma 
(γ) herpesvirinae (Reviewed in McGeoch et al. (20006). These subfamilies consist of 
viruses that infect reptiles, birds and mammals (Chan and Chan 2003). The 
herpesviruses isolated in humans include varicella zoster virus (VZV), 
cytomegalovirus (CMV), herpes simplex virus-1 and -2 (HSV-1 and -2), human 
herpesvirus variant 6A and 6B (HHV 6A and 6B), human herpesvirus 7 (HHV-7) and 
human herpesvirus 8 (HHV8 or KSHV) (Fishman 2013).   KSHV is the only member 
of the genus Rhadinovirus to cause diseases in humans (Bryan et al. 2005). Figure 
1.1 shows where KSHV fits in the herpesvirale order. 
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Figure 1.1: A brief overview of where KSHV fits into the Herpesvirale order. The human 
herpesviruses are shown in their respective sub-families (Based on Davison et al. (2009). 
KSHV is a γ-2 herpesvirus. HSV1 = Herpes simplex virus 1. HSV-2 = Herpes simplex virus 
2. VZV = Varicella zoster virus. CMV = Cytomegalovirus. HHV6 = Human herpesvirus. RRV 
= Rhesus Rhadinovirus (non-human virus). There are many more herpesviruses which are 
not shown, as they infect other non-human species 
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1.3.2 Historical overview 
Kaposi’s sarcoma was first described in 1872 by the Hungarian physician Moritz 
Kaposi (Kaposi 1872). It was presumed for a long that a virus was the causative 
agent of Kaposi’s sarcoma (KS). This led to the study of tissue culture of cell lines 
derived from different cases of KS. In 1972, Giraldo and colleagues identified 
herpesvirus-like particles in KS biopsies by electron microscopy (Giraldo et al.1972). 
They concluded that there was involvement of a virus that resembled 
cytomegalovirus in the pathology of KS. However, a new virus was discovered in 
1994 by Chang and colleagues. Representational difference analysis (RDA) was 
used to identify and characterize DNA sequences which were present in KS tissues 
but not in non-diseased tissue collected from the same patient. This analysis 
identified sequences that are homologous to but distinct from genes of γ-herpesvirus 
and further investigation led to the discovery of KSHV (Chang et al. 1994). 
1.3.3 Mode of transmission of KSHV 
The primary KSHV infection can occur at any point in childhood and in adulthood, 
and it can be transmitted through both sexual and non-sexual routes (reviewed in 
Minhas and Wood 2014). KSHV has been found in peripheral blood and 
mononuclear cells (PBMCS), oropharyngeal mucosa, saliva, cervicovaginal 
secretions, semen and prostate glands (Corbellino et al., 1996; Mbulaiteye et al., 
2003; Lisco et al., 2006). 
The mode of KSHV transmission may differ between endemic and non-endemic 
regions. In non-endemic regions, particularly in adults, sexual transmission has been 
suggested to be the main route of transmission both in homosexual and 
heterosexual individuals (Cannon et al. 2001; Martin et al. 1998). In endemic areas, 
specifically in children, a mother to child vertical transmission has been proposed as 
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the route of transmission (Mantina et al. 2001; Lisco et al. 2006). Lisco and 
colleagues demonstrated that KSHV is present in cervicovaginal secretions of HIV-1 
and KSHV co-infected women and suggested KSHV viral load in the female genital 
tract may perhaps prompt the vertical transmission of KSHV from mother to child 
(Lisco et al. 2006). 
1.4. Clinical diseases associated to KSHV 
1.4.1 Kaposi’s sarcoma (KS) 
KS is a slow growing tumor of endothelial origin and it is the commonest disease 
associated with KSHV (Fukumoto et al. 2011; Thakker and Verma 2016). Moritz 
Kaposi described it as “idiopathic multiple pigmented sarcomas” in case histories of 
five patients (Kaposi 1872). It is a multifocally developing tumour that primarily 
affects the skin (Gruffat et al. 2000). However, infection also takes place in viscera 
which includes lungs, liver and intestines (Moore and Chang 2003). KS has been 
divided into four clinical subtypes, each prevalent in particular areas of the world and 
it occurs among diverse demographic groups (Fukumoto et al. 2011). These are 
classic KS, endemic, AIDS-associated, iatrogenic KS (Geraminejad et al. 2002).  
Classic KS is the disease form that was identified by Moritz Kaposi and it is 
predominantly seen in elderly men of Mediterranean and eastern European origin 
and is mostly apathetic (Ganem 2006; Verma and Roberton 2003).  
Endemic KS also known as African KS affects human immunodeficiency virus (HIV)-
seronegative children and young adults in sub-saharan Africa (reviewed in Edicoat 
and Newton 2003). The incidence of endemic KS has increased significantly in the 
African subcontinent following HIV epidemic (reviewed in Edicoat and Newton 2003; 
Orem et al. 2004). For instance, in South Africa, before the HIV/AIDS epidemic, the 
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incidence of KS was 5 per 100 000 cases (Cook-Mozaffari et al. 1998). These 
figures have increased significantly over the years by about 20-fold. 
Acquired immunodeficiency syndrome (AIDS)-associated KS also known as 
epidemic KS is the most common and aggressive form of the disease. It is also the 
second most occurring tumour affecting HIV-infected patients worldwide (Martellota 
et al. 2009). The incidence of AIDS-KS has decreased in the western world due to 
highly effective antiretroviral therapy (HAART) for the treatment Human HIV infection 
(Franceschi et al., 2008). 
Iatrogenic KS is associated with the use of steroids and immunosuppressive drugs 
that contain anti-tumor necrosis factor (TNF) activity by patients with inflammatory 
conditions, autoimmune disorders or patients with solid organ transplantation (Cohen 
et al. 2003; Loutherenoo et al. 2003; Mendez and Paya 2000; Vincent et al. 2000). 
The discontinuation or lowering of dosage of therapy tends to alleviate iatrogenic KS 
(reviewed in Schwartz et al. 2008). 
1.4.2 Primary effusion lymphoma (PEL) 
PEL is a form of HIV-associated non-Hodgkin’s lymphoma (NHL) (Chen et al. 2007). 
It accounts for about 4% of all HIV-associated NHL and it has very poor prognosis 
(Simonelli et al. 2003). The disorder is restricted to body cavities such as pleural 
space, pericardium and peritoneum (Brimo et al. 2007; Chen et al. 2007). It primarily 
affects men with AIDS. However, it can also be seen in iatrogenically 
immunosuppressed transplant patients and elderly individuals (Caraway and Stewart 
2006). Although the frequency of PEL cases is low, PEL has played a major role in 
the study of KSHV. The first cell lines expressing KSHV were developed from 
patients with PEL. These cell lines retain large numbers of KSHV genomes of about 
 Chapter 1                                                                                         Introduction 
8 | P a g e  
  
40 to 80 copies per cell. As a result, these cell lines have been used as tools for 
virus purification and serological assays (Demania and Cesarman, 2013). 
1.4.3. Multicentric Castleman’s disease (MCD) 
MCD is a B cell lymphoproliferative disorder and like KS and PEL, it is predominantly 
reported in persons infected with HIV (Stebbing et al. 2008; Sullivan et al. 2008). 
This disorder is divided into hyaline vascular and plasma cell types based on the 
histologic characteristic of the affected lymph nodes (Stebbing et al. 2008). 
1.4.4 KSHV Induced Cytokine Syndrome (KICS) 
Uldrick et al. (2010) described a new inflammatory syndrome associated-KSHV that 
resembled MCD but did not show pathological evidence of MCD. KICS is a disorder 
that is characterized by a high viral load of KSHV and increases in both interleulin-6 
(IL-6) and a viral homologue of IL-6 (Polizzotto et al. 2012). 
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Figure  1.2. Kaposi's sarcoma on the skin and mouth of AIDS patient 
(Taken from National cancer institute (NIH) visuals online)  
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1.5. Virion structure of KSHV 
The herpesviruses share a similar structure. Their virions consist of four diverse 
components which include the DNA core, capsid, tegument, and envelope (see 
figure 1.1) (Pellet and Roizman, 2003). The DNA core consists of the double-
stranded (ds) DNA genome which is enclosed in an icosahedral capsid shell. The 
capsid shell is surrounded by a protein layer called the tegument which is enclosed 
in an envelope comprised of glycoproteins (reviewed in Diefenbach 2015). The 
capsid, tegument and envelope proteins can be visualized by using electron 
microscopy.  This method was previously used to define membership of the 
Herpesviridae family. Nowadays, genomic analyses are the means by which such 
assignments are made (reviewed in McGeoch et al., 2006). The KSHV capsid 
consists of 162 surface capsomeres, made from the major capsid protein. The 
capsid is held together and stabilized with triplexes made from triplex-1 protein (TRI-
1/ORF62) and triplex-2 protein (TRI-2/ORF26) (Wu et al., 2000). Surrounding the 
capsid is a protein-filled tegument. The tegument was previously considered 
amorphous, but it is now thought to be more organised due to interactions between 
the tegument proteins and also between tegument proteins and either envelope 
proteins or capsid proteins. The tegument protein is divided into outer tegument and 
inner tegument layers (Dai et al. 2008). Upon cell entry, the outer tegument proteins 
are released into the host cell cytoplasm where some of them carry out functions 
needed early in the infection process, while the inner tegument proteins remain 
associated with the nucleocapsid and participate in its transport to the nucleus via 
the microtubule/dynein motor system (reviewed in Smith and Enquist 2002). In 
addition, the KSHV proteins found in the tegument are involved in many stages of 
the viral lifecycle, such as assembly and transportation of viral particles and immune 
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evasion processes (reviewed in Sathish and Yuan, 2010). The outer layer of the 
virus particle is the envelope, comprised of numerous glycoproteins which are 
thought to facilitate KSHV entry. 
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Figure 1.3. Morphology of the KSHV virion Schematic representation of herpesvirus 
virion structure. KSHV shares similar morphology with other herpesviruses. 
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1.6. KSHV GENOME 
 KSHV has a large linear double-stranded DNA with an approximate size of 165kb 
which is protected by an icosahedral capsid (Chan and Chan 2003; Ganem 2010; 
Moore and Chang 2003). The genome of KHSV consists of a single, proximate long 
unique region (LUR) which is approximately 138 to 140.5 kb in length (Wen and 
Damania 2010) and contains all the known viral genes so far (IARC 2012). The LUR 
is flanked by noncoding tandemly repeated units termed terminal repeat (TR) region 
at each terminus (Boshoff 2002; Hayward 1999; Fukumoto et al. 2011; Wen and 
Damania 2010). This TR region is made up of variable number of repeats of 801-bp 
length and has a high G:C content of about 84.5% (Fukumoto et al. 2011; 
Dourmishev 2003). KSHV genome contains approximately 87 open reading frames 
(ORFs) that encode for proteins of more than 100 amino acids (Boshoff 2002; Russo 
et al. 1996). The viral genes encoded by KSHV can generally be divided into three 
groups which are: 1) genes common to other herpesviruses 2) genes that are unique 
to KSHV which are usually designated “K” followed by a number of ORFs and 3) 
genes that are homologous to cellular genes (Wong and Damania 2005). The last 
group of genes can either be unique to KSHV or shared with other herpesviruses. In 
addition, novel ORFs thought to be characteristic to KSHV have been labelled K1-
K15 although many of these are now found in related viruses (Sharp and Boshoff 
2000). 
The genes encoded by the LUR code for various proteins which are involved in 
different phases of KSHV gene expression. Functionally, these proteins play roles in 
viral replication, virion structure and regulation of host cell gene (Laurent et al. 2008). 
KSHV possesses homologs to a number of common cellular regulatory genes which 
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were reported to be as a result of KSHV evolvement through genetic piracy (Moore 
and Chang 1998). Figure 1.4 shows the genome organisation of KSHV. 
 
 
 
 
 
 
Figure 1.4: The unique region of the KSHV genome The genome consists of a unique 
region flanked at each end by terminal repeats. Coloured regions indicate protein coding 
regions. Red regions are genes inherited from α, β and γ herpesvirinae. Pink regions are 
genes inherited from β and γ herpesvirinae. Blue regions are immunomodulatory genes. 
Gene names are shown below while names of important latent proteins mentioned in this 
thesis are shown above. This figure is reproduced from (Rezaee et al., 2006). 
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1.7. Replication strategies of KSHV 
Like other herpesviruses, upon entry into the nucleus, KSHV adopts one of two 
replicative programs, the lytic or the latent cycle. The lytic cycle involves the 
expression of a highly ordered cascade of viral genes that ensures efficient 
replication of viral DNA and its packaging into new virions (reviewed in Wen and 
Damania 2010; Thakker and Verma 2016). The latent cycle, on the other hand, is 
characterised by limited gene expression that enables the virus to evade the host 
immune recognition and allows for long-term viral persistence (reviewed in Guito and 
Lukac 2012). Latency is the default option of replicative strategy for KSHV in most 
cell types (Gellermann and Schulz 2008) but it is reversible and can be reactivated to 
enter into the lytic phase by particular environmental and physical stimuli (reviewed 
in Purushothaman et al. 2015; Uppal et al. 2015). 
1.7.1. Lytic life cycle 
During the lytic phase, new KSHV virions are formed. Once the lytic phase is 
induced, it results in the full activation of viral replication and transcription processes. 
This leads to the production of new virions which will be packaged and released from 
the cell (Jarvilouma and Ojala 2006). Lytic replication happens in a cascade manner. 
At different stages of the lytic phase, different genes are expressed and these can be 
categorised into 4 groups. These are α or immediate early (IE) genes, β or early (E) 
genes, γ1 or partial late genes and γ2 or late genes (Chen and Lagunoff 2005; 
Edelman 2005). The IE genes typically encode regulatory proteins that participate in 
viral and cellular genes expression during infection or reactivation and their 
transcription requires no previous protein expression, as evidenced by resistance to 
protein synthesis inhibitors like cycloheximide (CHX) (Zhu et al. 1999). These 
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proteins include RTA, K5, and ORF45 (Ishido et al. 2000; Lukac et al. 1999; Zhu et 
al. 2002).  
RTA, encoded by ORF50, is a lytic switch protein for KSHV viral reactivation from 
latency which is both crucial and sufficient to trigger lytic replication cascade (Lukac 
et al., 1999, Sun et al., 1998). RTA can bind some KSHV promoters known as 
RBPJκ-independent promoters directly and initiate their transcription. Furthermore, it 
can also induce transcription through the RBPJκ protein, which recruits additional co-
activators of transcription (Guito and Lukac, 2012).  
ORF45 is a key tegument protein and an immediate-early gene that allows KSHV to 
target components of the host antiviral defenses (Zhu et al. 2002). It can inhibit virus-
mediated activation of type I IFN genes by suppressing IRF7 phosphorylation, which 
in turn prevents IRF7 the transport of IRF-7 from the cytoplasm to the nucleus and 
the subsequent transcription of IFNα and IFNβ (Zhu et al., 2002). Other IE gene 
products include K8, K9, K3, K5, K4.2 and ORF57 (Lacoste et al. 2004). 
The products of early genes are involved in KSHV viral replication. The products of E 
genes include vGPCR which is encoded by ORF74, vBcl-2 encoded by ORF 16 and 
vIRF1 which is encoded by K9. vGPCR has been shown to induce oxidative DNA 
damage through Rac1-mediated activation of reactive oxygen species (ROS) (Ma et 
al. 2013). 
The majority of the KSHV late genes are essential for the assembly and packaging 
of viral particles and as such their expression is required only after the viral DNA 
synthesis (Toth et al. 2010). Proteins encoded by the late genes are predicted to be 
part of the capsid proteins, the tegument or envelope layers (Zhu and Yuan, 2003; 
Zhu et al., 2005). KSHV has various glycoproteins, including K8.1, glycoprotein (g) B, 
gH, gL, gM, and gN, which have been identified by sequence analysis and have 
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been shown to be components of the envelope of KSHV virions (Akula et al., 2001; 
Baghian et al., 2000; Birkmann et al., 2001;  Pertel, 2002; Wang et al., 2001). 
Overall, lytic genes support viral replication as product of these genes induce 
oxidative DNA damage as shown by vGPCR (Ma et al. 2013)  which  disrupts the 
DNA damage response pathways which in turn promotes survival and evasion of 
immune response (Cavallin et al. 2014).  
1.7.2 Latent life cycle 
During latency, the KSHV viral episome is tethered to the host chromosome and it is 
thus replicated once during every cell division (reviewed in Purushothaman et al. 
2016). Latency silences the expression of lytic genes and it also allows the survival 
and continuous proliferation of infected cells (reviewed in Ye et al. 2011). KSHV 
expresses a restricted number of genes during latency. These genes aid the 
establishment of lifelong latency in the host and they enable KSHV to evade the host 
innate and adaptive immune surveillance mechanism (Purushothaman et al. 2016). 
These genes also play crucial roles in the growth of KSHV-associated malignancies 
as discussed later (section 1.8) (Moore and Chang 2003). The bulk of data on 
KSHV latent gene expression originates from studies performed with primary 
effusion lymphoma (PEL) cell lines (Schulz, 2006). 
The key latent genes of the KSHV are positioned between ORF 69 and Kaposin14 
(K14) in the latency locus within the KSHV genome (Figure 1.4). The latency locus 
encodes four genes in addition to a set of viral microRNAs (miRNA). These genes 
comprise of latency-associated nuclear antigen (LANA), viral cyclin (vCyc), viral 
FLICE inhibitory protein (vFLIP) and K12 (reviewed in Lieberman, 2013). It was 
thought that LANA, vCyc and vFLIP were all transcribed from multiple polycistronic 
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mRNAs, which consisted of a 5.8kb unspliced and 5.3kb differentially spliced 
mRNAs both of which encode the three ORFs (Dittmmer et al. 1998). Another 2.8kb 
mRNA included in the polycistronic mRNAs encodes only the vCyc and the vFLIP. 
However, a recent comprehensive annotation of the KSHV genome could only detect 
a tricistronic (LANA-vCyclin-vFLIP) but not the bicistronic (vCyclin-vFLIP) message 
transcripts in latent iSLK-219 cells (Arias et al., 2014). But the previously proposed 
bicistronic (vCyclin-vFLIP) mRNA was expressed in lytic iSLK-219 cells. This 
confirmed that the vFLIP is expressed from the bicistronic message but suggested 
that its expression is regulated at the RNA level during latency. Figure 1.5 shows the 
latency locus of the KSHV. 
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Figure 1.5 Schematic representation of KSHV major latency locus The four major 
open reading frames (ORFs) ORF73/LANA, ORF72/v-CYC, ORF71/vFLIP and ORF 
K12/Kaposins A-C along with the adjacent K14 and ORF74 genes are shown in blue. 
Shown in red are the positions of 12 pre-miRNA sequences. 
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1.8. Latently expressed genes of KSHV 
1.8.1. Latency associated nuclear antigen (LANA) 
LANA is a large (222-234kDa) multifunctional nuclear protein that migrates slower 
than the predicted molecular weight with 1162 amino acids that is encoded by ORF 
73 (An et al. 2005; Gao et al. 1996; Li et al. 2008). It is made up of 3 different 
domains. These domains are the N-terminal proline-rich domain which is responsible 
for chromatin attachment, central internal repeat domain (IRD) and C-terminal 
domain which is involved in DNA binding (Gao et al. 1999; Lan et al., 2005; Zhang et 
al. 2000). The KSHV DNA replication, maintenance, and segregation into daughter 
cells during mitosis have all been attributed to the presence of LANA (Hu et al. 2002; 
Si et al. 2008). LANA has also been shown to be a reliable indicator for the presence 
of infection by KSHV (Parravicini et al. 2000; Rainbow et al. 1997). Through its C-
terminal, LANA binds terminal repeat (TR) sequences within the KSHV genome and 
attaches to the host chromosome through its N-terminal chromatin binding domain 
(CBD) (Ballestas and Kaye 2001; Cotter et al. 2001; Fejer et al. 2003). This enables 
KSHV genome to piggyback on the host chromosome during mitosis. Hence, it 
maintains a stable copy number in latently infected cells (reviewed in Uppal et al. 
2014).  
1.8.2. v-Cyclin (vCYC) 
vCYC is encoded by ORF72 and it is the viral homolog of cellular cyclin D (reviewed 
in Purushothaman 2016). It binds to and activates cyclin-dependent kinase 6 (CDK6) 
(Sarek et al. 2010). vCYC has been shown to direct phosphorylation and inactivation 
of retinoblastoma protein (pRB)  in addition to phosphorylation of histone H1 which in 
turn promotes cell cycle progression and proliferation (Godden-Kent et al. 1997; Li et 
al. 1997; Moore et al. 1996 ). This enables the productive propagation of KSHV. 
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1.8.3. Kaposins (ORFK12) 
These are proteins that are encoded by the alternatively spliced ORF K12. The 
Kaposin proteins include Kaposin A, B, and C (Sadler et al., 1999). Kaposin B has 
been shown to support tumor microenvironment by increasing cytokine expression 
through its binding with MK2 (McCormick and Ganem, 2005). This, in turn, leads to 
p38/MK2 pathway activation which results in the inhibition of cytokine mRNA 
degradation (McCormick and Ganem, 2005). 
1.8.4. Viral microRNAs (miRNAs) 
miRNAs are single-stranded noncoding RNA molecules that are 21-23 nt long and 
they regulate gene expression post-transcriptionally by targeting 3' untranslated 
regions (UTRs) of messenger RNAs (reviewed in Bartel, 2004; Zhu et al. 2013).They 
maintain KSHV latency by regulating the viral lytic genes and the host survival 
pathways (Boss et al. 2009; Lei et al. 2010). Kaposi’s sarcoma-associated 
herpesvirus (KSHV) contains 12 miRNA genes that are located within the latency-
associated region, 10 in the intragenic region between v-FLIP and the Kaposin locus 
and two embedded within the K12 open reading frame (see Figure 1.5) (Grundhoff 
et al. 2006; Samols et al. 2005). Herpesvirus-encoded miRNAs were hypothesized to 
promote latency by targeting lytic genes  (Murphy et al. 2008). This is the case for 
KSHV-encoded miRNAs. For instance, KSHV miRNAs have been shown to 
modulate the latent/lytic transition through direct targeting of RTA, the product of the 
immediate early lytic gene ORF50, by miR-K12-9 (Ziegelbauer et al. 2009). Based 
on in vitro luciferase assays, direct miRNA targeting of RTA was also demonstrated 
for miR-K12-5 and miR-K12-7 (Lin et al. 2011; Lu et al. 2010). 
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1.8.5. v-FLIP 
This protein is encoded by ORF71. Its expression in KSHV during latency is due to 
the presence of an internal ribosome entry site (IRES) (section 1.13) that is located 
within the coding region of ORF72 (Bieleski and Talbot, 2001; Grundhoff and 
Ganem, 2001; Low et al. 2001).   
v-FLIP is the viral homologue of cellular Fas-associated death domain (FADD) 
interleukin -1β-converting enzyme (FLICE) inhibitory protein (FLIP) (Guasparri et al. 
2004). FLIP proteins are known as inhibitors of death receptor-induced apoptosis 
(Irmer et al. 1997; Thome et al. 1997). These proteins contain two death-effector 
domains (DED) and have been shown to inhibit DED-DED interactions between 
FADD and procaspases 8 and 10 (Guasparri et al. 2006). Thome et al. (1997) 
proposed that vFLIP plays a role in KSHV pathogenesis by inhibiting FAS-mediated 
apoptosis. More recently, it has been suggested that the main role of vFLIP is to 
activate the NF-κB pathway by interacting with the IκB kinase γ (IKKγ) (Bagneris et 
al. 2008; Field et al. 2003; Liu et al. 2002; Matta et al. 2003). This results in the 
expression of antiapoptotic and proinflammatory genes (Guasparri et al. 2004; Sun 
et al. 2006). These genes allow the persistence of infected cells and this explains the 
inflammatory phenotype observed in KSHV lesions (Ballon et al. 2011). Recently, a 
novel function for vFLIP was revealed. Ballon et al. (2015) showed that vFLIP 
induces in vivo expansion of myeloid cells with the appearance of a cellular 
component of immunosuppressive phenotype. In vitro or in vivo expression of vFLIP 
in both B-cells and endothelial cells resulted in increased expression of cytokines 
IL4, IL13,   L10, TNFα, INFγ, and VEGF which in turn leads to irregular myeloid 
differentiation. This brings about the emergence of myeloid subsets known to play a 
role in angiogenesis, tumor immune evasion and tumor progression (Ballon et al. 
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2015).  For the first time in vivo studies demonstrated that vFLIP is able to induce 
vascular abnormalities and changes in host microenvironment. Figure 1.6 shows the 
proposed model of vFLIP mediated tumorigenesis as shown by Ballon et al. 2015. 
The absence of a monocistronic transcript encoding for vFLIP only raised questions 
of how vFLIP is expressed. Subsequently, several studies have revealed and are all 
in agreement that vFLIP is expressed via an IRES within the coding region of vCyclin 
(see section 1.15) (Bieleski and Talbot 2001; Grundhoff and Ganem 2001; Low et 
al. 2001).  
Given that vFLIP as an oncogenic protein plays an important role in KSHV 
tumorigenesis, therefore, it is crucial to understand how the expression of vFLIP is 
regulated by the IRES. This could potentially be a means of blocking KSHV 
replication. 
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Figure 1.6: Model of vFLIP mediated tumorigenesis Ballon et al. (2015) proposed 
that KSHV vFLIP mediates tumorigenesis via endothelial alterations, aberrant 
myeloid differentiation and chronic proinflammatory changes in the tumor 
mircroenvironment (taken from Ballon et al. 2015).  
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1.9. Overview of translation initiation 
Translation initiation is an energy-dependent process and it is the first and rate-
limiting step in the translation of most mRNAs (reviewed in Sonenberg and 
Hinnebusch, 2009). Typical translation initiation in eukaryotes results in the 
recruitment of an 80S ribosome to an AUG start codon on the mRNA. This section 
describes the components required for the translation initiation machinery as well as 
the cap-dependent and cap-independent mechanisms of initiation in eukaryotes. 
1.9.1 Components of translation initiation  
Translation initiation is an intricate process that requires several components in order 
for the process to be carried out efficiently. These components include the mRNA, 
transfer RNA (tRNA), small and large ribosomal subunits and several translation 
proteins called eukaryotic initiation factors (eIFs) (reviewed in Sonenberg and 
Hinnebusch, 2009). mRNA is a product of  transcription. It carries the genetic 
information copied from DNA form of a sequence of a three-base code each one 
identifying a specific amino acid (reviewed in Lodish et al., 2000). The majority of 
eukaryotic mRNAs are capped with 5’-7 methlyguanosine (m7G) cap structure and 
contain 5’ untranslated regions (UTR) (Laursen et al., 2005). Figure 1.7 shows a 
typical eukaryotic mRNA. 
Furthermore, eukaryotic mRNAs have a stretch of adenylate residues known as 
poly(A) tail at the end of their 3’UTR. The poly(A) tail is a long chain of adenine 
nucleotides that is about 50-300nt in length and is added to a mRNA molecule during 
RNA processing to increase the stability of the molecule (Kahvejian et al. 2005; 
Sachs et al. 2000). The poly(A) tail is also crucial for the export of the mRNA from 
the nucleus after transcription (Preiss 2013). It is also required for efficient mRNA 
translation and is specifically recognized by the poly(A) binding protein (PABP). The 
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cap structure in combination with the poly(A) tail have been shown to synergistically 
enhance translation of an mRNA (Gallie 1991; Michel et al. 2000) and the eukaryotic 
initiation factor eIF4G plays a central part in this process. As a multifunctional 
adapter, eIF4G brings together various components of the translation apparatus. 
Through simultaneous interactions with the cap-binding protein eIF4E and the poly 
(A)-binding protein (PABP), eIF4G is able to bridge the two ends of the mRNA 
(Sachs, 2000, Malys and McCarthy, 2011). Figure 1.8 shows the circularization of 
mRNA through eIF4G interaction with eIF4E and PABP The resulting pseudo-
circular structure of the mRNA is thought to have important functional consequences 
for the translation process. 
Transfer RNAs (tRNAs) function as adapter molecules during translation initiation 
and are composed of 73-90 nucleotides. They deliver amino acids to the ribosome to 
decode the genetic information in the mRNA into a corresponding polypeptide chain 
(Hopper 2013; Raina and Ibba 2014; Kirchner and Ignatova 2015).  
Ribosomes are ribonucleoproteins (RNPs) complexes that catalyze protein synthesis 
in all cells (Cruz et al. 2015). They consist of small and large subunits designated 
based on their sedimentation coefficients in Svedberg units. They are made up of 
two-thirds of RNA termed ribosomal RNA (rRNA) and one-third of ribosomal proteins 
(Steitz and Moore, 2003). In eukaryotes, the ribosome is also referred to as 80S 
ribosomes. The 80S ribosome consists of small subunit (40S) and large subunit 
(60S) ribosomes. The 40S subunit is made up of 18S rRNA and 33 ribosomal 
proteins while the 60S subunit consists of 28S, 5.8S, 5S rRNA and 47 ribosomal 
proteins (De la Cruz et al. 2015; Hage and Tollervey, 2004; Fromont-Racine et al., 
2003). The large subunit catalyses peptide bond formation while the small subunit 
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serves as the decoding centre to the mRNAs and tRNAs to translate the genetic 
code (Cruz et al. 2015). Figure 1.9 shows a model of the eukaryotic ribosome. 
 
 
 
 
 
 
Figure 1.7 Model of a typical eukaryotic mRNA. UTR, untranslated region; 
ORF, open reading frame. 
Figure 1.8 Mechanism of mRNA circularization. Interaction between the 5’ cap and 
the 3’ poly (A) tail of mRNA enhances translation. This occurs as a result of PABP 
interacting with eIF4G which in turn binds eIF4E, bringing the 5’ and 3’ ends together. 
 Chapter 1                                                                                         Introduction 
28 | P a g e  
  
 
 
 
 
 
 
 
 
Figure 1.9 Model of the 80S eukaryotic ribosome The model was derived using 
cryoelectron microscopy reconstructions of Triticum aestivum. The rRNA and protein 
shown in yellow and orange for the 40S subunit and grey and blue for the 60S subunit 
respectively. The P-tRNA that carries the growing peptide chain is in green. (Armache 
et al. 2010). 
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Factor Function 
eIF1 Ensures the selection of appropriate AUG initiation codon  
eIF1A Cooperates with eIF1 to enhance ribosomal scanning  
eIF2 Forms a complex with GTP-met-tRNAi which binds 40S subunit 
eIF2B Nucleotide exchange factor needed for eIF2 recycling 
eIF3 Enhances binding of eIF2-GTP-met-tRNAi complex to 40S; binds eIF1, 
eIF4G and eIF5 
eIF4A ATPase and RNA helicase 
eIF4B RNA-binding protein; enhances activity of 4A 
eIF4E Binds to m7G cap structure of mRNA 
eIF4G Binds mRNA, eIF4E, eIF4A, and eIF3 
eIF5 Binds RNA; stimulates ATPase and helicase of eIF4A 
eIF5B Enhances GTPase activity of eIF2 
 
 
Table 1.2.  Summary of eukaryotic initiation factors of the translation initiation 
pathway and their respective roles in initiation (Adapted from Jackson et al. 2010). 
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1.10 Eukaryotic initiation factors 
Eukaryotic initiation factors are soluble proteins that facilitate the assembly of the 
translation-competent ribosome at the initiation codon of an mRNA (Sonenberg and 
Dever, 2003). Table 1.2 summarises the eukaryotic initiation factors involved in 
translation initiation and their functions.  
1.10.1 Initiation factor 4F complex 
Eukaryotic initiation factor 4F is the protein complex that binds the 5’-7 
methlyguanosine cap on mRNAs and it comprises the cap-binding protein eIF4E, the 
DEAD-box helicase eIF4A and the scaffold protein eIF4G (Pestova and Kolupaeva, 
2002). 
1.10.1.1 Initiation factor 4A 
Eukaryotic initiation factor 4A is a member of the DEAD box protein family (Rogers et 
al., 2002; Tuteja et al., 2008). It is an ATP-dependent RNA helicase and RNA 
ATPase. It is thought to disrupt the secondary and tertiary structures in the 5’ UTR of 
capped mRNAs in order to facilitate ribosomal attachment and to allow scanning to 
the initiation codon (Ray et al. 1985; Rozen et al. 1990) reviewed in (Hilbert et al., 
2009, Andreou and Klostermeier, 2013). It is the most abundant of the eukaryotic 
initiation factors and it is present as part of the cap-binding complex (4F) and also in 
free form (Linder and Fuller-Pace 2013). The ATPase and duplex unwinding 
activities of eIF4A have been shown to be stimulated by the helicase accessory 
proteins eIF4B and eIF4H (Ozes et al. 2011). Feokistova et al. (2013) also showed 
that eIF4E stimulates the rate of duplex unwinding by eIF4A.  
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1.10.1.2 Initiation factor 4E 
Eukaryotic initiation factor 4E is a 24-kD polypeptide and it exists as both a free form 
and as part of a multi-protein complex. It was thought that the primary role eIF4E in 
the eIF4F complex is to direct ribosomes to the 5’terminal cap structure of mRNAs 
(Kapp and Lorsch, 2004). However, it has been shown to interact with other proteins: 
eIF4A1 (Ewing et al., 2007), eIF4EBP1 (Connolly et al., 2006), eIF4EBP2 (Mader et 
al., 1995), eIF4EBP3 (Kleijn et al., 2002), , eIF4G2 (Gradi et al., 1998). 
1.10.1.3 Initiation factor 4G 
Eukaryotic initiation factor 4G (eIF4G) is known as the scaffold subunit of the eIF4F 
complex. In mammals, two isoforms of eIF4G (I and II) have been identified. In 
mammalian cells, eIF4GI is much more abundant than eIF4GII. The eIF4G functions 
as a protein bridge between the cap structure and the 43S pre-initiation complex. It 
has binding domains for eIF4E, eIF4A, eIF3, poly (A)-binding protein (PABP1), and 
the mitogen-activated protein kinase MNK1 (Berset et al., 2003) that are thought to 
enhance formation of activated eIF4F•mRNA•PABP complexes. The activated 
eIF4F•mRNA•PABP complexes are competent to recruit 43S pre-initiation 
complexes. Figure 1.10 shows a representation of the eIF4G structure. 
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Figure 1.10 Scematic representation of eIF4G. Shown are the binding sites for 
PABP, eIF4E, eIF3, eIF4A and Mnk1. The target sites for 2A and L protease of 
picornaviruses and HIV is also indicated, not drawn to scale (Adapted from Korneeva 
et al. 2001) 
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1.11 Mechanisms of translation initiation 
1.11.1 Cap-dependent translation initiation 
The majority of eukaryotic cellular mRNAs utilize cap-dependent or scanning mode 
to initiate translation (Martinez-Salas et al. 2012). This mechanism requires the 
recognition of the 7-methyl-guanosine (m7G) cap structure at the 5’ end of the mRNA 
and ribosomal scanning for translation to be initiated (Sonenberg and Hinnebusch, 
2009). The cap structure also plays major roles in other cellular processes such as 
RNA splicing, transport, and stabilisation (Lopez-Lastra et al. 2010). But only its 
involvement in translation initiation will be discussed. The cap-dependent translation 
initiation is a multistep process that can be divided into several stages as described 
below. Figure 1.11 summarises the cap-dependent translation pathway. 
1.11.1.1 Ribosomal dissociation  
In order for initiation to begin, a pool of dissociated ribosome subunits is required.  
This is accomplished by the recycling of post ternary complexes. The 80S ribosome 
is separated into the 40S and 60S subunits. Eukaryotic initiation factors moderate 
this recycling process. eIF3 in association with its loosely related eIF3j subunit with 
eIF1 and eIF1A dissociates post-ternary complexes into free 60S subunit and mRNA 
and tRNA-bound 40S subunit (Jackson  et al. 2010). Thereafter, eIF1 promotes the 
release of the tRNA and eIF3j mediates the dissociation of the mRNA. The 40S 
subunit remains bound to eIF3, eIF1 and eIF1A in order to prevent the re-association 
of the 40S subunit to the 60S subunit (reviewed in Lopez-Lastra et al. 2010). 
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1.11.1.2 Formation of the 43S preinitiation complex (PIC) 
The preinitiation complex is formed by a ternary complex which consists of initiation 
methionyl-tRNA (Met-tRNAi), guanosine-5’-triphosphate (GTP) and eIF2 which binds 
to the 40S subunit. The process begins with the binding of GTP with eIF2 to form a 
binary complex. This binary complex then binds to Met-tRNAi to form a ternary 
complex. This complex is then bound to the 40S ribosomal subunits to form the 43S 
pre-initiation complex. eIF2 selects the initiation tRNA (tRNAi) and guides it to the 
40S subunit and places it in the P site (Komar and Hatzoglous 2005; Majumdar  et 
al. 2003). 
1.11.1.3 Preinitiation complex assembly onto mRNA 
In preparation for ribosomal attachment, a combined action of eIF4F and eIF4B or 
eIF4H unwinds the cap-proximal region of mRNA. eIF4F consists of eIF4E (a cap-
binding protein), eIF4A (DEAD-box RNA helicase) and eIF4G, a scaffold protein that 
binds eIF4E, eIF4A, eIF3 and poly(A)-binding protein (PABP) (for review see  
Hinnebusch 2014; Hinnebusch and Lorsch, 2012; Jackson et al. 2010). It was shown 
that the eukaryotic initiation factors 4B and 4H modulate the helicase activity of 
eIF4A (Rogers et al. 2001). The affinity of eIF4E for the cap structure is boosted by 
the binding of eIF4G to its N-terminus (Gross et al. 2003; Volpon et al. 2006). The 
mRNA cap-eIF4E interaction promotes the binding of 43S PIC to the mRNA.  
As a result of the RNA-binding activity as well as the binding domains for eIF4E and 
PABP, eIF4G is able to interact independently with the mRNA via the cap, poly (A) 
tail, and sequences within the mRNA body. This leads to the assembly of a stable 
circular messenger ribonucleoprotein (mRNP) termed “close-loop” structure 
(Hinnebusch and Lorsch, 2012). 
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The interaction between eIF4G and eIF3 builds a protein bridge between the “closed 
loop” structure and the 43S PIC to trigger the attachment of the 43S to the mRNA. 
Subsequently, the eIF4A through its helicase activity is thought to develop a single-
stranded ‘landing pad’ in the mRNA for the 43S PIC to load proximate to the 5’cap 
(Hinnebusch and Lorsch, 2012). 
1.11.1.4 Ribosome scanning of mRNA 5’UTR 
Following the 43S PIC loading near the 5’cap, it scans the mRNA in the 5’-3’direction 
in order to locate an initiation codon. It uses complementarity with the anticodon of 
Met-tRNAi to identify the AUG. ATP either directly or indirectly drives this scanning 
process. There are two main conditions to be fulfilled for the process of scanning 
these are unwinding of the secondary structures in the 5’UTR and the movement of 
the ribosome along it.  
The recognition of the start codon is primarily through the complementarity of the 
mRNA with the anticodon in the Met-tRNAi. However, other factors are involved in 
selecting a start codon. The context of the AUG is one such factor. Translation 
generally initiates at the 5′-proximal AUG, regardless of the length or sequence of 
the 5′-UTR, inferring selection by a process of scanning from the 5′-end (reviewed in 
Asano 2014). The efficiency of recognition and selection of the 5′-proximal AUG is 
influenced by a Kozak consensus sequence ([A/G]xxAUGG) (Kozak 1991) in 
eukaryotes. According to the Kozak model, AUG codons with a specific nucleotide 
(nt) context (i.e. the nucleotides before and after a codon) surrounding are 
recognised by the pre-initiation complex. Where multiple AUGs appear in an mRNA, 
the first AUG from the 5' end will be selected as the site for initiation except it is 
disadvantaged by being too close to the cap or if it is in a poor context sequence. In 
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other words, a specific context surrounding the initiating AUG codon is required for it 
to be recognised by the pre-initiation complex; and Kozak proposed that this context 
appeared only in the vicinity of the initiating (START) AUG codon of the open 
reading frame (Kozak, 1986, Zur and Tuller, 2013). The most crucial elements of 
AUG context in eukaryotes are purine at position −3 and guanine at position +4 
(Lukaszewicz et al., 2000; Kozak, 2002).  
Movement of the 43S PIC requires it to have a scanning-competent conformation 
which is induced by eIF1 and eIF1A (Passmore et al. 2007) so that it becomes 
competent for threading along the mRNA with base-by-base inspection of the 
nucleotide sequence for an appropriate AUG. eIF1 plays a major part in maintaining 
the fidelity of initiation. It permits 43S complexes to discriminate against non-cognate 
AUG triplets and cognate AUG. The selection of a start codon triggers irreversible 
hydrolysis of GTP in the ternary complex. GTP hydrolysis reduces eIF2's affinity for 
Met-tRNAi, leading to partial dissociation of eIF2–GDP from 40S subunit. eIF2B 
mediates guanine nucleotide exchange on eIF2, recycling it for the next initiation 
round. The complex formed by the 40S subunit and the initiation factors positioned at 
the AUG codon is referred to as the 48S complex (reviewed in Hinnebusch 2014; 
Hinnebusch and Lorsch, 2012; Jackson et al. 2010). 
1.11.1.5 Ribosomal subunit joining 
The final stage in the initiation is the formation of the 80S ribosome. Once the 
appropriate AUG start codon has been recognized, the residual initiation factors 
must dissociate from the 48S complex and the 60S subunit must join the 40S subunit 
to form the 80S ribosome. This process is mediated by a GTPase initiation factor, 
eIF5B (Pestova et al. 2000). The eIF5B activity is facilitated by the interaction of its 
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c-terminal domain (CTD) with the c-terminal tail of eIF1A. The complete ribosome 
(80S) is then ready for the next stage of translation which is elongation, during which 
the sequence between the 'start' and 'stop' codons is translated from mRNA into an 
amino acid sequence. 
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Figure 1.11: Cap-dependent Translation initiation pathway in eukaryotes 
 The 80S ribosome dissociates to yield separated 40S and 60S ribosomal subunit and this 
enables the 40S ribosomal subunit to bind eIF1A, eIF3 and met tRNA to form the 43S pre-
initiation complex. The 43S pre-initiation complex binds mRNA at the 5' cap structure (a 
process aided by eIF4E, eIF4G, eIF4A and eIF4B) and scans along the RNA until it reaches 
the initiating AUG codon. At the initiating codon the GTP molecule from eIF2 complex is 
hydrolysed to GDP, releasing the initiation factors and enabling the 43S complex to associate 
with 60S subunit. This produces a functional 80S ribosome positioned at the initiating codon, 
which is able to translate the mRNA open reading frame (Adapted from Jackson et al., 2010). 
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1.12 Alternative Mechanisms of translation initiation  
The main pathway for translation initiation is cap-dependent and the conventional 
scanning mechanism as described above. However, there are alternative 
mechanisms used mostly by viruses to overcome unfavourable conditions imposed 
on the translational machinery. Figure 1.12 shows a schematic representation of 
these alternative mechanisms.  
1.12.1 Leaky scanning 
In accordance with the general rule of selection of initiation codon, ribosomes initiate 
translation at the first AUG proximal to the 5’ end of the mRNA. However, if the first 
AUG is not in the right context, the scanning ribosomes can bypass the first AUG 
and continue scanning until it reaches a favourable AUG codon, a mechanism 
known as leaky scanning (reviewed in Lopez-Lastra et al., 2005).  This mechanism is 
mostly utilized by viral mRNAs and leads to the synthesis of two or more proteins 
from the same mRNA (Ryabova et al. 2006). Human papillomavirus type 16 
predominantly uses this mechanism to translate its E7 oncoprotein from E6/E7 
bicistronic mRNA (Stacey et al. 2000). It also mediates the translation of minor 
capsid of the rabbit hemorrhagic disease virus (RHDV) (Meyers 2003; Meyers 2007). 
1.12.2 Reinitiation 
It was revealed that eukaryotic ribosomes could translate an upstream ORF (uORF) 
and reinitiate translation at a downstream ORF. In this instance, the 40S ribosomal 
subunit remains associated with the mRNA after termination at the uORF and 
resumes scanning. This mechanism is termed reinitiation (Kochetov et al. 2008). In 
mammalians, resumption of scanning and reinitiation only occurs if the first ORF is 
short (Poyry et al. 2004; Kozak 2001).  
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1.12.3 Ribosome shunting 
In this mechanism, ribosomes are loaded onto an mRNA by a cap-dependent 
process but they shunt or bypass strong secondary structure elements encountered 
in the 5’UTR before initiating translation at a downstream AUG (Jackson 1996). This 
mechanism of translation initiation has been described for cauliflower mosaic virus 
(CaMV) 35S mRNA (Futterrer et al. 1993) and for the papillomavirus E1 mRNA 
(Remm et al. 1999). 
1.12.4 Ribosomal frameshifting 
During translation, this mechanism allows the reading frame of an mRNA to be 
changed at a specific site or sites driven by a local RNA secondary structure, which 
results in the expression of proteins from overlapping open reading frames (ORFs) 
(Hatfield and Oroszlan 1990). 
1.12.5 Cap-independent translation initiation 
Cap-dependent mechanism of initiation was considered the only possible pathway 
through which eukaryotic mRNA translation could be initiated. However, early 
studies of viral gene expression led to the discovery of an alternative mode of 
translation initiation in eukaryotic cells that evades the requirement for 5’cap-binding 
complex and its associated proteins and permits the direct internal recruitment of 
40S ribosome to the proximity of an initiation codon (Jang et al. 1988; Pelletier and 
Sonenberg 1988). This mechanism of initiation is driven by elements known as 
internal ribosome entry sites (IRES). These will be discussed later in the chapter.  
In conditions where the cap-dependent initiation is impaired, this alternative 
mechanism of translation initiation is activated in some viral and cellular mRNAs and 
this enables the continuous expression of the viral and cellular proteins (Holcik and 
Pestova 2007; Ul-Hussain et al. 2012). Such conditions that can affect the 5’-cap 
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mediated initiation include endoplasmic reticulum (ER) stress, hypoxia, mitosis and 
cell differentiation (Komar and Hatzoglou 2011). In addition, infection by some 
viruses also impairs the functioning of the cap-dependent initiation. IRES elements 
are RNA sequences that form secondary or tertiary structures in mRNAs upstream of 
the start codon for initiation of translation (Jang et al. 1988; Pelletier and Sonenberg 
1988). This mechanism results in the 43S pre-initiation complex recognising and 
binding with IRES RNA sequences either alone or in combination with a class of 
RNA-binding proteins known as IRES transacting factors (ITAFs) (Semler and 
Waterman 2007). This mechanism has been shown to be utilized by several viral 
and cellular mRNAs for translation (Semler and Waterman 2007).  
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1.13. Internal ribosome entry site (IRES) elements 
 IRES elements were first discovered in picornavirus RNAs (Pelletier and Sonenberg 
1988). Picornaviral mRNAs are uncapped at their 5’ end and yet were still able to 
initiate translation; this prompted the study of the mechanism by which their mRNA is 
translated. In 1988, Pelletier and Sonenberg demonstrated that the 5’ untranslated 
region (UTR) of poliovirus had the ability to drive internal initiation of protein 
synthesis from within a synthetic dicistronic mRNA. They described the element for 
the initiation of translation as a “ribosome landing pad”. Jang et al. (1988) also 
reported that the 5’UTR of encephalomyocarditis virus (EMCV) is able to drive 
translation initiation internally and later coined the term IRES. During IRES-mediated 
translation initiation, attachment of the 40S ribosomal subunit to the IRES does not 
require the presence of a cap structure because the ribosome is recruited internally 
to the IRES, within the 5′ UTR of the mRNA. The distance from the 3′ end of the 
IRES to the initiating codon differs from one IRES element to another. The ribosomal 
subunit binds to the 3′ end of the IRES structure and scans along the mRNA until it 
reaches the initiating codon. Immediately the 40S ribosomal subunit reaches the 
initiating codon, the 60S ribosomal subunit attaches and translation is initiated. This 
process functionally replaces the need for the cap and a many (in some cases, all) of 
the proteins needed for initiation (Kieft, 2008).   
Since their discovery in poliovirus (PV), IRES elements have also been identified in 
other viruses such as flaviviruses, plant viruses and some DNA viruses (Bonnal et al. 
2003) and in cellular eukaryotic mRNAs (Martinez-Salas, 1999). In 1991, Macejak 
and Sarnow identified the first eukaryotic cellular IRES. According to IRESite, a 
database of experimentally verified IRES, there are least 68 viruses and 115 
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eukaryotic cellular mRNAs that have been reported to contain IRES elements as of 
2009 (http://iresite.org/). 
Presently, IRESs are defined only by functional criteria and cannot yet be predicted 
by the presence of characteristic RNA sequences or structural motifs (Xia and 
Holcik, 2009; Jackson, 2013). The presence of an IRES element in a specific mRNA 
must be experimentally verified in each and every case following a set of defined 
tests (Van Eden et al., 2004). Figure 1.13 shows the different types of IRES 
elements and mechanisms they use to initiate translation initiation. 
 Viral IRESs are divided into four groups based on some factors which are  the 
requirement for specific eIFs, RNA structure, the location of the AUG relative to the 
IRES and the ability to function in rabbit reticulocyte lysate (RRL) (Kieft, 2008). This 
group of IRESs are discussed below. 
1.13.1 Type I IRES elements 
These IRESs were one of the first to be identified in picornaviruses (Walsh and Mohr 
2011). This type of IRES occurs in PV, enterovirus 71 and coxsackievirus (Bonderoff 
and Lloyd 2008; Jackson 1995; Pelletier and Sonenberg 1988). They are about 450-
nt in length and have four major domains (II, IV, V, and IV) ( reviewed in Hanson et 
al. 2013). A requirement for ITAF for their activity has been suggested as these 
IRESs function efficiently in rabbit reticulocyte lysate (RRL) when supplemented with 
extracts from other cell types (Kieft 2008).  The stem loop I of these IRESs have a 
tetraloop, clover leaf structure which interacts with an ITAF called poly c-binding 
protein 2 (PCBP2) and the viral protein 3CD, a protein involved in replication (Blyn et 
al. 1997; Gamarnik and Andino 2000). This enables a bridge to be formed between 
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the 5’ and 3’ ends which allows replication to occur. Type I IRESs require eIF2, eIF3, 
eIF4A and the central domain of eIF4G (reviewed in Sweeney et al. 2014).  
Studies to evaluate the requirement for eIFs by type I IRES elements showed that 
type I IRESs specifically bind domains V of the coxsackievirus B3, EV71, and PV 
IRESs independent of other factors (De Breyne et al. 2009). The bound eIF4G 
recruits eIF4A and forms an eIF4G/eIF4A complex. This complex seems to induce 
conformational changes in domain ohanVI and its surrounding area. This led to the 
suggestion that the conformation change induced by eIF4G/eIF4A is essential for the 
subsequent attachment of 43S complexes (de Breyne et al. 2009). 
1.13.2. Type II IRES elements 
This type of IRES is found in the Aphthovirus, Cardiovirus, and Parechovirus genera 
(Belsham and Jackson, 2000). The encephalomyocarditis virus (EMCV) and foot-
and-mouth disease virus (FMDV) IRESs are the most documented of the type I IRES 
(Walsh and Mohr 2011). 48S complex formation by these IRESs require Met-tRNAi 
eIF2, eIF3, eIF4A, the central domain of eIF4G and ITAFs (Pestova et al. 1996; 
Lomakin et al. 2000). Noteworthy, the requirement for eIF1 and eIF1A was shown for 
the foot and mouth disease virus (FMDV) during initiation on a second downstream 
AUG (Andreev et al. 2007). In 2006, Jang showed that eIF4G, eIF4A, and eIF4B 
interacted with stem loop J/K/L regions of type II IRES, as mutations to these 
domains resulted in a reduction in the IRES activity. Kolupaeva et al. (2003), showed 
that binding of the eIF4A/4G complex to the central J-K domain of EMCV IRES 
promoted the restructuring of its 3’ border and this was proposed to facilitate the 
direct attachment of 43S complexes to the initiation codon, a notion also suggested 
by De Breyne et al. (2009). 
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A recent study has proposed a new model for initiation complex assembly on EMCV 
IRES. Chammond and colleagues showed that EMCV IRES can directly recruit the 
40S subunit through its H and I domains without the need for initiation factors or 
ITAFs (Chamond et al. 2014). But suggested that the recruitment of the eIF4G/eIF4A 
complex is needed to restructure the 3’ border of the IRES in order to facilitate the 
release of initiation codon to allow functional assembly of the 48S. This could be a 
new mechanism shared by the type I IRESs and not just the EMCV IRES.  
1.13.3. Type III IRES elements (HCV-like IRES) 
These IRESs directly and independently bind 40S subunit thus in the absence of 
eIF4F or any of its component subunits eIF4B and ATP hydrolysis (Hanson et al. 
2013; Walsh and Mohr, 2011). They require only a 40S subunit and the eIF2-tenary 
complex. They have the ability to stimulate conformational changes to the ribosome 
that affects its position, entry, and stability (Hellen, 2009). These IRES have three 
major domains labelled as II, III and IV and the initiation codon is found in domain 
IV (Hanson et al. 2013). The mechanism by which this group of IRESs initiate 
translation is based on specific interactions of the IRES RNA structure with the 40S 
subunit, which involves the pseudoknot and subdomains IIId and IIIe of their RNA 
structures (Kieft et al. 2001; Kolupaeva et al. 2000; Lukavsky, 2009). Pestova et al. 
(1998) showed that the HCV-like IRESs can capture the 40S ribosomal subunit 
directly in the absence of any initiation factors. Once the IRES interacts with the 40S 
subunits, domain IIIb regulates the recruitment of eIF3 and Met-tRNAi-eIF2 (Ji et al. 
2004). Biochemical, mutational and structural analysis of the HCV-like IRESs 
revealed that the structural elements of domain III are involved in making most of the 
direct contacts with the host translational components, the 40S, and eIF3 (Jubin et 
al. 2000; Kieft et al. 2001; Lukavsky, 2009).The deletion of domain IIIb results in 
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reduced affinity for eIF3, which has been shown to affect the stable association of 
eIF2 with the 48S complex (Ji et al. 2004; Otto and Puglisi 2004). Binding of these 
IRESs to the 40S subunit positions the initiation codon of the IRES in the P- site 
where it directly base-pairs with the anticodon of Met-tRNAi as a part of the eIF2-
ternary complex, resulting in the formation of the 48S complex. Subsequent joining 
of the 60S subunit to this complex is mediated by eIF5 and eIF5B. The domain II of 
these IRESs stimulates eIF5-mediated hydrolysis of eIF2-bound GTP and joining of 
a 60S subunit (Fraser et al., 2009; Locker et al., 2007). The hepatitis C virus (HCV) 
is an example of a virus that uses this IRES (Walsh and Mohr 2011).  
 1.13.4. Type IV IRES elements 
This group of IRES element represents the simplest mode of action of an IRES 
identified to date. They are commonly found in the intergenic region (IGR) of the 
Dicistroviridae viral family (Kieft, 2008, Nakashima and Uchiumi, 2009).The 
dicistroviruses are positive single-stranded RNA viruses encoding a dicistronic 
genome, in which each open reading frame (ORF) is expressed from an independent 
IRES (Hertz and Thompson 2011). The IGR IRES can initiate translation by binding 
directly to the 40S subunit or to the 80S ribosome without the need for canonical 
initiation factors or initiation Met-tRNAi (Jan et al., 2003; Nishiyama et al., 2003). 
Contrary to typical AUG codon selection for translation initiation, analysis of the type 
IRES has revealed that initiation does not occur at a cognate AUG codon or even a 
weak cognate codon such as CUG or GUG. The N-terminal residue of the capsid 
protein precursor is either alanine (encoded by GCU or GCA) or glutamine (encoded 
by CAA) (Domier et al., 2000; Sasaki and Nakashima, 1999). The IGR IRES initiates 
translation from the ribosomal acceptor site (A-site) and as a result, does not require 
Met-tRNAi and an AUG codon (Kamoshita et al. 2009; Wilson et al. 2000). In this 
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case, the ribosomal P-site is occupied by a CCU codon that base-pairs with IRES 
sequence located upstream to form a pseudoknot structure (PKI) (Wilson et al. 
2000). This PKI structure occupies the P-site and structurally mimics a tRNA 
anticodon-codon interaction (Constantino et al. 2008).  This mode of mechanism by 
IGR IRES is more suggestive of elongation rather than initiation (Hertz and 
Thompson 2011).  A prototypical of type IV IRESs is the cricket paralysis virus 
(CrPV) IRES.  
1.13.5. IRES of Lentiviruses 
The HIV IRESs signify a new group of IRESs, as their characteristics do not fit into 
the previously discussed type I to IV IRES. These IRESs have the ability to directly 
and indirectly bind to the 40S subunit and eIF3, a characteristic of type III IRESs 
(Locker et al. 2011). It also needs all eukaryotic initiation factors with the exception of 
eIF1 and eIF4E, a characteristic of type I and type II IRESs (Locker et al. 2011).  
The IRESs discussed so far are found in the 5’UTR of RNA viruses, below are 
eukaryotic cellular IRESs, as well as those found in DNA viruses.  
1.13.6 Cellular IRES 
In similarity to viral IRESs, cellular IRESs also use ITAFs and limited eIFs to initiate 
translation internally (Hellen and Sarnow 2001). These IRESs are usually located in 
mRNAs that contain long 5'UTRs that are rich in GC (Holcik et al. 2005).  
Sarnow and colleagues found that a cellular mRNA coding the immunoglobulin 
heavy chain binding protein (BiP) can be translated in poliovirus (PV) infected cells 
at a period when cap-dependent initiation is decreased. This led to the conclusion 
that the BiP mRNA can mediate internal entry of ribosomes in mammalian cells. This 
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was the first indication that IRES-mediated mechanism of initiation can be utilised by 
cellular eukaryotic mRNAs (Macejak and Sarnow 1991). 
It was shown that 3-5% of cellular mRNAs stay associated with polyribosomes in PV 
infected cells at a period when cap-dependent initiation is impaired (Johannes et al. 
1999). But presently, it is estimated that 10-15% of cellular mRNAs are capable of 
initiating translation via the cap-independent mechanism (Graber et al. 2010; Spriggs 
et al. 2008; Qin and Sarnow, 2004). Several of the ITAFs used by the viral IRESs are 
also utilized by cellular IRES elements, including PTB, PCBP1, and La autoantigen 
(Stoneley and Willis, 2004). 
The majority of IRES elements identified so far are mostly found in mRNAs that are 
involved in regulating gene expression during development, differentiation, cell cycle 
progression, apoptosis, cell growth and stress (Bonnal et al. 2003; Helen and 
Sarnow, 2001; Stoneley and Willis, 2004). 
1.13.7. DNA virus IRESs 
Unlike RNA virus and cellular IRESs, IRES elements of DNA viruses are much less 
understood due to lack of sufficient studies. Presently, there are six DNA viruses that 
are thought to have IRESs, four of which belong to the Herpesviridae family. The 
KSHV IRES is the most documented of all the known DNA viral IRESs. Other DNA 
viruses reported to contain IRESs include Herpes simplex virus (HSV), Marek’s 
disease virus (MDV), Epstein-Barr virus (Griffiths and Coen, 2005; Tahiri-Alaoui et 
al., 2009; Isaksson et al. 2003).  
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Figure 1.13 Structures and Mechanism of IRES elements (A) mechanism of initiation by 
type I IRESs typified by PV requires eIF4G, 4A, 2 and 3 but not eIF4E (B) type II IRESs is 
similar to type I in its requirements, EMCV is shown as an example (C) type III IRES initiate 
translation with the aid of eIF3 and eIF2 as shown in HCV IRES (D) Type IV IRESs bypass 
eIFs and tRNAi and binds 40S directly (E) the HIV-2 gag IRES requires most of the eIFs 
except eIF4E and eIF1 (Adapted from Jackson et al., 2010; Locker et al. 2011).  
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1.14. Role of IRES trans-acting Factors (ITAFs) in IRES-mediated initiation 
ITAFs are proteins that are able to modulate and enhance IRES-dependent initiation 
(Komar and Hatzoglou 2011). They act as RNA chaperones and enable the mRNA 
to have the exact conformation for interaction with the 40S subunit (Cobbold et al. 
2008). ITAFs have a distinctive characteristic by which they are identified (Komar 
and Hatzoglou 2011). They belong to a group of heterogeneous nuclear 
ribonucleoproteins (hnRNP) which are known to shuttle between the nucleus and the 
cytoplasm (Komar and Hatzoglou 2005; Spriggs et al. 2005). The precise 
mechanism by which ITAFs mediate IRES-dependent translation and their regulation 
are not yet fully understood but it is an active field of investigation (Lewis and Holcik 
2008). Several ITAFs have been identified over the years both in cellular and viral 
IRESs (Cobbold et al. 2008; Hellen and Sarnow 2001). An ITAF called pyrimidine 
tract-binding protein (PTB) has been shown to bind all picornaviral IRESs as it was 
shown in EMCV and FMDV by using chemical and enzymatic footprinting 
(Kolupaeva et al. 1996; Pilipenko et al. 2000). Other ITAFs such as Y-box binding 
protein (YB-1) and G-rich RNA sequence binding factor 1 (GRSF-1) have been 
shown to bind and interact with the Myc family of IRESs (Cobbold et al. 2008). The 
La autoantigen, a protein involved in polymerase III transcription, functions as an 
ITAF by binding and stimulating the PV, EMCV, and HCV IRES-mediated translation 
(Kim and Jang 1999; Meerovitch et al. 1993; Mondal et al. 2008). La protein has an 
inhibitory effect on the HAV IRES as it was shown to suppress its IRES activity 
(Cordes et al. 2008).   
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Known ITAFs Interacting IRES element 
PTB PV                 FMDV 
HAV              EMCV 
HRV              HCV 
 
La autoatigen HIV-type I      HRV 
EMCV           HCV 
FMDV           PV 
 
PCBP2 PV 
HCV 
HAV 
 
Table 1.3 IRES-trans-acting factors and the corresponding IRESs with which 
they interact (adapted from Fitzgerald and Semler, 2009). 
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1.15. KSHV IRES 
KSHV is the first DNA virus to be reported to express mRNAs containing IRES 
(Semler and waterman, 2008). Unlike other IRES that are found in the 5’UTR, the 
KSHV IRES is located in the coding sequence of the upstream cistron, vCyclin.  In 
2001, Bieleski and Talbot investigated whether the vFLIP protein could be expressed 
from the vCyclin/vFLIP bicistronic transcript. In order to do this, the investigators 
utilized a bicistronic luciferase reporter system. They cloned DNA fragments 
upstream of the initiation codon of vFLIP into a bicistronic luciferase reporter 
plasmid. The results showed the presence of IRES (with a minimum fragment of 233 
bp) within the coding sequence of vCyclin. 
Grundoff and Ganem (2001) also investigated the mechanism that drives the 
expression of KSHV vFLIP. They used SLK cells, BCBL-1 cells, and a CMV based 
promoter plasmid to explore this. A bicistronic reporter system was also used. The 
presence of an efficient IRES overlapping ORF 72 coding sequences was reported 
which led to the conclusion that IRES-mediated translational initiation primarily drives 
the expression of vFLIP during latency. Figure 1.14 shows the proposed locations of 
the vFLIP IRES. 
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Figure 1.14 Schematic representation of the vCyclin-vFLIP fragment. 
Higlighted are the proposed locations of the putative vFLIP IRES. 233, 232 and 
363 were previoulsly identified as the the minimal sequence for the KSHV vFLIP 
IRES. 252 is the proposed suffient IRES in the present study. 
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1.16. Relevance of RNA structures for IRES function 
IRES are organised into high order structures. In viruses, these structures differ 
between distant families but usually find conserved domains between the RNA 
structures of related viruses (Martinez-Salas et al., 2008). However, cellular IRESs 
do not share overall structure similarity. Studies to evaluate the functional and 
structural relationship of IRES elements have shown a close correlation between 
folding and IRES activity (Martinez-Salas and Fernadez-Miragall 2004). These 
correlations suggest that the RNA structure of IRES elements regulate the efficiency 
of IRES-mediated translation initiation.  
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1.17. Project aims 
It has been established that the expression of the KSHV vFLIP is directed by an 
IRES element which has been shown to be located within the KSHV vCyclin ORF 
(Bieleski and Talbot 2001). But its mechanism of action is yet to be understood. 
Therefore it is paramount to dissect the function of the vFLIP IRES in order to begin 
to comprehend its mechanism of action. This work follows on from a previous 
research by a Ph.D. student (Zulkefley Othman) who has carried out studies to 
ascertain the function of the vFLIP IRESin in vitro translation systems. With this in 
mind, the aims of this study are:  
(1) Investigate the function of the vFLIP IRES in cells 
(2) To determine the structure of the vFLIP IRES and ascertain elements required 
for its function. As well as identifying regions of the IRES significant for its 
functionality. A combination of chemical and enzymatic structure probing 
assays will be utilized.  
(3) To identify and characterise ITAFs that modulate vFLIP IRES function. In order 
to achieve this, RNA-protein binding studies with proteomic analysis will be 
used. 
Achieving these aims will lead to an increased knowledge on the mechanism by 
which the KSHV vFLIP expression is regulated during KSHV infection. Given the role 
of vFLIP in tumorigenesis, results from this study may also make possible defining 
new mechanisms by which KSHV-induced tumour formation can be inhibited. 
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Materials and Methods 
2.1. Transformation with competent E.coli DH5α  
A vial of frozen competent E. coli DH5α (prepared in house) were thawed on ice. The 
plasmid or the product of a ligation reaction (200 to 400 ng) was added to 50µl of 
competent cells, it was mixed, and kept on ice for 30 minutes. The cells were subject 
to a heat shock at 42°C for 45 seconds and then it was cooled on ice for 5 mins. 
200µl of 2xYT medium (Appendix I) was added to the cooled mixture and incubated 
at 37oC for 1 hr. At the end of the 1hr, the 250µl mixture was plated on to YT agar 
plates containing 50μg/ml ampicillin to select transformed cells.  
2.2. Plasmid DNA Minipreparation (QIAGEN KIT) 
A single bacterial colony from an agar plate was selected and used to inoculate 5ml 
of 2xYT medium containing 100μg/ml of ampicillin. The cells were cultured at 37˚C 
overnight in a shaking incubator (240rpm). The following day the cells were pelleted 
by centrifugation (5 minutes 16,000 rpm) and DNA was extracted from the pellet 
using a QIAprep spin miniprep kit (Qiagen) according to the manufacturer’s 
directives. 
2.3. Plasmid DNA Midipreparation (QIAGEN KIT) 
For this, a 5ml starter culture of 2xYT media with ampicillin was inoculated with a 
single colony and grown overnight at 37˚C in a shaking incubator (240rpm). 250ml of 
2xYT (containing 100μg/ml of ampicillin) was inoculated with 1ml of the starter 
culture and grown overnight at 37°C in a shaking incubator (240rpm). The cells were 
centrifuged (15 minutes 5000 rpm) and the resultant pellets were subject to a 
midiprep kit (Qiagen) according to the manufacturer’s directives. The recovered DNA 
was then precipitated using 2.5 volumes of 100% EtOH and 1/10th volume of 3M 
NaAC at room temperature for 30mins. The solution was centrifuged at 14000 rpm 
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for 15 mins and the pellet was washed with 70% EtOH and the centrifuged again. 
The supernatant was discarded the pellet was air dried and resuspended in 
appropriate volume of autoclaved distilled water. The DNA was quantified using a 
nanodrop (Nanodrop 2000, Thermo Scientific) at 260/280 nm and agarose gel 
electrophoresis. 
2.4  Agarose gel electrophoresis 
Agarose (0.8% or 1.2% w/v; Melford) was dissolved in a solution of 1 x Tris/Boric 
EDTA (TBE) using a microwave, resulting in a final concentration of 0.8-2.0% (w/v) 
depending on the size of fragments to be separated. SYBR safe DNA gel stain 
(Invitrogen) was added to a final concentration of 0.5μg/ml prior to pouring into a Mini 
Sub Gel GT Electrophoresis Tank (BioRad). DNA samples were mixed with 2 x 
loading buffer (PROMEGA) (at a ratio of 5:1) and loaded on the gel. The gel was run 
at 125V, for an adequate time to separate desired bands, in 1 x TBE. DNA bands 
were visualised with a UV light box. 
2.5. Gel extraction of DNA 
After electrophoresis of the DNA (section 2.4) the correct bands were excised. The 
QIAquick gel extraction kit (Qiagen) was used to extract DNA according to the 
manufacturer’s protocol. 
2.6. Cloning KSHV IRES into pRF vector 
The KSHV fragments used in this project were kindly provided by Professor David 
Blackbourn (University of Surrey). These fragments (252, 856 nt) corresponds to 
sequences upstream of the KSHV vFLIP gene, within the vCyclin gene. The 
bicistronic pRF construct was provided by Anne Willis (MRC Toxicology Unit, 
Leicester). 
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2.7. Blunt ending restriction digested DNA 
This was carried out as described in specific chapters (refere to chapter 3 for more 
details).  
2.8. Self-ligation of DNA fragments 
This was carried out as described in specific chapters (refere to chapter 3 for more 
details).  
2.9. Polymerase chain reaction (PCR) 
PCR reactions were carried out using GoTaq DNA Polymerase (PROMEGA). In 
sterile PCR tubes, the desired amount of template cDNA was mixed with 10μl of 5x 
GoTaq Reaction Buffer 1, 1μl of dNTPs (10mM), 1μl of forward primer (200ng/µl), 1μl 
of reverse primer (200ng/µl) and 0.5μl of GoTaq DNA Polymerase and made up to 
50 µl with sterile water. The tubes were spun (5 seconds) in a microcentrifuge and 
PCRs were performed as indicated in related chapters. 
2.10. Restriction enzyme digestion 
The plasmids used were digested using PROMEGA enzymes. The reactions were 
made up as 1ug of plasmid DNA, 1µl each of 10x buffer, 10x BSA and appropriate 
enzyme (10units/µl) with the volume made up to 20µl with sterilised water. The 
mixture was then incubated in 37oC heating block for 1hr. The DNA was then 
analysed by agarose gel electrophoresis to make sure it has digested. The digested 
DNA was then cleaned by chloroform extraction and precipitated by sodium acetate 
and ethanol. 
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2.11. In vitro production of RNA transcripts 
2.11.1. Production of uncapped RNA transcripts in vitro 
The reaction was assembled in a RNase- free microcentrifuge tube at room 
temperature.  In order to prepare the transcripts, 1 µg of linearised plasmid DNA and 
AMBION MEGAscript kit was used. The transcripts were prepared following the 
manufacturer’s instructions. An agarose gel was used to check the integrity of the 
RNA and the concentration of the RNA was measured using a Nanodrop (Nanodrop 
2000, Thermo Scientific). 
2.11.2. Production of Capped RNA transcripts 
1 µg of linear template was required for the reaction. The T7 mMESSAGE 
mMACHINE (AMBION) was used. The reaction was assembled and incubated 
according to the manufacturer’s instructions. 
2.12. Phenol/chloroform purification of RNA 
In order to purify the RNA from the transcription reactions, an equal volume of 
phenol:chloroform:Isoamyl alcohol (25:24:1 v/v, Sigma) was added to the reaction 
and the sample was briefly vortexed. The mixture was centrifuged for 2 mins at 
14000 rpm. The upper layer (aqueous phase) was then transferred to a fresh tube. 
An equal volume of chloroform was added to the aqueous solution. It was vortexed 
and centrifuged as before and the aqueous transferred to another tube. The RNA 
was then precipitated with equal volume of isopropanol at -20οC for 1 hr. The 
samples were then centrifuged at 14000 rpm for 15 mins at 4οC. The supernatant 
was discarded and the pellet was air dried. It was then resuspended in 20 µl of 
sterile nuclease-free water. The RNA was checked and quantified on agarose gel 
and the nanodrop (Nanodrop 2000, Thermo Scientific) respectively. 
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2.13. SDS-Polyacrylamide Gel electrophoresis (PAGE) 
SDS-polyacrylamide gels were cast using Mini-PROTEAN electrophoresis kit 
(BioRad, UK) and gels were prepared according to standard recipes (Table 2.1). The 
resolving part of the gel was prepared first depending on the SDS percentage 
needed. Subsequent to addition of the ammonium persulphate (APS) and TEMED, 
the solution was poured into glass plate sandwiches and allowed to polymerise. The 
stacking gel was then prepared (Table 2.6), poured on top of the resolving gel, and 
combs were inserted. Once the gel had polymerised, the combs were removed and 
the wells were washed with sterile distilled water. Mini gels were run for 2 h at 100 V 
and 0.2 A in 1X SDS running buffer. 10X Running buffer (30.0 g of Tris base, 144.0 g 
of glycine, and 10.0 g ofSDS) in 1000 ml of H2O and buffer was diluted to 1X before 
use. After the 2 h, the gel was rinsed 3 times in changes of sterilized water for 5 
mins. Then it was rocked for 1 hr at room temperature in Coomasie blue stain 
(Invitrogen SafeBlue stain), and destained in sterilized water.  
 
 
 
 
 
 
 
 
Chapter 2  materials and methods 
62 | P a g e  
 
 
Stock solution Source 10% w/v Acrylamide 
resolving gel (mls) 
Acrylamide 
stacking gel (mls) 
Distilled H2O   4.6 3.75 
1.5M Tris pH8.8 Lab made solution 10 - 
1.0M Tris pH6.8 Lab made solution - 5 
40% w/v Acryl/bis 
Acrylamide (37.5:1) 
SIGMA 5 1 
20% SDS Lab made solution 0.1 0.005 
10% APS SIGMA 0.2 0.1 
TEMED SIGMA 0.05 0.03 
 
2.14 Tissue culture methods 
All tissue culture work was carried out in laminar flow hoods under sterile conditions. 
Table 2.2 provides a list of media and supplements used for tissue culture methods. 
 
 
 
 
 
Table 2.1 Composition of the 10% SDS gels used in the study 
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  Source 
Foetal Bovine Serum (FBS)  
 
 Invitrogen 
Penicillin/Streptomycin (P/S) 
 
Invitrogen (15070063)  
 
Glutamine  
 
Invitrogen (25030123)  
 
Versene/Trypsin  
Non essential amino acids 
(NEAA)  
 
Invitrogen  
 
Dulbecco’s Modified Eagle’s 
Medium (DMEM)  
 
Invitrogen 
RPMI  
 
Invitrogen 
Trypan blue Sigma (T10282)  
 
Freezing media  
 
90% FCS, 10% Dimethyl 
sulfoxide (DMSO)  
 
 
2.14.1 Cell Lines 
Summary of the cell lines used throughout this project, including details of the media 
required for their growth and maintenance is shown in table 2.3. All cells lines were 
grown and maintained at 37°C in a humidified incubator supplied with 5% CO2. 
Adherent cells were passaged by removing the existing medium, washing the cells 
Table 2.2 Tissue culture media and supplements. 
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with phosphate buffered saline (PBS) and then adding trypsin/versene at 37°C to 
detach the cells. Appropriate culture medium was then added to inactivate the 
trypsin and the cells were pelleted by centrifugation (5 minutes, 300g). Pellets were 
resuspended in fresh media, plated at the required number and stored incubated. 
For suspension cells, cells were pelleted by centrifugation (5 minutes, 300g), washed 
in PBS and resuspended at the required concentration using fresh media. 
 
Cell line Type Source Origin Culture 
media 
BCBL-1 Supension PEL Human RPMI 
HEK293T Adherent Embryonic 
kidney  
 
Human DMEM 
SLK Adherent Kidney Human RPMI 
 
2.14.2. Cell counting 
Cell suspensions were diluted in Trypan blue solution at a 1:1 ratio and 10μl of this 
mixture was transferred to each chamber of a heamocytometer. The cells were 
counted using a light microscope. It was possible to distinguish between dead and 
live cells since dead cells take up trypan blue dye. 
2.14.3. Cryopreservation of cell lines  
 
To keep a permanent stock, cells were stored as frozen stocks in liquid nitrogen. 
Cells were pelleted through centrifugation (5 minutes, 300g), the supernatant was 
Table 2.3 Summary of cell lines used in this study 
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removed and the cell pellet was resuspended in 1ml of freezing medium and added 
to a sterile 1.5ml cryovial. These vials were placed in a cryopreservation box, which 
was placed in a -80oC freezer, allowing the cells to cool at 1oC per minute. This 
method prevents lysis of cells through the freezing of water molecules. Vials were 
transferred into liquid nitrogen for long term storage.  
2.14.4. Recovery of cryopreserved cells  
 
Stock culture cell lines stored in liquid nitrogen were thawed in a 37 oC water bath 
and washed in 10ml of appropriate complete media. The cells were then centrifuged 
(5 minutes, 300g) and the resultant pellet was resuspended in appropriate complete 
media before seeding in the normal way. 
2.14.5. Growth of BCBL-1 cells 
BCBL-1 cells were grown in Roswell Park Memorial Institute 1640 (RPMI1640; 
Gibco) containing 10% heat-activated foetal bovine serum (FBS) (Gibco), 100 U/ml 
penicillin (Gibco), 100 µg/ml streptomycin (Gibco) and 1% (v/v) Glutamine (Gibco). 
The cell lines were grown in a humidified incubator at 37 °C with 5% CO2. When the 
cells were 90% confluent, the cells with the medium were collected in a 20 ml 
universal and then centrifuged at 2,500 rpm for 2.5 mins. The supernatant was 
discarded and the pellet was resuspended in 6 ml of growth media. Of this 6 ml, 2 ml 
were used to seed a new 75 cm2 flask containing 15 ml fresh medium. The cells 
were then maintained as described above until the next passage was necessary.  
2.14.6. Growth of Sofia Levinton-Kriss (SLK) cells 
SLK cells, an immortalized but KSHV-negative spindle cell line derived from a 
classical Kaposi’s sarcoma tumor (from Dr. David Blackbourn, University of 
Birmingham, UK) were grown in Roswell Park Memorial Institute 1640 (RPMI1640; 
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Gibco) containing 10% heat-activated foetal bovine serum (FBS) (Gibco), 100 U/ml 
penicillin (Gibco), 100 µg/ml streptomycin (Gibco) and 1% (v/v) Glutamine (Gibco). 
The cell lines were grown in a humidified incubator at 37 °C with 5% CO2. The cells 
were maintained as described.  
2.14.7. Growth of HEK293 cells 
These cells are embryonic kidney cells and there were grown in 25 cm2 tissue 
culture flasks ( Nunc , Thermo Scientific) in DMEM including L-Glutamine (292 
mg/ml), supplemented with 10% foetal bovine serum (FBS, GibcoBRL) and 
penicillin/streptomycin (100 IU/ml, 50 µg/ml). Cells were maintained at 37oC with 5% 
carbon dioxide in a Galaxy S+ (RS Biotech) carbon dioxide incubator. When cells 
were 80- 90% confluent, the growth media was removed and the monolayer cells 
were washed with 5 ml of 1:10 (v/v) trypsin/versene. The cells were incubated with 5 
ml trypsin/versene for 2-5 min at 37oC until the cells detached from the bottom of the 
flask. Growth media was added and the cells were centrifuged at 2500 rpm for 3 min. 
The media was removed and the pellet was re-suspended in 5ml media and seeded 
into a 75 cm2 tissue culture flasks. 
2.15. Transfection of plasmid DNA into mammalian cells (Transient expression 
system) 
 2.15.1. Transfection into BCBL-1 cells 
BCBL-1 cells were seeded into 35 mm tissue culture dishes. Once the cells were 
80% confluent monolayer, 25 µl of vaccinia (vTF7-3) was added and incubated for 1 
h at 37 °C and 5% CO2. For each 35 mm dish, 7 µl Lipofectin reagent (Invitrogen) 
was mixed with 193 µl Optimem (GibcoBRL) and incubated at room temperature for 
15 mins. Plasmid DNA in CAT/IRES/LUC (2 µg) in 200 µl sterilised water was added 
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to the Lipofectin/Optimem mixture and incubated at RT for 20 mins. After the 1 hr, 
inoculum was removed from the cells and the cells were washed with 1 ml of 2% 
FBS medium. The DNA/Lipofectin/Optimem mix was added to the cells, which were 
incubated for 5 h at 37 °C. Growth medium was added to each dish and the cells 
incubated at 37 °C. The cells were harvested in 200 µl cell lysis buffer (PROMEGA) 
and spun at 14,000 rpm for 5 mins at 4 °C. CAT and LUC assays were then 
performed. 
2.15.2. Transfection into SLK cells  
SLK cells were seeded into 35 mm tissue culture dishes. Once the cells were 80% 
confluent, the growth medium was removed from the dishes and the cells were 
washed with 1 ml 2% FBS medium. Before this, 2 µg of plasmid DNA was diluted in 
100 µl of Optimem. 5 µl of FuGENE HD transfection reagent was then added to the 
plasmid DNA/optimem mix. This was mixed and left to incubate for 15 mins. 1 ml of 
2% FBS medium was added to the dishes. Subsequently, the transfection 
reagent:DNA complex was added to the dishes in a drop wise manner. The dishes 
were incubated at 37 °C for six hours after which 1 ml of 10 % FBS medium was 
added to the dishes. Then they were incubated for 24 hrs. Then the cells were 
harvested as described in section 2.4.1. 
2.15.3 Transfection into HEK293 cells 
HEK293 ells were transfected with FuGENE HD (PROMEGA) according to the 
manufacturer’s protocol. The cells were then seeded into 35mm tissue culture dish at 
2.5 x 105 cells per dish. 
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2.16. Assaying luciferase activity of IRES reporters 
The PROMEGA dual-luciferase reporter assay was used to assay luciferase activity 
in reporter plasmids. The dual luciferase reporter assay (DLA) system (PROMEGA) 
measures the activities of two distinct luciferase enzymes, firefly (Phontinus pyralis) 
and Renilla (Renilla reinformis), expressed from the same sample. The firefly 
luciferase signal is expressed by the promoter of interest and relates to the activity of 
that promoter. The constitutively active Renilla luciferase signal serves as internal 
control, to which the experimental reporter gene (firefly signal) is normalised. Cells 
were transfected (using FuGENE HD as described in section 2.15) with reporter 
plasmids containing the Renilla luciferase and the firefly luciferase gene plasmid. 
After a specific time, the cell medium was removed and the cells were washed gently 
with PBS. Cells were lysed using active Lysis Buffer (PROMEGA) by scrapping the 
cells into the buffer. Samples were frozen and thawed two times before assaying. To 
assay, 20μl of each sample was added to 100μl of Luciferase Assay Reagent II 
(LARII) this was mixed and the first measurement (firefly luciferase) was taken using 
a manual luminometer (Labtech). The second measurement was taken by adding 
100μl of Stop & Glo Reagent. The luminometer programme was set as: 2-second 
premeasurement delay, followed by a 10-second measurement period for both 
Renilla and firefly luciferase. Relative activity was calculated by normalising the 
firefly values to their Renilla measurements. 
2.17. Identifying RNA Interacting Partners Using RNA affinity chromatograghy 
Different variation of RNA affinity chromatograph, were used to investigate the 
proteins that may interact with the vFLIP IRES. Detailed protocol is described in 
related chapter. 
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2.18 Statistical Analyis 
The GraphPad Prism 6.0 software used to analyse all data. The standard error of 
mean (SEM) was calculated for every analysis made. One-way (Dunnett’s multiple 
comparison test) and two-way (Sidak’s multiple comparison test) ANOVA were used 
to determine significant difference between two mean. 
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3.1 Introduction to chapter 3 
The latent gene products are thought to be the major effectors of cell proliferation in 
infections by gammaherpesviruses. As a result, much attention has been focused on 
the KSHV latency program. One crucial cluster of KSHV latency maps to open 
reading frames (ORF) 71, 72 and 73 encoding vFLIP, vcyclin and LANA respectively 
(Grundhoff and Ganem, 2001).  
Analysis and examination of the transcription and splicing of ORFs 71, 72 and 73 
revealed that that the three genes encoded by these ORFs are transcribed from a 
common transcription site. The resulting transcript is spliced to yield a 5.32kb 
message which encodes LANA, vcyclin and vFLIP and a 1.7kb bicistronic message 
that encodes vcyclin and vFLIP (Dittmer et al.1998; Talbot et al. 1999). Since a 
monocistronc transcript coding for vFLIP only was not detected, this raised questions 
about how vFLIP would be expressed. Subsequently, several studies have revealed 
and are all in agreement that vFLIP is expressed via an IRES within the coding 
region of vCyclin (Bieleski and Talbot 2001; Grundhoff and Ganem 2001; Low et al. 
2001, Othman et al. 2014). However, there have been inconsistencies concerning 
the sufficient IRES sequence required for IRES activity. Grundhoff and Ganem 
(2001) used a bicistronic luciferase reporter construct in SLK cells to identify a 
sufficient IRES within the 233-nt located upstream of ORF71. In other reports, it was 
suggested that the IRES activity was within an internal 363-nt fragment (Bieleski and 
Talbot 2001) while Low et al.  (2001) identified 232-nt as the sufficient IRES 
sequence. 
In order to begin to understand how the vFLIP IRES functions, it is crucial to initially 
identify the location of the IRES. Therefore, present study sets out to identify the 
sufficient sequrence required for the vFLIP IRES activity. 
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3.2 Chapter aims 
In order to reconciliate previous studies, our group has previously identified a 
sufficient domain of 252-nt as the sufficient sequence required for IRES activity in 
the in vitro RRL model system (Figure 3.1) (Othman et al. 2014).  
Therefore, this chapter will focus on analysing this identified sufficient domain in the 
in cellulo system. The aim of this chapter include: 
 Test the activity of the sufficient vFLIP IRES (252-nt) sequence in SLK and 
HEK293 cells. 
 Identify eukaryotic initiation factors required for the vFLIP IRES activity by 
using chemical inhibitors of translation. 
 
 
 
 
 
 
 
Figure 3.1: Previously identified sufficient sequence required for IRES activity 
In vitro transcribed capped bicistronic mRNAs (vCyclin-vFLIP mRNA cloned 
between the CAT and LUC ORFs) were translated in RRL containing 35S 
Methionine. The CAT and LUC products are specified (Othman et al. 2014). 
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3.3 Materials and Methods 
3.3.1 Cell lines 
3.3.1.1 SLK cells 
SLK cells, an immortalized but KSHV-negative spindle cell line derived from a 
classical Kaposi’s sarcoma tumor (obtained from Prof. David Blackbourn, University 
of Surrey, UK) were grown and maintained as described in section 2.14.6. 
3.3.1.2 Human embryonic kidney 293 cells (HEK293)  
These cells are embryonic kidney cells and there were grown in 25 cm2 tissue 
culture flasks as described in section 2.14.7. 
3.3.2 Construction of plasmids 
3.3.2.1 Bicistronic plasmid 
The bicistronic plasmid was previously constructed by the Locker group. Briefly, to 
generate the bicistronic constructs, fragments encoding the different IRES 
sequences were amplified by PCR from a genomic fragment corresponding to the 
second exon of the bicistronic ORF72/71 mRNA (Genbank U75698). The c-myc 
IRES was kindly provided by Prof Anne E. Willis (MRC Toxicology Unit, University of 
Leicester) and the IRES sequence from encephalomyocarditis (EMCV, nucleotides 
406–930) and hepatitis C virus (HCV; nucleotides 1–426) were described previously 
(Easton et al. 2009). The IRES fragments were cloned into the pGL3-rLUC/fLUC 
plasmid described which encode Renilla luciferase (rLUC) and firefly luciferase 
(fLUC) under the control of an SV40 promoter. 
3.3.2.2 Monocistronic plasmid 
A monocistronic plasmid was generated based on the bicistronic plasmid. The rLUC 
gene was excised by digesting bicistronic constructs 252/pRF, cMyc/pRF and pRF 
vector with EcoRV and Spe I in a 100 μl reaction. The resulting product was checked 
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on 1.2% agarose gel to ensure that they cut. The products were phenol/chloroform 
extracted, precipitated with sodium acetate and ethanol and dried as described in 
section 12.12. The pellets were then re-suspended in 25 μl of H2O. The re-
suspended products were blunt-ended using T4 DNA polymerase and the reaction 
was set up according to table 3.1. 
 
 
3 μl 10x T4 DNA polymerase buffer 
1 μl 5mM dNTP mix 
0.5 μl 10mg/ml BSA 
1 μl T4 DNA polymerase 
Mix and incubate at 37◦C for 30 min 
 
At the end of the 30 min, the products were loaded on agarose gel and the vector 
size band for each was extracted and DNA was recovered using the QIAquick gel 
extraction kit according to manufacturers’ instructions. 
The recovered DNA was self-ligated. The self-ligation reaction was assembled 
according to table 3.2. 
 
 
Table 3.1 Assembly of blunt ending reaction using T4 DNA polymerase 
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20 ng vector DNA 
2 μl 10x DNA ligase buffer 
2 μl PEG 
1 μl DNA ligase enzyme 
H2O to 20 μl 
Mix gently and incubate at 14 to 18◦Covernight 
 
4 μl of ligation mix was transformed into competent E.coli DH5α as described in 
section 2.1 and DNA minipreparation was prepare as described in section 2.1. The 
DNA minipreps were then sent for sequencing (Eurofins MWG Operon). 
 
A B 
Figure 3.2 Schematic representation of plasmids (A) shows the bicistronic  plamid and 
(B) shows the monocistronic plasmid generated from (A) as described in materials and 
methods. 
Table 3.2 Assembly of self-ligation reaction  
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3.3.3 Transfection of plasmid DNA into mammalian cells 
3.3.3.1 Transfection into SLK and HEK cells  
The SLK and HEK cells were transfected as previously described in sections 2.15.2 
and 2.15.3 respectively.  
3.3.3.2 Assaying luciferase activity of IRES reporters 
The PROMEGA dual-luciferase reporter assay was used. The assay was carried out 
according to the manufacturers’ instructions as described is section 2.16. 
3.3.4 Cell viability assay 
In order to determine the number of viable cells in culture and determine the 
concentration of inhibitor to use, the PROMEGA CellTiter-Glo® Luminescent assay 
was used according to manufacturers’ manual.  
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3.4 Results 
3.4.1 Analysing 252-nt sufficient IRES domain in cells 
3.4.1.1 Analysis of bicistronic construct 
As highlighted in the introduction (section 3.1), previous studies have identified 
different location for the  IRES element responsible for vFLIP expression in different 
cell lines, while our results identified a 252-nt sequence responsible for vFLIP 
expression in the in vitro RRL system. In order to further confirm this data, this 
chapter aimed to analyse the identified 252-nt sufficient domain in cells using SLK 
and HEK293 cells. To this end, 252-nt vFLIP (pRF 252), EMCV (pRF EMCV) and c-
myc (pRF cmyc) IRESs were inserted in the intergenic region of a bicistronic pGL3 
plasmid between the renilla luciferase (rLUC) and firefly luciferase (fLUC) open 
reading frames. In this plasmid the downstream cistron (fLUC) would usually be 
translated inefficiently by ribosomes, which have completed translation of the 
upstream cistron (rLUC). However, if an IRES sequence is inserted before the 
downstream ORF, its translation is promoted. This system gives the benefit that both 
reporter enzymes can be assayed in the same cell lysate preparation, In addition, 
the upstream reporter (Renilla luciferase) acts as an internal control to account for 
differences in transfection efficiency. The activities of Renilla and firefly luciferases 
were assayed using the dual luciferase system as described in section 2.16. 
The Renilla luciferase and firefly luciferase activities were measured in cell lysates 
28 h post-transfection. The ratio of fLUC activity to rLUC activity was calculated and 
used as a measure of IRES function. The IRES elements from EMCV (pRF EMCV) 
and c-myc (pRF cmyc) served as positive controls and the F:R ratio generated by 
the parental (IRES-negative) vector was set to 1.0. 
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In SLK cells, which support KSHV replication, but do not represent a model for KS 
(Herndier and Ganem 2001; Sturzl et al. 2013), the well characterized EMCV IRES 
activity could not detected above background. However, the positive control pRF-c-
myc IRES and the pRF-252 both displayed efficient internal initiation of translation, 
with a 33.3 and 35.8 fold increase in relative IRES activity respectively (Figure 3.3). 
On the other hand, in the HEK293 cells, the well characterized EMCV IRES was 
significantly above background but was less efficient translated than the cellular c-
myc IRES (5.4 vs 28.4 fold increase in IRES activity). The 252-nt vFLIP IRES was 
able to efficiently direct internal translation initiation with 10.4 fold increase in relative 
IRES activity (Figure 3.4). These data therefore support that the 252 nt IRES 
element directly upstream of ORF71 IRES element drive translation in vitro, but also 
in cellulo in both HEK293 and SLK cells. 
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Figure 3.3 Assay of IRES activity in SLK cells  
SLK cells were transfected with bicistronic reporter plasmids as indicated. Rluc and 
Fluc activities were measured as described in Material and Methods. The relative 
Fluc/Rluc ratio was set to 1 for the empty pRF plasmid as relative IRES activity. 
Values are the mean ± SEM from three independent experiments and were analyzed 
by one-way ANOVA with Dunnett's multiple comparison test: (*) P < 0.05, (**) P < 
0.01, (***) P < 0.001, and (****) P < 0.0001 (GraphPad Prism 6.0). 
* *
* * *
n s
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Figure 3.4 Assay of IRES activity in HEK293 cells 
 HEK293 cells were transfected with bicistronic reporter plasmids as indicated. Rluc and Fluc 
activities were measured as described in Material and Methods. The relative Fluc/Rluc ratio 
was set to 1 for the empty pRF plasmid as relative IRES activity. Values are the mean ± SEM 
from three independent experiments and were analyzed by one-way ANOVA with Dunnett's 
multiple comparison test: (*) P < 0.05, (**) P < 0.01, (***) P < 0.001, and (****) P < 0.0001 
(GraphPad Prism 6.0). 
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3.4.1.2 Analysis of monocistronic constructs 
In order to further support the data in section 3.3.1.1, the rLUC gene was excised 
from the biscistronic construct as described in materials and methods so as to 
generate a monocistronic plasmid that contains the 252-nt fragment and the fLUC 
gene under the control of a SV40 promoter. Monocistronic plasmids containing the c-
myc and EMCV IRES with the fLUC gene and SV40 promoter were also generated. 
The mononcistronic plasmids were transfected into HEK293 cells as described 
previously and IRES activity for each plasmid was analysed. This was aimed at 
designing a further positive control to confirm that the upstream cistron rLUC in the 
bicistronic plasmid was not responsible for driving the expression of the downstream 
cistron fLUC observed in the bicistronic plasmid. The positive controls c-myc and 
EMCV IRES efficiently expressed IRES activity but to a lesser extent with the well 
characterized EMCV IRES (1334 vs 4622 fold increase in IRES activity). The 252-nt 
fragment showed a significant IRES activity compared to the fLUC control plasmid. 
Therefore, we conclude that the expression of the downstream fLUC gene is driven 
by an IRES. 
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Figure 3.5 Assay of monocistronic reporter IRES activity  
 HEK293 cells were transfected with monocistronic reporter plasmids as described. 
Fluc activities were measured as described in Material and Methods. Values are the 
mean ± SEM from three independent experiments and were analyzed by one-way 
ANOVA with Dunnett's multiple comparison test: (*) P < 0.05, (**) P < 0.01, (***) P < 
0.001, and (****) P < 0.0001 (GraphPad Prism 6.0). 
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3.4.2 vFLIP IRES requirement for eukaryotic initiation factors 
Viral IRESs utilize diverse molecular mechanisms for function and have diverse 
requirements for canonical initiation factors (Hundsdoerfer et al. 2005). In 
encephalomyocarditis virus (EMCV) IRES-mediated translation, an interaction of 
eIF4G and eIF4A with the IRES is required to recruit 40S ribosomes to the IRES (De 
Breyne et al. 2009). This is also the case for FMDV IRES as it has been shown that 
eIF4A, eIF4G, eIF2 and eIF3 are necessary for 48S complex formation in vitro. In 
contrast, the HCV IRES depends on the ternary eIF2/GTP/initiation tRNA complex 
and on eIF3 for 48S complex formation, but does not require any eIF4 family 
members (Hellen and Sarnow 2001). The cricket paralysis virus (CrPV) IRES on the 
other hand can assemble 80S ribosomes without any eIFs (Wilson et al. 2000). In 
order to further define the vFLIP IRES functionality, it is essential to assess its 
requirement eukaryotic initiation factors. To this end, the vFLIP IRES requirement for 
eIF4A and the eIF4E:eIF4G was analysed using small inhibitors in HEK293.  
The requirement for eIF4A was analysed by using a well recognised inhibitor of 
eIF4A, hippuristanol. Hippuristanol is a polyoxygenated steroid, isolated from the 
seacoral Isis huppuri (Higa et al. 1981). It inhibits the RNA-binding, RNA-dependent 
ATPase and RNA helicase activities of both free and eIF4G bound forms of eIF4A 
(Bordeleau et al. 2006). The requirement for eIF4E/eIF4G interaction was analysed 
by suing an inhibitor known as 4ERCat. 4E2RCat is a compound that blocks cap-
dependent translation in vitro and in cells and it was identified using a high–
throughput screening as a eIF4E/eIF4G inhibitor (Cencic et al. 2011).  
In order to analyse the requirement of these eIFs by the vFLIP IRES, we ascertained 
that hippuristanol and 4E2RCat did not affect the viability of the HEK293 cells at the 
concentrations used in the experiments, 1 µM for hippuristanol and 20 µM for 
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4E2RCat. The inhibitors did not have adverse effect on the HEK293 cell viability at 
the concentrations used in the study (Figure 3.6). 
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Figure 3.6 Cell viability assay in HEK293 cells (A) in the presence of 
hippuristanol an inhibitor of eIF4A activity (B) in the presence of 4E2RCat an 
inhibitor of eIF4E/eIF4G interaction. The viability was determined using CellTiter-
Glo® luminescent cell viability assay (Promega). Viabilty is expressed as 
percentage of the DMSO control set to 100%. Results show the means ± SEM 
from three independent experiments.  
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3.4.2.1 vFLIP IRES requirement for eukaryotic initiation factor 4A (eIF4A) 
Eukaryotic initiation factor 4A (eIF4A) is a component of the eIF4F family. It is an 
ATP-dependent RNA helicase that is considered to unwind duplex content in the 5’ 
untranslated region (5’UTR) of the mRNA (Lin et al. 2008)/ 
The requirement of vFLIP IRES for eIF4A was investigated in HEK293 cells using 
bicistronic plasmid DNAs which included pRF-252, pRF-cmyc, pRF-EMCV and pRF-
HCV. The HCV and EMCV IRES served as controls. Previous studies have shown 
that the HCV IRES is not dependent eIF4A and the EMCV IRES requires it for its 
activity. The bicistronic plasmids were transfected into HEK 293 cells as described in 
section 3.3.3.2. Transfected cells were treated with or without 1μM of hippuristanol 
for 10 hrs. Cell lysates were assayed using PROMEGA dual-luciferase reporter 
assay (section 3.3.3.3). 
In order to evaluate the effect of hippuristanol on the expression rLUC, non-
normalised data for rLUC and fLUC activitity (Figure 3.7). As expected, the 
hippuristanol significantly reduced the expression of rLUC (P value < 0.0001) in all 
the plasmids (Figure 3.7A). The expression of rLUC which depicts the cap-
dependent translation initiation requires the activity of eIF4A, which this data re-
affirms.   
The IRES activities (luciferase ratio) were represented as fLUC/rLUC ratio 
normalised to pRF by setting pRF to 1 (Figure 3.8). As expected, HCV IRES activity 
was not impaired by the addition of hippuristanol as the HCV IRES does not require 
eIF4A. The IRES activity of the EMCV significantly declined when treated with 
hippuristanolcompared with the untreated by (52.6 vs 7.8). This supports that the 
EMCV IRES requires the eIF4A. The cellular c-myc IRES control was also sensitive 
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to the treatment of hippuristanol with when compared with the untreated (108.5 vs 
20.5). Treatment with hippuristanol caused the vFLIP IRES activity to significantly (P 
value <0.0001) reduce when compared to the untreated cells (95.5 vs 15). 
Therefore, these data suggest that optimal vFLIP IRES activity in HEK293 cells has 
a functional requirement for eIF4A. 
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Figure 3.7 rLUC and fLUC expression with or without hippuristanol 
HEK293 cells were transfected with bicistronic reporter plasmids and treated with or without 
hippuristanol as indicated. RLUC and FLUC were measured as described in material and methods. 
(A)Non-normalised data for rLUC expression and (B) Non-normalised data for fLUC expression. 
Values are the mean ± SEM from three independent experiments and were analysed by two-way 
ANOVA with Sidak's multiple comparison test: (****) P < 0.0001 (GraphPad Prism 6.0). 
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Figure 3.8 Assay of IRES activity with or without hippuristanol 
HEK293 cells were transfected with bicistronic reporter plasmids and treated with or without 
hippuristanol as indicated. RLUC and FLUC were measured as described in material and methods. 
IRES activity are represented as fLUC/rLUC ratio normalised to pRF by setting pRF value to 1. 
Values are the mean ± SEM from three independent experiments and were analysed by two-way 
ANOVA with Sidak's multiple comparison test: (****) P < 0.0001, ns- no significant difference 
(GraphPad Prism 6.0). 
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3.4.2.2 vFLIP IRES requirement for eIF4E/eIF4G interaction 
Eukaryotic initiation factor 4E (eIF4E) is involved in the mRNA-binding step in 
capped translation while eIF4G is an essential scaffold for the eIF4F complex and 
facilitates in the recruiting the 40S ribosomal subunit to the mRNA. The protein-
protein interaction between eIF4E and eIF4G is crucial for the formation of the 
trimeric eIF4F complex consisting of eIF4E, eIF4G and eIF4A (Papadopoulos et al. 
2014). 
In order to investigate the vFLIP IRES requirement for the eIF4E/eIF4G interaction, 
bicistronic plasmids were transfected in HEK293 cells as described previously. A 
concentration of 20μM of the 4E2RCat inhibitor was used to treat transfected 
HEK293 cells for 10 hrs and the cells were harvested and assayed using dual-
luciferase assay reporter (PROMEGA). The IRESs of EMCV and HCV do not require 
the eIF4E/eIF4G interaction to function and therefore were used as controls. The 
cellular c-myc IRES was also included as a control. 
The effect of 4E2Rcat on the expression rLUC and fLUC was evaluated by plotting 
the non-normalised data for rLUC and fLUC activitity (Figure 3.9). As expected, the 
4E2Rcat reduced the expression of rLUC in all the plasmids with varying significance 
(Figure 3.9A). The expression of rLUC which depicts the cap-dependent translation 
initiation requires the eIF4E/4G interaction, which this data re-confirms.   
 The IRES activities (luciferase ratio) were represented as fLUC/rLUC ratio 
normalised to pRF by setting pRF to 1 (Figure 3.10). Addition of 4E2RCat did not 
impair translation mediated by the EMCV IRES as it does not require the eIF4E–
eIF4G interaction. In addition, 4E2RCat had no effect on translation driven by the 
HCV IRES, which does not require either the eIF4E or eIF4G for activity. 
Surprisingly, the c-myc IRES activity was significantly impaired with the addition of 
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the inhibitor. The c-myc IRES has been shown not to require the eIF4E/eIF4G 
interaction for its activity. The results showed that the vFLIP IRES activity was 
significantly (P value <0.0001) impaired by the addition of 4E2RCat. Its activity 
reduced when compared to the untreated cells (84 vs 15). Therefore, these results 
imply that the vFLIP IRES activity is susceptible to inhibition of the eIF4G–eIF4E 
interaction and the IRES activity may require the presence of eIF4G and eIF4E, 
which is atypical of an IRES. 
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Figure 3.9 rLUC and fLUC expression with or without 4E2Rcat 
HEK293 cells were transfected with bicistronic reporter plasmids and treated with or without 
4E2Rcat as indicated. RLUC and FLUC were measured as described in material and methods. 
(A)Non-normalised data for rLUC expression and (B) Non-normalised data for fLUC expression. 
Values are the mean ± SEM from three independent experiments and were analysed by two-way 
ANOVA with Sidak's multiple comparison test: (****) P < 0.0001 (GraphPad Prism 6.0). 
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Figure 3.10 Assay of IRES activity with or without 4E2Rcat 
HEK293 cells were transfected with bicistronic reporter plasmids and treated with or without 
4E2Rcat as indicated. RLUC and FLUC were measured as described in material and methods. 
IRES activity are represented as fLUC/rLUC ratio normalised to pRF by setting pRF value to 1. 
Values are the mean ± SEM from three independent experiments and were analysed by two-way 
ANOVA with Sidak's multiple comparison test: (****) P < 0.0001 (GraphPad Prism 6.0). 
**** **** n s
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3.5 Discussion 
Analysis of KSHV gene expression revealed a cluster of latently expressed 
transcripts that encode LANA (ORF 73), vCyclin (ORF 72), and vFLIP (ORF 71). The 
vCyclin and vFLIP coding sequences are present on a bicistronic transcript and a 
monocistronic transcript coding for for vFLIP alone was never detected (Bieleski and 
Talbot 2001; Kellam et al. 1997; Talbot et al. 1999). As a result, efforts were made to 
assess how the vFLIP IRES is expressed. Eventually, an IRES element was 
identified within the vCyclin coding sequence that has the potential to direct the 
translation of vFLIP from this bicistronic transcript (Bieleski and Talbot 2001). It is 
evident that vFLIP is expressed via an IRES within the coding region of vcyclin 
(Bieleski and Talbot 2001; Grundhoff and Ganem 2001; Low et al. 2001, Othman et 
al. 2014). However, the question of where the bonafide IRES is located remains 
elusive. In order to address this question, the Locker group previously identified a 
sufficient 252-nt vFLIP IRES in vitro using a translation assay in RRL (Othman et al. 
2014). Therefore, the in cellulo experiments using SLK and HEK293 cells in this 
chapter was based on the previously identified 252-nt. To this end, 252-nt vFLIP 
(pRF 252), EMCV (pRF EMCV) and c-myc (pRF cmyc) IRESs were inserted in the 
intergenic region of a bicistronic pGL3 plasmid between the renilla luciferase (rLUC) 
and firefly luciferase (fLUC) open reading frames. The ratio of fLUC activity to rLUC 
activity was calculated and used as a measure of IRES function. The 252-nt vFLIP 
IRES was tested in SLK cells and HEK293 cells. The vFLIP IRES was efficiently 
expressed in both cells but it was better expressed in the HEK293 cells. This result 
supports the suggestion by Othman et al. (2014) that the 252-nt is the sufficient 
sequence required for the vFLIP IRES activity. This is in contrast to previous reports. 
Grundhoff and Ganem (2001) used a bicistronic luciferase reporter construct in SLK 
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cells and identified a sufficient IRES within the 232-nt located upstream of ORF71. 
Bieleski and Talbot (2001) on the other hand showed that a minimum fragment of 
233-nt within the coding region of vCyclin was found to direct efficient expression of 
the downstream cistron (firefly luciferase) in BCP-1 cells. The present result also 
contradicts the Low et al. (2001) report identified 363-nt as the sufficient IRES 
sequence. This identified minimum 252-nt was subsequently used for further 
experiments. 
Viral IRESs utilize diverse molecular mechanisms for function and have diverse 
requirements for canonical initiation factors (Hundsdoerfer et al. 2005). In order to 
characterize its mode of action, the requirement for eukaryotic initiation factors for 
the vFLIP IRES activity was dissected using specific inhibitors of translation. The 
vFLIP IRES requirement for eIF4A and the eIF4E:eIF4G was analysed in HEK293 
cells using inhibitors hippuristanol and 4E2RCat to inhibit the activities of eIF4A and 
the eIF4E/eIF4G interaction respectively. The results showed that the vFLIP IRES 
activity was significantly impaired with the treatment of hippuristanol and this data 
suggests a functional requirement for eIF4A. In addition, the inhibition of the 
eIF4E/eIF4G activity revealed that the vFLIP IRES requires this interaction for 
efficient functioning of its activity. The functional requirement for eIF4A, is typical of 
type I and type II IRESs, such as PV or EMCV IRESs respectively. It was shown that 
EMCV was not able to efficiently drive translation with the inhibition of eIF4A 
activities. It was shown that the association of eIF4A with eIF4GI increases the 
affinity of this latter factor for the EMCV IRES, and induces conformational 
rearrangements of the RNA (Kolupaeva et al. 2003; Lomakin et al. 2000). A 
requirement for the eIF4A was strongly suggested for the poliovirus IRES by the 
strong inhibition of the IRES by the dominant-negative form of eIF4A (Pause et al. 
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1994). Lentiviral gag IRESs require eIF4A activity as well and form initiation 
complexes that comprises eIF4A and eIF4G, but do not interact directly with eIF4G, 
nor require the eIF4G–eIF4E interaction (Chamond et al. 2010; Locker et al. 2011). Our 
group further assessed whether eIF4E played a role in vFLIP IRES-mediated 
translation using cap analog to inactivate eIF4E, and showed impairment to the 
vFLIP IRES activity (Othman et al. 2014). Othman et al. (2014) further analyzed the 
association of the core initiation factors eIF4G and eIF4E with either isolated vFLIP 
IRES or within initiation complexes. It was found that eIF4G can associate with the 
vFLIP IRES but also that eIF4E interacts with the vFLIP IRES during translation 
initiation, which is unprecedented for an IRES as far as we know. 
Overall, these results suggest that not only eIF4G and eIF4A, but also eIF4E are 
required for vFLIP IRES activity. These results suggest that viral IRES may exhibit a 
broader functional requirement than those used to define the four groups of IRES 
elements. In addition, to understand the role that each eIFs plays and their 
interaction with the viral mRNA, a better understanding of the RNA structure of the 
vFLIP IRES is required. This will be the focus of the next chapter.  
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4.1 Introduction to chapter 4 
Internal ribosome entry site (IRES) elements are specialized RNA regulatory 
sequences mediating cap-dependent translation as previously discussed in section 
1.13. The majority of viral IRES elements are composed of structured RNA domains 
that play vital roles in IRES function by interacting with eIFs or the ribosome to 
coordinate the assembly of ribosomal complexes. 
Several studies have demonstrated the importance of studying these structured RNA 
domains in order to decipher how IRES elements regulate initiation of translation. 
Computer prediction studies combined with mutational analysis of picornavirus RNAs 
have shown the presence of several stem loops organized in stable structural 
domains all along the 5’UTR (reviewed in Helen and Sarnow 2001). The type II 
IRESs of encephalomyocarditis (EMCV) and foot-and-mouth disease virus (FMDV) 
have been shown to contain five major domains H-L (Yu et al. 2011). The ability of 
these IRESs to initiate translation has been reported to be dependent on the binding 
of eIF4G/4A to the J-K domain of their IRES (Lomakin et al. 2000). In addition, the 
deletion or mutation of elements at the apex of domain I in EMCV IRES has been 
reported to abolish the activity of the IRES (Kolupaeva et al. 1998). Therefore, 
understanding how viruses organize their RNA domains can help understand their 
function. 
There was limited information known about the KSHV vFLIP IRES secondary 
structure as at the start of this thesis, and experimental data to probe the RNA 
structure of the vFLIP IRES was lacking. In 2001, Bieleski and Talbot presented an 
RNA secondary model (Figure 4.1) within the 233 nt of the vcyclin coding region. 
However, the predicted structure has not been experimentally validated. Therefore, 
further studies to probe the RNA secondary structure chemically and enzymatically 
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are required and most importantly validating the predicted structure in order to 
confirm that the structure is authentic is also essential. 
 
 
 
 
 
Figure 4.1 Predicted vFLIP IRES secondary structure. The model is based on 
the 233-nt sequence identified as the minimum sequence by Bieleski and Talbot 
(taken from Bieleski and Talbot 2001). 
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4.2 Chapter aims  
The KSHV vFLIP IRES potentially represent a new group of IRESs as the element is 
found within the coding sequence of the vCyclin, unlike most known viral IRESs that 
are found in the 5’ UTR. Therefore, in order to characterize the vFLIP IRES, a better 
understanding of the structures accessible to its RNA is required. The previously 
defined sufficient IRES (Chapter 3) will be the focus of the structural and mutational 
analysis of the vFLIP IRES. 
Our approach includes the following steps:  
 Determination of the secondary structure model with experiments using 
chemical and ezymatic probes with different specificities building on 
preliminary data collected by a previous PhD student Z.Othman. 
 Prediction of likely secondary structures of the vFLIP IRES based on primary 
sequence, using RNA prediction software. 
 Mutating specific domains of the predicted structure to validate it and 
decipher which region of the structure are important for the IRES-mediated 
translation. 
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4.3 MATERIALS AND METHODS  
4.3.1 Plasmid construct 
DNA plasmid encoding the vFLIP IRES was cloned previously by the Locker group 
(Othman et al. 2014). Briefly, the 252-nt fragment upstream of the vFLIP gene was 
inserted in the intercistronic region of the pGEM-CAT/LUC vector, between the 
genes encoding chloramphenicol acetyltransferase (CAT) and firefly luciferase 
(fLUC), using the BamHI cloning site. This plasmid uses a T7 promoter to express 
dicistronic mRNAs encoding CAT and fLUC (Figure 4.2). 
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4.3.2 Transcription 
The plasmid was linearised with the enzyme xho I in a 100 μl reaction as described 
in section 2.10. The linearised plasmid was transcribed in vivo to generate capped 
RNA using the T7 mMessage mMachine kit as described in section 2.11.1. 
4.3.3 Modification of RNA 
The various roles of RNA is dependent on its capability to fold back on itself to form 
biologically functional structures (Weeks 2010). These structures can be structurally 
interrogated by using chemical and enzymatic mapping experiments. The principle of 
RNA modification is based on the theory that specific atomic positions on each base 
are reactive to certain chemical probes. Therefore, subjecting the RNA to base-
specific chemicals combined with primer extension can reveal nucleotides that are 
involved in base pairing or tertiary interactions (Xu and Culver 2009). 
The vFLIP IRES RNA structure was mapped in vitro by using nucleobase-specific 
probes 1-cyclohexyl-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate 
(CMCT), dimethyl sulfate (DMS) and RNAse V1. Selective 2’hydroxl acylation 
analysed by extension (SHAPE) analysis was also used by our collaborators at 
France at the Université Paris Descartes. The modifications were carried out as 
outlined below. 
4.3.3.1 Modification of RNA with CMCT 
1-cyclohexyl-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate (CMCT) is 
a chemical  known to modify the exposed bases of nucleotides uracil and guanine. It 
primarily reacts with N3 of uracil and to a lesser extent N1 of guanines. Chemical 
modifications with CMCT were carried out with 1 μl, 2 μl, and 5 μl of CMCT (40 mg 
ml−1) in 5X buffer (250 mM Borate-NaOH pH 8.0 mM EDTA) at 20 °C for 20 mins. 
The reaction was stopped and precipated by adding 20 μl of 0.3M ammonium 
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acetate and 200 μl of 100% ethanol and put on dry ice for 20 mins. Samples were 
phenol/chloroform extracted as described in section 12.12. Resultant pellets were 
vaccum dried and resuspended in 8 μl of H2O. Table 4.1 depicts the assembly of the 
reaction and process of reaction. 
 
 
 
Tube  A  B  C  D  
KSHV 252 RNA  1μM (μl) 2  2  2  2  
H2O  (μl)  13 12 11 8 
5x CMCT buffer (Appendix I) (μl)  4 4 4 4 
Incubated for 10 min at 20 ˚C 
tRNA  (2mg/ml) (μl)  1  1  1  1  
CMCT (40 mg/ml) (μl)  -  1  2  5  
Total (μl)  20  20  20  20  
Incubated for 20 min at 20 ˚C 
 
 
 
 
 
 
 
 
 
Table 4.1 Assembly and process of the CMCT RNA modification reaction.  
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4.3.3.2 Modification of RNA with DMS 
Dimethyl sulphate (DMS), a methylating agent, reacts with unpaired adenine and 
cytosine residues. It methylates the N1 of adenine and N3 of cytosine, and to a 
lesser extent N7 of guanosine (Behm-Ansmant et al. 2011; Tijerina et al 2007). 10μl 
of 7.9 M DMS dissolved in 10μl 100% Ethanol, in 2X DMS buffer (see Appendix I 
for recipe), for 1min, 5mins and 10mins at 20oC. Reactions were stopped using 3μl 
3M ammonium acetate. Modified RNA was recovered by ethanol precipitation and 
the resulting pellet re-suspended in 8 μl milliQ water. The reaction was assembled 
and carried out as depicted in table 4.2. 
4.3.3.3 Hydrolysis of RNA with RNase V1 
RNase V1, a ribonuclease enzyme, cleaves double stranded RNAs in a non-specific 
manner (Nilsen 2013). Enzymatic digestions with RNase V1 (0.1 U/μl) diluted in a 
1:10 ratio with 1X DMS buffer (Appendix I) was used as 0.5 μl, 1 μl and 2 μl of 
RNase V1. The reactions were stopped by precipitation with 40 μl of 0.3 M sodium 
acetate and 100 μl of absolute ethanol at -80°C for 30 mins. Samples were re-
suspended in 40 μl of 0.3 M sodium acetate, extracted with phenol and precipitated 
with ethanol, washed with 70% (v/v) ethanol and vacuum dried. Pellets were re-
suspended in 8 μl milliQ water and stored at-80oC. Assembly and process of reaction 
is depicted in table 4.3. 
 
 
 
 
 
 
Chapter 4                        Structural and mutational analysis of vFLIP IRES 
103 | P a g e  
 
Tube  A  B  C  D  
KSHV 252 RNA  1μM (μl)  2  2  2  2  
H2O  (μl)  7  6  6  6  
2x DMS buffer (μl)  10  10  10  10  
Incubated for 10 min at 20 ˚C 
tRNA  (2mg/ml) (μl)  1  1  1  1  
DMS (7.95 M) (μl) -  1  1  1  
Incubation time with DMS 
(mins) 
-  1  5  10  
 
 
 
Tube  A  B  C  D  
KSHV 252 RNA  1μM (μl) 2  2  2  2  
H2O  (μl)  7  6.5  6  4.5  
2x DMS buffer (μl)  10  10  10  10  
Incubated for 10 mins at 20 ˚C 
tRNA  (2mg/ml) (μl)  1  1  1  1  
RNase V1 (0.02 U/μl) (μl)  -  0.5  1  2.5  
Incubated for  5 mins at 20 ˚C 
 
 
 
 
Table 4.3 Assembly and process of the RNase V1 RNA modification reactions 
 
Table 4.2 Assembly and process of the DMS RNA modification reactions. 
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4.3.3.4 SHAPE 
Selective 2’hydroxl acylation analysed by extension (SHAPE) uses reagents that 
specifically modify the backbone of RNA in structurally flexible regions. It 
interrogates the RNA backbone flexibility at single-nucleotide resolution as flexible 
nucleotides can sample local conformations increasing the nucleophilic reactivity of 
2′-hydroxyl groups toward 1M7 Mortimer and Weeks 2007). The SHAPE analysis for 
this study was carried out by our collaborators in Paris, France at the Université 
Paris Descartes. Briefly, the SHAPE analysis was conducted by using 1-methyl-7-
nitroisatoic anhydride (1M7) as a modifying agent. The sites of modification were 
then mapped as stops by primer extension reaction, followed by capillary 
electrophoresis analysis, allowing individual nucleotides to be assigned a 
quantitative SHAPE reactivity. The SHAPE studies were repeated three times.  
4.3.4 32-P Primer Labelling 
In order to amplify the modified RNA, four primers sequences (table 4.4), 
complementary to residues in the 252-nt sufficient vFLIP IRES sequence (Figure 
4.3) were designed. The primers were designed to span across the sequences of the 
252 nt fragment of KSHV; so that at the end of the experiments, they will overlap 
across the sequence. The reaction was set up as 11 µl sterilised water, 2 µl 10x 
polynucleotide kinase (PNK) buffer, 1 µl 10 µM primer, 5 µl ATP 32-P-γ (2.85 MBq) 
and 1 µl PNK enzyme. The reaction was incubated at 37◦C for 60 mins on a heating 
block. After which, 30 µl of water was added to increase the volume to 50 µl.  
The reaction mix was applied on a previously prepared G-50 column to remove 
unincorporated radioactive nucleotide. The column was spun at room temperature at 
2000 rpm for 2 mins in a VWR MICRO STAR 17R microcentrifuge and the labelled 
primers recovered in the flow-through fraction.  
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Primer Primer sequence 5’-3’ Annealed to 252-nt 
Rev1 ACCTCGCTATACTAAGCC  
Rev2 TGCGCAGATCAAGTCCG nt136 to nt153 
Rev4 CCGCCTGTAGAACGGAAAC nt195 to nt213 
Rev5 CCACCCTAAACAAAATCACAA nt171 to nt193 
 
 
 
f 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5’GTGCGCTGTTGGTTCCTGCCAACGTCATTCCGCAGGATACCCACTCGGGTGGGGTA
GTTCCTCAGCTGGCAAGCATATTGGGATGCGATGTTTCCGTTCTACAGGCGGCAGTG
GAACAGATCCTAACATCTGTTTCGGACTTTGATCTGCGCATTCTGGACAGCTATTAAGC
TTGTGATTTTGTTTAGGGTGGAAAAATAAATTTTCCTTTGTTTTTCCACATCGGTGCCTT
CACATATACAAGCCG GCACC 3’ 
 Primer 1 was designed to bind a few bases downstream of the 252-nt sequence 
 
 Primer 2 binds to bases indicated in red 
 
 Primer 4 binds to bases indicated 
 
 Primer 5 binds to bases indicated 
 
 
 
                        
 
 
 
 
 
Figure 4.3 The 252-nt fragment sequence of the vFLIP IRES. The binding locations of 
the primers that were designed to analyse structure are highlighted in colours. 
Table 4.4 Primer sequences used for vFLIP IRES structure probing. 
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4.3.5 Primer extension 
The reaction was carried out on each of the modified RNAs. Equal molar amounts of 
modified RNA and 32-P labelled primer were annealed for 1 min at 90oC, 1 min at 
4oC and 5 min at 20oC. 1 µl of 5x AMV buffer was then added and incubated again 
for 10 min at 20oC. 2 µl of 5x AMV buffer, 2 µl of 2.5 mM dNTP mix, 4 µl of H2O and 
1 µl of 2U/µl of AMV reverse transcriptase (RT) (PROMEGA) was added to the 
mixture. The reaction was incubated for 30 min at 37oC. 
The reaction was stopped by adding 20 µl 0.3 M sodium acetate and 100 µl 100% 
EtOH, this was then mixed and incubated in dry-ice for 20 min. It was then spun at 
13000 rpm, at room temperature for 20 min. The supernatant (s/n) was removed and 
200 µl 80% EtOH was added, it was then mixed and spun at 13000 rpm for 5 min. 
The pellet was dried as described in previous sections. The pellet was then 
resuspended in 6µl of Formamide + Xylene Cyanol (Appendix I). 
4.3.6 Sequencing ladder preparation  
Sequencing ladder reactions were carried out and used to detect the positions of the 
modifications on the 252-nt IRES RNA. Standard sequencing reactions were carried 
as depicted in Table 4.5. Primer sequences previously 3'-end labelled with [γ-32P] 
ATP and chemically modified vFLIP RNA were used in these reactions. The reaction 
was stopped and precipitated and pellets dried as previously described. The pellet 
was then resuspended in 8 µl of Formamide + Xylene Cyanol. 
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4.3.7 Sequencing gel 
Electrophoresis was carried out on 40 cm x 30 cm x 0.4 cm 8% gels prepared as 
outline in Appendix I. The gel was pre-run for 30 min in 1x TBE buffer at power 
pack set as 40W, 200V. The samples from the extension reactions and the 
sequencing ladder were treated at 90oC for 3 min. 4 μl each of the samples for the 
sequencing ladder (A, C, G, T) were loaded on the gel and 3 μl of each sample from 
the extension reaction were loaded. The gel was ran for 2 hrs.  Upon completion of 
the run the gel was fixed in 10% acetic acid; 20% ethanol in water for 20 min and 
vacuum dried on 3MM paper for 90 min at 70oC. The dried gel was then exposed to 
a Bio-Rad Imaging screen for visualisation. 
4.3.8 RNA structure prediction 
Sequencing gel foot printing analysis was carried out and the experimental data 
obtained were converted into structural restraints. These restraints combined with 
the SHAPE reactivity results was used to predict a model of the 252-nt KSHV IRES 
with a RNA secondary structure prediction software “QuSHAPE” (Bellaousov et al. 
2013; Hajdin  et al.  2013). Briefly, the stops identified on the sequencing gel were 
first mapped on to the 252-nt sequence and colour coded. Each nucleotide was 
assigned a specific modification site corresponding based on DMS, CMCT or RNase 
V1 modifications. Mapping constraints were derived as per M-fold rules for RNA 
structure prediction. The constraints from the sequence were then used to predict 
the preliminary secondary structure of the vFLIP IRES using M-fold software. 
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4.3.9 Mutational analysis  
In order to validate the predicted secondary structure of the vFLIP 252-nt IRES, 
some mutations and deletions were carried out on the structure. The mutational work 
included deletions of some of the domains and point mutations in specific domains. 
4.3.9.1 Overlapping PCR 
Several primers as listed in table 4.7 were designed for each pair of PCRs. Four 
deletions in the plasmid described in section 4.3.1 were carried out. In order to 
introduce deletions in domains 1c-1f of the predicted secondary structure of the 252-
nt IRES (Figure 4.7) the plasmid pGEM-CAT/252-nt/LUC was used as the template. 
Two PCR reactions, one with each primer set. For instance, for the deletion of 
domain 1c, D1c LH PCR (252 LH For + D1c LH Rev) and for D1c RH PCR (D1c RH 
For + 252 RH Rev). The PCR reactions were carried out using pfu DNA polymerase 
enzyme (PROMEGA) in a total volume of 100 µl reaction. The products were 
checked on 2% agarose gel and then gel extracted. Subsequently, overlap PCR was 
used to join the two pieces of the left hand (LH) PCR product and right hand (RH) 
PCR product. Primer sequences, PCR reaction assembly and PCR cycle details are 
shown in tables 4.7, 4.8, 4.9, 4.10 and 4.11. The resultant PCR fragment was 
ligated (see section 2.8) into BamHI digested and dephosphorylated CAT-Luc 
vector. It was then transformed using competent E.coli DH5 as described in section 
2.1, plated onto ampicillin (Amp) plates and colonies were picked. Orientation PCR 
(section 2.22) was carried out on each construct. The constructs thought to be in the 
right orientation were sent for sequencing to confirm the deletions in each construct. 
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Primers Primer sequence 5’-3’ 
252LH For GTCTGGATCCATTCGCCCTTCGTGC 
252RHRev TTTTGGATCCGGTGCCGGCTTG 
D1c RH 
For 
GTCATTCCGCATCAGCTGGCAAGCATATTGGGATG 
D1cLH 
Rev 
CTTGCCAGCTGATGCGGAATGACGTTGGCAGG 
D1dRH 
For 
GTAGTTCCTCAGCATATTGGGATGCGATGTTTCG 
D1dLHRev CATCCCAATATGCTGAGGAACTACCCCACCCG 
D1eRHFor GCGATGTTTCGCAGTGGAACAGATCCTAACATC 
D1eLHRev CTGTTCCACTGCGAAACATCGCATCCCAATATGC 
D1fRH For CAGGCGGCAGTGCGGACTTTGATCTGCGCATTC 
D1fLH Rev GATCAAAGTCCGCACTGCCGCCTGTAGAACGG 
 
 
 
 
 
Table 4.7 Sequences of primers designed for PCR reactions to delete domains 
1c to 1f IRES loop of the predicted KSHV IRES structure. Primers were obtained 
from SIGMA, life science Underlined are the BamHI restriction enzyme sites. Primers 
were resuspended at 1 mg/ml and prepared as a 1/67 dilution to give approximately 
250 µM stock of each. Abbreviations; LH- left hand, RH- right hand. 
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Each set of Left and Right Hand PCRs were set up and PCR reaction was ran as 
shown in table 4.8 and 4.9 below. 
 
 
 
 
 
Steps Conditions 
1 95oC 5 min 
2 95oC 1 min 
3 55oC 30 sec 
4 72oC 40 sec   
5 Repeat from step 2 X27 
6 72oC 10 min 
 
   
 
 
 252/CAT-Luc template (400 ng) 2  μl 
MQ water 57 μl 
10 x Pfu buffer 10 μl 
2 mM dNTPs 10 μl 
250 µM appropriate For primer 10 μl 
250 µM appropriate Rev primer 10 μl 
 Pfu DNA polymerase   (PROMEGA) 2U/μl 1  μl 
Mixed and over layered 
Table 4.9 PCR cycle details for left and right hand PCR.  
 
Table 4.8 Assembly of left hand and right hand PCR reactions. 
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Left hand PCR x μl 
Right hand PCR x μl 
10 x Pfu buffer 10 μl 
2 mM dNTPs 10 μl 
250 µM  of LH primer 10 μl 
250 µM RH primer 10 μl 
 Pfu DNA polymerase   (PROMEGA) 2U/μl 1 μl 
MQ water Make up to 100 μl total 
Mixed and over layered 
 
   
 
 
 
 
Steps Conditions 
1 95oC 5 min 
2 95oC 1 min 
3 52oC 1 min 
4 72oC 45 sec   
5 Repeat from step 2 X30 
6 72oC 10 min 
 
 
Table 4.10 Assembly of the overlapping PCR reactions. Equimolar (about 80 ng 
each) of the LH and RH PCR product was used in the preparation of the reactions. 
 
Table 4.11 PCR cycle for the overlapping PCR reactions. 
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4.3.9.2 Preparation of IRES pseudoknot mutants 
(a) Mutations of domain II and IV 
The Stratagene QuikChange site was used to mutate fives bases in the domain II 
(DII) and domain IV (DIV) of the proposed IRES structure in order to disrupt the 
putative pseudoknot structure according manufacturer’s protocol. To mutate bases 
171-175 (GCTTG) in DII to CGAAC and   241-245 bases (CAAGC) to GTTCG in 
DIV, two pair of overlapping primers were designed as per the kit instructions see 
table 4.12 for list of primers used. 
 
Primers Primer sequence 5’-3’ 
D IV forward 
primer 
CGGTGCCTTCACATATAGTTCGCGGCACCGGATCCAAAAGGGC 
D IV reverse 
primer 
GCCCTTTTGGATCCGGTGCCGCGAACTATATGTGAAGGCACCG 
D II forward 
primer 
GATCTGCGCATTCTGGACAGCTATTAACGAACTGATTTTGTTTAGGGTGG 
D II reverse 
primer 
CCACCCTAAACAAAATCAGTTCGTTAATAGCTGTCCAGAATGCGCAGATC 
 
 
 
 
 
 
Table 4.12 Sequences of primers designed to mutate five bases in domains II and IV 
of the predicted KSHV IRES structure. Underlined are the mutated bases. Primers were 
obtained from SIGMA, life science. Primers were resuspended at 1 mg/ml and prepared as 
a 1/10 dilution for the PCR reactions. 
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PCR reactions were assembled as shown in table 4.8 and PCR cycle was ran as 
shown in table 4.13 below. 
 
Steps Conditions 
1 95oC 30 sec 
2 95oC 30 sec 
3 55oC 1 min 
4 68oC 45 sec   
5 Repeat from step 2 X18 
6 72oC 10 min 
 
 
(b) Dpn I Digestion of the Amplification Products 
 1 µl of the Dpn I restriction enzyme (10 U/µl) (PROMEGA) was added directly to 
each amplification reaction to digest the nonmutated supercoiled dsDNA. Each 
reaction mixture was thoroughly mixed by pipetting the solution up and down several 
times. The reaction mixtures were immediately incubated at 37°C for 1 hour  
The PCR-derived plasmid was then transformed with competent E coli DH5s (from 
kit) as described in section 2.1 chapter 2 and plated onto ampicillin (Amp) plates 
and colonies were picked and sent for sequencing. 
 
 
Table 4.13 PCR cycle for D II and IV mutation PCR reactions.  
 
Chapter 4                        Structural and mutational analysis of vFLIP IRES 
115 | P a g e  
 
4.3.9.3 Translation of mRNA transcripts in Flexi rabbit reticulocyte lysates 
(RRL) kit  
 In order to test the mutants against the wild type, the FLEXI RRL kit (PROMEGA) 
was used to translate the RNA transcripts of each mutant in vivo. The reaction was 
assembled as shown in table 4.14. 
 
252-CAT/LUC RNA (1 μg) 0.5 μl (from a 450 ng 
concentration) 
Flexi RRL 16.5  μl 
Amino acid mixture-methionine (1mM) 57 μl 
35S-labelled methionine (500 μCi; PerkinElmer) 1 μl 
Magnesium acetate (25mM) 0.5 μl 
Potassium chloride (2.5M) 1 μl 
RNAsin 20  (U/μl) 0.5 μl 
Add MQ water up to 25 μl 
Reaction was incubated at 30oC for 90 min 
 
 
In order to analyse the samples, 4 μl of each sample was mixed with 6 μl of MQ 
water, 5 μl of NEB red buffer (New England BioLabs) and 0.5 μl of DTT ((New 
England BioLabs). The samples were heated at 100oC for 5 mins and loaded and 
analysed on a 10% SDS-PAGE (section 2.13). 
 
 
Table 4.14 Assembly of Flexi RRL reactions.    
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4.4 Results 
4.4.1 RNA structure probing  
In order to determine the structure of the vFLIP IRES (252-nt), base specific 
reagents DMS and CMCT and enzymatic probe RNase V1 were used to modify the 
252-nt sequence RNA. In addition, SHAPE reactivity analysis was also used to 
modify the backbone of the 252-nt RNA using 1M7. The mean of reactivity for each 
position on the RNA combined with accessibility data generated CMCT and DMS 
reactivity, to detect single stranded regions and RNase V1 reactivity to detect double 
stranded regions were used to model the IRES structure using the software 
QuSHAPE. Figures 4.4, 4.5 and 4.6 show fragments of the sequencing gels 
obtained from primer extension analysis with corresponding DMS, CMCT, and 
RNase V1 modifications with each primer (table 4.4) designed for the study and 
Figure 4.7 highlights the modified nucleotides within the 252-nt sequence. Probing 
data obtained by a previous PhD student was combined with present data and a total 
of 65 nucleotides were found modified. The RNAse V1 modified 31 nucleotides, 
CMCT modifications have 21 hits and DMS modified 12 nucleotides. 
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Figure 4.4 Sequencing gel analysis showing RNAse V1 modifications.  
A representative sequencing gel showing mapping of primer extension stops 
following chemical probing in solution with RNAse V1 (0.1U/µ) from 0, 0.5, 1 
to 2 µl . The arrows indicate modified bases on the KSHV 252-nt IRES 
sequence. 
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Figure 4.5 Sequencing gel analysis showing RNAse V1 and CMCT 
modifications. A representative sequencing gel showing mapping of primer 
extension stops following chemical probing in solution with RNAse V1 
(0.1U/µ) from 0, 0.5, 1 to 2 µl and CMCT (40 mg/ml) from 0, 1, 2 to 5 µl. The 
arrows indicate modified bases on the KSHV 252-nt IRES sequence. 
Chapter 4                        Structural and mutational analysis of vFLIP IRES 
119 | P a g e  
 
 
 
 
 
 
 
 
Figure 4.6 Sequencing gel analysis showing CMCT and DMS modifications. 
A representative sequencing gel showing mapping of primer extension stops 
following chemical probing in solution with CMCT (40 mg/ml) from 0, 1, 2 to 5 µl 
and DMS from 0, 1, 5 to 10 mins . The arrows indicate modified bases on the 
KSHV 252-nt IRES sequence and natural stops. 
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Figure 4.7 Map of 252-nt sequence highlighting the locations of the modified 
nucleotides. The nucleotides modified by RNase V1, CMCT and DMS are shown in 
colours. Overall, 65 nucleotides were modified. The RNAse V1 modified 31 
nucleotides, CMCT modifications have 21 hits and DMS modified 12 nucleotides. 
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The RNA prediction software QuSHAPE predicted several models for the vFLIP 
IRES structure. These models were evaluated for consistency with RNase V1, 
CMCT and DMS data. The model that tallies best with all the data is shown in Figure 
4.8. On the whole, the vFLIP IRES adopts a compact structure, which is largely 
mirrored by the overall low SHAPE reactivity. Two major domains can be identified 
on the structure. The first and second domain corresponds to 1-154nt and 155-252nt 
respectively. The first section of the IRES structure is formed by domain I (dI) which 
comprises of subdomains Ia to If arranged into two consecutive junctions: a four-
helix junction made up of Ia, Ib, Ie and If, followed-by a three-helix junction 
consisting of Ib, Ic and Id. Domains Ic and Id are capped by a UCGG and a GGCA 
tetraloop respectively whereas domains Ie and If are capped by CUACA and 
CCUAAC loops respectively. The second section of the IRES structure is made of 
three stem loop structures represented by domains II, III and IV. Domains II and IV 
are capped by large loops consisting of 17 and 16-nt respectively whereas dIII is 
capped by a pyrimidine-rich (U4C2) loop. 
 Most of the RNase V1 modified nucleotides are found in helical regions with the 
exception of a few that are located in loops of domains Id, II and IV which could 
suggest the formation of a tertiary structure or local noncanonical base pairs yet to 
be determined. Most of the CMCT and DMS modified nucleotides are in single 
stranded regions or at the edge of helices but only the ones located in the 3’ region 
of domain II (dII) challenges the model. The shapeknot module highlighted a 
putative pseudoknot by paring of dII 5’-171GCUUGUG177-3’ with dIV 5’-
239UACAAGC245-3’. 
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Figure 4.8 Secondary structure of the vFLIP IRES. The chemical and enzymatic 
modifications induced by DMS, CMCT, and RNAse V1 are indicated using red circles, 
red diamonds and blue arrows respectively. The mean SHAPE reactivity from three 
independent experiments is indicated for each position on the vFLIP IRES according to 
the color code boxed. The major domains determined are indicated in the model. 
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4.4.2 Deletion analysis of the vFLIP IRES 
In order to validate and characterize fundamental domain boundaries of the 
predicted vFLIP IRES structure in vitro translation assays using wild type and 
domain deletion mutants of vFLIP IRES RNA was employed. Deletion mutants of the 
vFLIP IRES were constructed to alter the proposed structural model. In their entirety, 
subdomains Ic, Id, Ie and If were deleted as described in section 4.3.9 to create 
four mutants of the vFLIP IRES namely ΔIc, ΔId, ΔIe and ΔIf. These mutants were 
tested against the wild-type vFLIP IRES RNA in rabbit reticulocyte lysates in vitro 
translation assay. The reactions separated on a 10% acrylamide SDS gel and the 
bands were quantified and used to deduce relative IRES activity as shown on Figure 
4.9.  
Visual inspection of the gel suggests that the deletion of domain If completely 
abolishes the function of the IRES as there was no band present for the firefly 
luciferase (FLuc). Comparison of the WT activity (100%)  with the deleted domain 
mutants  showed that deletion of domains Ic (113%), Id (90.1%) and Ie (71%) do not 
affect the vFLIP IRES function, as there was no significant difference in their relative 
translation activity. On the contrary, the deletion of domain If significantly diminished 
the function of the vFLIP IRES. The relative translation activity of the deleted domain 
If (9.1%) mRNA decreased about 10 folds compared to the wild-type. This suggests 
that part or the whole of the subdomain If is crucial for the vFLIP IRES to function 
properly. 
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Figure 4.9 Comparison of vFLIP IRES activity wild-type and mutant RNAs in 
dicistronic translation assay. (A) Autoradiograph of WT and deleted subdomains Ic 
to If RNAs translated in rabbit reticulocyte lysate with 35S labelled net-tRNAimet and 
separated by electrophoresis on a 10% acrylamide SDS gel. Expression of CAT from 
the upstream cistron had a similar efficiency for all plasmids as expected. (B) 
Quantification of firefly luciferase of WT and mutants with WT set to 100. Values are 
the mean ± SEM from five independent experiments and were analyzed by one-way 
ANOVA with Dunnett's multiple comparison test: (*) P < 0.05, (**) P < 0.01, (***) P < 
0.001, and (****) P < 0.0001 (GraphPad Prism 6.0). 
 
A 
B 
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4.4.3 vFLIP IRES putative Pseudoknot mutagenesis 
As previously mentioned in section 4.4.1 the RNA structure probing highlighted a 
putative kissing complex by paring of dII 5’-171GCUUGUG177-3’ with dIV 5’-
239UACAAGC245-3’.  These interactions have the potential to form Pseudoknot-like 
structures. Pseudoknot may arise from base pairing of nucleotides of a single-
stranded loop region with complementary sequence outside of this loop. 
Pseudoknots identified within some IRESs elements such as those found in HCV 
and PTV IRES (Berry et al., 2010; Fletcher and Jackson 2002) have been shown to 
be essential for the activity of these IRESs. To test the highlighted vFLIP IRES 
potential pseudoknot, mutagenesis experiments were designed to disrupt the 
predicted base pairs in the domain II and IV stem loops.  A total of three mutants 
were designed for the experiments. Five nucleotides at nt171-175 GCTTG was 
altered to CGAAC in domain II (M1) and nt 241-245 CGAAC was altered to GCTTG 
in domain IV (M2) as described in section 4.3.9.2. The base pairing interactions was 
then restored by introducing a compensatory mutation (M3).  The mutants together 
with the wild-type were translated in rabbit reticulocyte lysates (RRL) followed by 
SDS PAGE as described in section 4.3.9.3. 
The results of translation assays of discistronic mRNAs with these mutants and the 
wild-type are shown in Figure 4.10. Visual inspection suggests that mutations in the 
loops of domain II and IV had no significant effect on IRES activity and this was also 
confirmed by densitometry quantification. The disruptions in domains II (M1) and 
domain IV (M2) had relative IRES activity of 112% and 106% respectively when 
compared to the WT which was set to 100%. 
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The kissing complex highlighted by the shapenot when disrupted does not seem to 
have a significant effect on the vFLIP IRES activity. Therefore, the putative 
pseudoknot does not appear to be to be crucial for vFLIP IRES function. This is in 
contrast to the observations found in other well-known and documented IRESs. For 
instance, mutations in the pseudoknot found in the basal domains of IIIf, the 40S 
binding domain of the HCV IRES, showed a decrease in IRES activity (Ji et al. 2004; 
Lukavsky et al., 2009; Pisarev et al., 2005). The predicted secondary structure of the 
PTV-1 IRES revealed that it harbours a pseudoknot structure just as the HCV IRES 
and it is essential for the PTV-1 IRES activity (Easton et al., 2009; Hellen and de 
Breyne, 2007). In c-myc IRES, a double pseudoknot that was identified within its 
IRES was shown to have an inhibitory effect on the function of its IRES (Le Quesne 
et al., 2001). 
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Figure 4.10 Comparison of IRES activity of vFLIP IRES wild-type and mutant RNAs 
in dicistronic translation assay. (A) Autoradiograph of WT and deleted subdomains Ic 
to If RNAs translated in rabbit reticulocyte lysate with 35S labelled net-tRNAimet and 
separated by electrophoresis on a 10% acrylamide SDS gel. Expression of CAT from the 
upstream cistron had a similar efficiency for all plasmids as expected. (B) Quantification 
of firefly luciferase of WT and mutants with WT set to 100. Values are the mean ± SEM 
from five independent experiments and were analyzed by one-way ANOVA with 
Dunnett's multiple comparison test: ns-no significant difference (GraphPad Prism 6.0). 
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4.5 Discussion 
It has been established that the function of IRES is governed by the RNA structure of 
the IRES (Lukavsky 2009). IRES elements are usually made up of a modular 
organization with diverse functions amongst the different domains (Lozano and 
Martinez-Salas 2015). Thus, deciphering of the RNA structure organization of IRES 
elements is critical to understanding how IRES elements function. The lack of 
observable similarity in sequences of known IRESs led to the notion that IRESs likely 
possessed stable secondary structure that allowed them to interact with the 
components of the translation machinery. Viral IRES elements are grouped into 
families based on the structure they adopt, the translation factors they require and 
the potential ITAFs contributing to their function. 
In this analysis, we experimentally investigated the structure of the KSHV IRES by 
chemically and enzymatically probing the sufficient sequence (252 nt) required for 
the IRES activity. The set of data obtained from the probing combined with SHAPE 
analysis data were used as constraints in a structure prediction program. The 
software predicted a few structures but the structure that best fitted our data was 
selected. 
Up until now, only one other group has proposed a structure for the SH\\KSHV vFLIP 
IRES structure. In 2001, Bieleski and Talbot presented an RNA secondary model 
within the 233 nt of the vCyclin coding region. RNA secondary model was 
determined using the program RNA mfold that was used to produce a structure with 
the lowest free energy (ΔG = −61.4 kcal/mol). The model (see Figure 4.1) showed 
that the RNA sequence folds into two stable stem-loop structures separated by a 
short non-base-paired region. However, the proposed structure was not validated. 
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In the present study, analysis of the KSHV vFLIP IRES structure using footprinting 
techniques has allowed the determination of a secondary structure model. The 
model predicted here was experimentally determined by investigating the 
accessibility of KSHV IRES RNA to modifications with DMS, CMCT and RNAse V1 
as well as SHAPE analysis using 1-methyl-7-nitroisatoic anhydride (1M7) to 
interrogate the RNA backbone was used. Unlike most viral IRESs that adopt 
complex RNA structures, here we propose a compact structure for the KSHV IRES. 
The structure consists of two major domains. The first segment of the IRES structure 
constitutes domain I (dI) and its subdomains Ia to If arranged into two consecutive 
junctions. Domains Ia, Ib, Ie and If make up a four-helix junction which is followed 
by a three-helix junction consisting of Ib, Ic  and Id. The second section of the IRES 
structure is made of three stem loop structures corresponding to domains II, III and 
IV. Domains II and IV are capped by large loops consisting of 17 and 16-nt 
respectively while dIII is capped by a pyrimidine-rich (U4C2) loop.  
Previous studies have shown that pyrimidine-rich sequences are attractive binding 
sites for a protein termed polypyrimidine tract-binding (PTB) protein (Singh et al. 
1995). The PTB protein has been shown to interact and sometimes required for 
IRESs found in certain picornaviruses such as poliovirus (Hellen et al. 1994), HAV 
(Schultz et al. 1996), FMDV (Niepmann 1996), EMCV (Kaminski and Jackson 1998), 
and HCV (Ali and Siddiqui 1995; Anwar et al. 2000). It was demonstrated that over 
expression of PTB had considerable stimulatory effects on the HAV, poliovirus and 
HCV IRES elements (Gosert et al. 2000; Kafasla 2010). In EMCV IRESs, an 
interaction with PTB has been shown to stabilize the three-dimensional folding of the 
IRES (Kafasla 2009).  In HCV IRES however, there has been contradictory evidence 
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in regards to its requirement for PTB protein. In 1995, Ali and Siddiqui showed that 
the activity of the HCV IRES was reduced in Hela and rabbit reticulocyte translation 
lysates that were PTB immunodepleted. This observation was contradicted by 
Kaminski et al. that showed that PTB depletion from HeLa lysates passed through an 
encephalomyocarditis virus RNA affinity column permitted the translation of HCV 
(Kaminski et al. 1995). However, Anwar et al. provided more evidence to support the 
notion that the HVC IRES requires PTB for its function. They used SELEX RNA 
ligands raised against human PTB and showed that this interfered with the HCV 
IRES-mediated translation (Anwar et al. 2000). Therefore, investigating the 
pyrimidine-rich loop of domain III in the proposed structure can provide interesting 
insights into the function and requirement of the vFLIP IRES. 
The proposed structure also highlighted a “kissing complex” by pairing of dII 5’-
171GCUUGUG177-3’ with dIV 5’-239UACAAGC245-3’ which have the potential to form 
Pseudoknot-like structures. Pseudoknot may arise from base pairing of nucleotides 
of a single-stranded loop region with complementary sequence outside of this loop. 
The interruption of this interaction by mutating five out of the seven bases did not 
have an effect on the function of the vFLIP IRES when compared to the wild-type. 
Although pseudoknots have been identified and well documented in numerous IRES 
elements and their function is best exemplified in HCV and Cricket paralysis virus 
(CrPV). The HCV forms a secondary structure that consists of two major hairpins 
(domain II and III) and an essential pseudoknot structure at the base of domain III 
(Wang et al. 1995). This pseudoknot structure has been shown to play a role in the 
initial binding of 40S subunit to the basal region of domain III (Kieft et al. 2001; Otto 
and Puglisi 2004). 
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Pseudoknots also play critical role in the function of intergenic region (IGR) IRES of 
CrPV (Wilson et al. 2000). The CrPV has three defined domains I to III. These 
domains harbour three separate pseudoknots termed PKI, II and III (Kanamori and 
Nakashima 2001). The PKI pseudoknot is thought mimic the initiation tRNA/mRNA 
interaction and this enables the establishment of the correct reading frame in the 
viral mRNA upon interaction with the ribosome (Costantino et al.  2008). Other IRES 
elements that depend on the presence of a pseudoknot to function include Classical 
swine fever virus (CSFV) (Fletcher and Jackson 2002; Rijnbrand et al. 1997). 
In order to characterise the structure-function of the vFLIP IRES subdomains Ic, Id, 
Ie and If were deleted and the effects on the IRES-mediated translation initiation was 
tested in RRL translation system. The deletion of subdomains Ic, Id and Ie did not 
affect the efficiency of IRES dependent translation whereas the deletion of domain If 
completely abolished the activity of the vFLIP IRES. This suggests the domain If in 
part or as a whole in required for the vFLIP IRES to function. In several IRES 
elements, mutational analysis of their domains has revealed the importance of those 
domains for the IRES function. For instance, mutation/deletion studies of the HCV 
IRES has revealed that the integrity of domain III is of importance for the IREs 
function (Wang et al 1994). Tang et al. (1999) demonstrated that single point 
mutations in domain IIIc of the HCV IRES led to the dramatic loss of IRES function 
and suggested that the stem-loops IIIa and IIIc of the HCV IRES is critical for IRES 
function. Data was also presented that suggested that the apical region of domain III 
(consists of IIIa and IIIc) represents a binding site for the canonical eIF3 and these 
structures may also influence the binding of the ribosome at the initiation codon 
(Pestova et al. 1998; Sizova et al. 1998). Clearly, deletion/mutation studies are 
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important in order to functionally characterise our proposed vFLIP IRES structure. 
The domain If needs to be studied further in order to establish which part of the 
stem-loop is required for the vFLIP IRES to function. For instance, deleting the loop 
only or mutating the stem of domain If. So far, only the subdomains have been 
investigated for the effect they have on the vFLIP IRES activity. More 
mutation/deletion studies are required to in order to investigate whether the other 
identified domains are required for the functioning of the vFLIP IRES or not. 
In conclusion, here for the first time we have predicted a secondary structure of 
KSHV IRES by using chemical and enzymatic modifications. Specific deletion of 
IRES subdomains to begin to define the structure/function of the vFLIP IRES has 
revealed that the vFLIP IRES secondary structure play an important role for the 
vFLIP IRES to function. Further studies are required to fully define the structure-
function of the vFLIP IRES. 
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5.1 Introduction to chapter 5 
It is well documented that cellular factors, named ITAFs, can modulate and enhance 
IRES-mediated translation initiation (Komar and Hatzoglou 2011). ITAFs are RNA-
binding proteins that interact functionally with IRES elements to positively or 
negatively regulate internal initiation (Fox and Stover 2009). The majority of the 
ITAFs identified to date belong to the group of heterogeneous nuclear 
ribonucleoproteins (hnRNPs). hnRNPs are located mainly in the nucleus, where they 
exert their splicing-related function, but are also known to translocate to the 
cytoplasm in specific cell or tissue types and as part of specific stress responses. In 
the case of the human rhinovirus-2 IRES, a cellular RNA-binding protein 
polypyrimidine tract binding (PTB) protein is necessary but not sufficient for efficient 
translation initiation (Hunt and Jackson 1999). The PTB protein is also required for 
IRES-mediated translation directed by other picornaviruses such as poliovirus (PV) 
and FMDV (Kafasla et al. 2011; Kaminski and Jackson 1998; Pilipenko et al. 2000). 
Another ITAF identified is the human La autoantigen which stimulates IRES-
mediated translation directed by PV, HCV and cellular human immunoglobin heavy-
chain binding protein (BiP) (Ali et al. 2000; Kim et al. 2001; Meerovitch et al. 1993). 
Most of these factors were identified from analysis of IRES-binding proteins using 
UV cross-linking and RNA-based affinity purification or investigation of proteins 
enhancing specific IRES function in an in vitro translation system through 
fractionation of cellular extracts (Choi et al. 2004). 
The present study aims to identify cellular proteins that interact with the vFLIP IRES 
in an in vitro system using RNA affinity isolation. 
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5.2 Materials and methods 
5.2.1 Plasmid constructs 
5.2.1.1 Cloning of 252-nt fragment into pSP64poly(A) vector 
A plasmid containing the putative KSHV IRES fragments of 252 nt in length in TOPO 
TA vector (Invitrogen) were provided by Prof. David Blackbourn (University of 
Surrey). The vFLIP IRES 252-nt fragment, was subsequently cloned into 
pSP64poly(A) (PROMEGA)  vector by our group. Briefly, the 252 insert from the 
TOPO TA vector was digested with BamHI restriction enzyme and blunt-ended. The 
pSP64 poly(A) vector was digested with SmaI restriction enzyme and then 
dephosphorylated. Both the insert and the vector were ligated and the ligation 
products were transformed. The colonies from the transformation were then selected 
and grown overnight and the plasmid DNA was extracted. The positive clones were 
screened by sequencing and subjected to midiprep for large scale production of the 
plasmid DNA.  
The plasmid DNA was digested with EcoRI restriction enzyme as described in 
section 2.10. RNA transcript was prepared using AMBION Sp6 Megascript kit 
according to manufacturer’s protocol. RNA was cleaned and recovered as described 
in section 12.13. 
5.2.1.2 Cloning of 252-nt vFLIP IRES fragment into pUC18 vector 
The plasmid was prepared previously by our group. Briefly, the 252 KSHV IRES 
fragment in TOPO TA vector was digested and cloned into pUC18 vector 
(Invitrogen). The IRES fragments were cloned into a pUC18 plasmid between a T7 
promoter and the tobramycin aptamer sequence using standard protocols. The 
tobramycin aptamer was created using overlapping PCR using the following primers: 
5’gactctctGGCTTAGTATAGCGAGGTTTAGCTACACTCGTGCTGAGCCctctctgaattc
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ctct-3’ and 5’-agagagGGCTCAGCACGAGTGTAG-3’. The ligated DNA was then 
transformed into E. Coli DH5α cells, and the positive clones were analysed by 
sequencing. Once the positive clone was confirmed, plasmid midipreparation was 
performed by using QIAGEN midiprep kit.  
The plasmid DNA was digested with EcoRI restriction enzyme as described in 
section 2.10. RNA transcript was prepared using AMBION Sp6 Megascript kit 
according to manufacturer’s protocol. RNA was cleaned and recovered as described 
in section 12.13. 
5.2.2 Preparation of HEK293 cytoplasmic cell lysates 
The HEK 293 cells were grown as described in section 2.15.7. Once the cells were 
70%-80% confluent, cells were harvested and washed twice with ice cold PBS and 
spun at 400g for 5mins. The cell pellet was re-suspended in 1 ml of ice cold RIPA 
buffer (50 mM Tris, 150 mM NaCl, 0.1 % SDS) with 0.5 % Sodium Deoxycholate, 1% 
Triton, and Protease inhibitor tablet (Roche Complete) (Appendix I). The cell 
suspension was incubated on ice for 5 min, then centrifuged at 8000 rpm at 4oC for 
10 min and the supernatant harvested and stored at -80oC. 
5.2.3 Preparation of BCBL-1 cytoplasmic cell lysates 
The BCBL-1 cells were grown as described in section 2.15.5. Once the cells were 
70%-80% confluent, cells were harvested and lysate was prepared as described in 
section 5.2.2. 
5.2.4 Protein Assay  
Protein concentration was determined using BCA assay kit (Pierce-Thermo 
Scientific). The assay was conducted according to manufacturer’s specifications and 
measured at 540nm wavelength using an ELISA plate reader (Perkin-Elmer). 
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5.2.5 Labelling of RNA 
5.2.5.1 Periodate oxidation of RNA 
Periodate cleaves the bonds between adjacent carbon atoms having hydroxyl 
groups to create two aldehyde groups. It is used to selectively label the 3′-termini 
of RNA (Kurata et al. 2003). Figure 5.1A depicts the periodate oxidation reaction 
and the RNA biotinylation. 
In order to carry out the periodate oxidation of the 252-nt RNA, the reaction was set 
up in a 50 μl volume as shown in table 5.1.  
 
RNA 600 pmoles 
Sodium periodate (100mM) 100mM 
Sodium acetate PH5 100mM 
MiliQ water To 50 μl 
Incubate reaction for 90 min at 25°C 
 
 
The reaction was stopped by adding 250mM Kcl and the reaction was incubated on 
ice for 10 min. The reactions were spun in benchtop microcentrifuge (BOECO M-24) 
at 13000 rpm for 10 mins. The supernatant was put through a G50 cleanup column 
and spun at 2000 rpm for 2 min. 
 
 
 
Table 5.1 Assembly of periodate oxidation reaction. 
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5.2.5.2 Biotinylation of RNA 
Two strategies were adopted for the preparation of biotinylated 252-nt RNA 
transcript which were then used as probes in RNA-protein binding assays. The first 
strategy involves using the oxidized RNA from section 5.2.4.1 and biotinylaing it with 
biotin hydrazide. In this case, fifty times molar excess over RNA of biotin hydrazide 
was added to the oxidized RNA (section 5.2.4.1). For 600 pmoles of RNA used in 
oxidation reaction, 30 000 pmoles of biotin hydrazide was added to the oxidized 
RNA. The RNA and biotin was incubated at 25°C for 4 hrs. The RNA was then 
precipitated with 1/30th volume of sodium acetate and 2.5 volume of ethanol and 
incubated on ice for 30 mins and was put through G50 cleanup column. The integrity 
of the RNA was checked on agarose gel.  The RNA was then stored at -80°C. The 
schematic representation of biotin tagged RNA is depicted in Figure 5.1B. 
The second strategy of RNA biotinylation involves internally using biotinylated 
nucleotides during in vitro transcription. For this strategy, biotinylated RNA was 
prepared using Biotin RNA labelling mix kit (Roche Applied Science), following 
manufacturer’s specified protocol and used as a probe in pull down interactions. 
Briefly, 10X mix of 10 mM each ATP, CTP, GTP, 6.5 mM UTP, 3.5 mM Biotin-16-
UTP, and pH 7.5 was used. A standard labelling reaction; 1 μg linear template DNA, 
50mM DTT, RNAsin 0.5 U/ml, 10X buffer (100 mM spermidine, 1 M MgCl2, 1 M Tris 
pH8.0) was mixed with T7 polymerase and incubated at 37oC for 2 hr. The resulting 
biotinylated RNA was ethanol precipitated and spun through a G-50 column spin 
column. 
  
 
 
Chapter 5                        Identification of vFLIP IRES transacting proteins 
138 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 3′-End labelling of RNA. (A) The 3′-end labelling strategy involves 
reacting vicinal hydroxyls of an RNA molecule through sodium periodate cleavage 
followed by an addition reaction with hydrazide activated compound (B) shows the 
schematic representation of the biotin tagged RNA.  
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5.2.6 RNA-protein binding assay 
5.2.6.1 Binding experiment using Oligo(dT)25 Dynabeads  
The assay was performed by using the Dynabeads Oligo(dT)25 (500 µl; Dynal-
Invitrogen) and a magnetic stand. The beads which contains an oligo-dT will bind to 
poly(A) chain in the poly(A)-252 fragment. The beads were first equilibrated and 
washed with 500 µl 0.5x SSC (Appendix I). The beads were then washed with 500 
µl of 1x Bead Binding Buffer (BBB; Appendix I), and then placed back on the 
magnetic stand. The supernatant was removed and the beads were resuspended in 
500 µl 1X BBB before adding 5 µg of mRNA transcripts and incubating on a rotor at 
4°C for 30 min. The beads were washed twice in 500 µl 1X BBB as before. An 
amount of 50 µl of RRL (PROMEGA) or 100 µl of BCBL-1 lysate was added along 
with 5 µg tRNA as competitor (Sigma) and incubated with the immobilised RNA 
transcripts for 60 min at 4 °C as before. After the incubation, the supernatant was 
removed and the beads were washed twice with 500 µl 1X BBB. The RNA bound 
proteins were eluted in 20 µl sterile water, 1 µl DTT (New England Biolabs), and 10 
µl NEB red PAGE buffer (New England Biolabs) and incubated as above for 10 min. 
The eluted proteins were then centrifuged for 1 min and collected for analysis by 
SDS-PAGE (section 2.2). 
5.2.6.2 Using Streptavidin M280 Dynabeads 
RNA binding proteins were pulled down from HEK293 cytoplasmic lysate or rabbit 
reticulocyte lysate (RRL) (PROMEGA) using biotinylated RNA immobilised onto a 
support containing streptavidin. This was achieved with magnetic Streptavidin M280 
Dynabeads® Invitrogen. The bead binding assay was as follows: The beads were 
initially blocked for 1 hour in IP buffer (100 mM Tris pH 8.0, 150 mM NaCl, 1 mM 
EDTA, 5% glycerol, 1 mM DTT, 0.1 mg/ml tRNA, Roche Complete mini EDTA free 
tablet) then combined with 10 pmoles of biotinylated RNA and 30 mg/ml HEK293 
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lysate in IP buffer supplemented with 2 units of DNAse Rq I (PROMEGA). The 
bead/lysate mixture was incubated at 25 °C for 30min at 950 rpm then washed 4 
times with 750 μl of IP buffer at 4°C. The eluates were recovered on a magnetic 
stand in 2X Laemmli loading buffer, and then denatured at 95 °C for 5min. 
The samples were run on a 4-20% SDS PAGE gel and stained as described in 
section 2.13. 
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Figure 5.2 Strategy for terminally biotinylated tagged mRNA-based isolation of the 
binding proteins. RNA was chemically tagged at the 3’end using sodium periodate to 
oxidize RNA followed by addition reaction with hydrazide activated compound as 
described in materials and methods. The RNA with HEK293 lysate is incubated with the 
streptavidin beads and binding buffer. The biotin molecule binds the streptavidin beads 
and captures cellular proteins. Specific bound preoteins are subsequently eluted and 
separated on SDS PAGE. 
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Figure 5.3 Strategy for internally biotinylated tagged mRNA-based isolation 
of the binding proteins. RNA was tagged through incorporation during in 
vitro synthesis of biotin-containing ribonucleotide using a biotin labelling mix kit as 
described in materials and methods. 
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SDS-PAGE separation 
of captured proteins 
Figure 5.4 Strategy for poly(A) tagged mRNA-based isolation of the 
binding proteins. Oligo(dT)25  Dynbeads which contains an oligo-dT are 
incubated with RNA (252nt) that is tagged with a poly(A) chain at the 3’end and 
with RRL or BCBL-1 lysate. After rigorous washings, specific proteins bind to 
the Dynabeads. Proteins captured by the beads are eluted and seprerated on 
SDS-PAGE gel. 
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5.3 Results 
The aim of this chapter was to identify potential ITAFs that interact with the vFLIP 
IRES in order to gain a better understanding of the function of KSHV vFLIP IRES. To 
achieve this, different variations of RNA affinity chromatography, a technique that 
allows the isolation and characterization of various RNA binding proteins (Thakor 
and Holcik 2012) was used to investigate the proteins present in RRL, BCBL-1 and 
HEK293 lysates that may interact with the vFLIP IRES. Data (unpublished) by a 
previous PhD student Zulkefley Othman, showed that beading binding experiments 
with the BCBL-1 lysate was able to pull down specific proteins that interacted with 
the KSHV IRES. However, the same result was not achieved during the course of 
this thesis. After several attempts with BCBL-1 lysate the same outcome, 
subsequent pull down experiments was carried out with HEK293 lysates. 
In the Oligo(dT)25 Dynabeads bead binding experiments, the 252-nt fragment in 
pSP64poly(A) was used to assess the vFLIP IRES interacting ITAFs and a poly(A) 
oligonucleotide was used as a negative control to detect non-specific protein binding 
in RRL and BCBL-1 lysates. Figure 5.5 shows the analysis of the products of the 
bead experiment on silver stained 10% SDS-PAGE gel using RRL (Figure 5.5A) and 
BCBL-1 lysate (Frigure 5.5B). Lane 1 represents a product by pulled down 
Oligo(dT)25 Dynabeads with  control RNA which poly(A) oligonucleotide was used as 
a negative control for non-specific binding proteins while Lane 2 represents the 
pulled down product from KSHV 252 RNA. Contrary to what was expected, analysis 
of the 10% SDS PAGE gel using silver staining to visualise the bands did not detect 
the presence of any specific interactions as no significant differences in the banding 
patterns were observed (Figure 5.5). Several protocol parameters such as 
lysate/RNA ratio, clearing of lysate, pre-binding of RNA and buffers were adjusted to 
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optimise bead binding experiments.  In spite of this, no significant differences in the 
banding patterns were noted using the approach above, therefore another strategy 
was explored. 
The 252-nt fragment RNA transcript was biotinylated during in vitro transcription 
using Biotin RNA labelling mix kit (Roche Applied Science) as described in section 
5.2.5.2. The potential interacting ITAFs was assed as described in section 5.2.6.2. 
The bound proteins were analysed on 4-20% SDS PAGE gel and silver staining was 
used to visualise the bands (Figure 5.6). There were no specific interactions 
between the vFLIP IRES and the cellular proteins detected. Although, there was less 
background non-specific biding compared to the initial approach.  
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A 
B 
Figure 5.5 Bead binding assay using Oligo(dT)25 Dynabeads  SDS-PGE analysis of 
bead binding assay of vFLIP RNA incubated with RRL and BCBL-1 lysates. After they 
had been washed and dissociated from RNA, the eluted proteins were boiled and 
subjected to SDS–PAGE (10% gel). Silver stain was applied for visualization. (A) 
Pulled down product with RRL lysate. (B) Pulled down product with BCBL-1 lysate. 
Lane 1 shows the pulled down proteins with poly(A) oligonucleotide as a negative 
control and lane 2 shows the pulled down proteins with  the KSHV 252 RNA. 
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Figure 5.6 Bead binding assay using terminal biotinylated RNA and Streptavidin 
M280 Dynabeads. KSHV 252-nt IRES was labelled with biotin during in vitro 
transcription as described in methods and incubated with HEK293 cell lysate. 
Streptavidin was then used to pull down biotin-labelled RNA (KSHV 252-nt) and its 
associated cellular proteins (lane 4). After they had been washed and dissociated from 
RNA, the eluted proteins were boiled and subjected to SDS–PAGE (4-20% gradient gel). 
Lane 2 (RNA only) represents the KSHV 252 non- biotinylated RNA (10pmoles), lane 3 
(input) represents the lysate only control, lane 4 (control RNA) represents a CAT-LUC 
vector (without IRES) and lane 5 (vFLIP IRES) represents the KSHV vFLIP IRES (252) 
inserted  between the CAT and LUC gene. 
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In a final attempt to identify cellular proteins interacting with the vFLIP IRES, M280 
streptavidin beads were used to capture terminally biotinylated KSHV 252-nt RNA 
bound to HEK293 cellular proteins. Figure 5.7 presents the results of the 
subsequent analysis on 4-20% SDS-PAGE gel. Lane 2 represents the control with 
non-biotinylated RNA. Lane 3 and lane 4 represent the input (lysate only) and a 
CAT-LUC vector (without IRES) control respectively. Lane 5 represents the KSHV 
biotinylated RNA incubated with HEK293 extract.  The patterns of the pull-down 
protein bands of the HEK293 cell lysates only (lane 3) and the non-biotinylated RNA 
incubated (lane 2) were similar. The patterns of the pull-down protein bands for the 
CAT-LUC control (lane 4) were also similar to that of lane 2 that represented the 
non-biotinylated RNA. The result showed that at least one band (boxed in red) 
approximately 125 kDa in size (lane 5) was present, suggesting that this protein may 
be associated specifically with the KSHV IRES.  
The protein band that was specifically associated with biotinylated KSHV RNA (lane 
5) in Figure 5.7 was then excised and frozen down and it is awaiting further analysis. 
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Figure 5.7 Identification of cellular proteins interacting with KSHV IRES. RNA-protein 
pull-down experiments were performed as described in Materials and methods section. 
KSHV 252-nt IRES was labelled with biotin and incubated with HEK293 cell lysate. 
Streptavidin was then used to pull down biotin-labelled RNA (KSHV 252-nt) and its 
associated cellular proteins (lane 4). After they had been washed and dissociated from RNA, 
the eluted proteins were boiled and subjected to SDS–PAGE (4-20% gradient gel). Coomasie 
blue staining was applied for visualization. The potential protein interacting with KSHV IRES 
is boxed in red. Lane 2 (RNA only) represents the KSHV 252 non- biotinylated RNA 
(10pmoles), lane 3 (lysate only) represents the lysate only control, lane 4 (control RNA) 
represents a CAT-LUC vector (without IRES) and lane 5 (vFLIP IRES) represents the KSHV 
vFLIP IRES (252) inserted between the CAT and LUC gene. 
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5.4 Discussion 
Internal ribosomal entry site (IRES) directs the initiation of translation by coordinating 
the recruitment of the ribosome in the presence of a subset of initiation factors and in 
some cases through cellular proteins or ITAFs. The mechanism through which ITAFs 
positively or negatively mediate internal initiation is not fully understood but It is 
hypothesized that ITAFs mediate IRES activity by aiding the recruitment of the 40S 
ribosomal subunit through their interactions with the canonical initiation factors or 
ribosomal components or by acting as RNA chaperones to control the configuration 
of the IRES (reviewed in Stoneley and Willis 2004).  
The present study investigated the trans-acting factors associated with KSHV vFLIP 
IRES in order to elucidate the mechanism of the internal initiation translation of the 
vFLIP IRES. This work utilized a biotinylated RNA-protein pull-down assay to provide 
a view of cellular proteins that associate with the vFLIP IRES. We were able to 
identify a protein band approximately 125 kDa (Figure 5.7) in molecular weight that 
potentially interacts with vFLIP IRES. The band was excised and frozen down and 
awaiting further analysis.The putative binding protein would be identified by mass 
spectrometry and followed up with analysis to functionally validate their role in the 
vFLIP IRES activity would have been carried out. The expression of the protein in 
cells would be depleted and the ability of vFLIP IRES to mediate translation initiation 
would have evaluated. 
ITAFs have been shown to regulate internal initiation of several viral and cellular 
IRES elements. PTB protein is the most studied and documented ITAF highlighting 
its crucial role as a RNA chaperone required for the IRES to adopt the correct 
translation-competent conformation (Kafasla et al., 2010). PTB was the first RNA-
binding protein identified as an ITAF using UV-crosslink assays using 
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radiolabelled IRES transcripts (Jang and Wimmer, 1990; Luz and Beck, 1991). 
PTB consists of four RNA recognition motifs (RRMs) and bind a short pyrimidine-rich 
sequence but preferentially binds sequences contained within a longer pyrimidine 
tract containing cytosines (Auweter et al., 2007). It has been shown that PTB 
interacts with a number of sites within the picornaviral IRESs, each consisting of 
short polypyrimidine tracts with the consensus sequence CUUU (Kolupaeva et al., 
1996; Mitchell et al., 2005).  
The requirement for PTB by picornaviral IRESs differs quite widely amongst the 
species. In type I IRESs tested so far in, PV and human rhinovirus-2, PTB is 
absolutely required for internal initiation (Hunt and Jackson, 1999). However, the 
response of type I IRES to PTB exhibit more variability. 
In EMCV IRES, the requirement for the PTB protein is apparently dependent on the 
nature of the reporter and the IRES variant used as demonstrated by Kaminski and 
Jackson (1998). The FMDV IRES on the other hand showed stronger dependency 
on PTB for it IRES activity (Niepmann 1996; Pilipenko et al. 2000). 
 Aside from PTB other ITAFs have been suggested to modulate the internal initiation 
by viral IRES elements and one of such proteins is the poly(rC)-binding protein 2 
(PCBP2). PCBP2 has been shown to bind 230-430nt of the PV IRES and depletion 
of it from HeLa cell lysates inhibited the activity of the PV IRES element (Blyn et al., 
1997).  
Several methods of RNA-protein interactions have been used to identify ITAFs. 
These methods include RNA affinity chromatography, UV induced cross-linking and 
immunoprecipitation (reviewed in Popova et al. 2015). In RNA affinity 
chromatography, RNA–protein complex from a sample is selectively isolated by 
using high affinity epitopes, such as biotin, as utilized in the present study. An RNA 
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sample is biotinylated and incubated with cellular proteins and the resulting complex 
is immobilized on streptavidin agarose (Popova et al. 2015). The array of proteins 
potentially interacting with a given RNA can be identified by mass spectrometry. The 
high affinity binding of biotin to avidin has made the biotin-avidin interaction a 
powerful tool for affinity chromatography and has been widely used to identify ITAFs 
interacting with IRESs. For instance, Lin et al. (2008) utilized this method in 
combination with matrix-assisted laser desorption ionization-time of flight mass 
spectrometry analysis to identify 12 cellular proteins which interact with the 5′UTR of 
EV71. The proteins identified include polypyrimidine tract-binding protein (PTB), 
poly(rC)-binding protein 1 (PCBP1), PCBP2, the autoantigen and La. In some cases, 
RNAs chemically modified with biotin may lead to structural changes that can inhibit 
RNA-protein complex formation. In addition, this method can only be used in in vitro 
studies, and the RNA-protein complexes formed may not mirror the true nature of the 
complexes formed in vivo (Jazurek et al. 2016). 
An alternate strategy that could have been exploited is a RNA tagging method that 
involves the use of aptamer sequences to tag RNAs followed by purification by 
affinity chromatography (Walker et al. 2011). Aptamer sequences are natural or 
artificial RNA sequences that bind with high affinity to specific ligands or proteins. 
Several RNA aptamers have been utilized for the purification of RNA–protein 
complexes from cellular extracts, these include aptamers that bind to immobilized 
streptavidin, tobramycin, streptomycin, or sephadex (Srisawat et al. 2001a; Srisawat 
et al. 2001b; Hartmuth et al. 2002). 
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The tobramycin aptamer RNA chromatography affinity purification was successfully 
used to identify DEAD-box RNA Helicase 6 (DDX6) as a cellular regulator of the 
Vascular Endothelial Growth Factor (VEGF) IRES (de Vries et al. 2013). 
The aforementioned UV induced cross-linking and immunoprecipitation methods for 
identifying ITAFs are more specific and the experiments are dependent on testing 
against already known ITAFs. 
The RNA affinity chromatography is usually used in combination with other methods. 
For instance, when potential ITAFs are isolated by the RNA affinity chromatography 
and identified by mass spectrometry, their interaction with the relevant IRES can be 
studied further using UV crosslinking of RNA-protein complexes. Unlike RNA 
chromatography, the UV crosslinking assays the direct interaction between the 
purified protein and RNA (Thakor and Holcik 2012). Subsequently, electrophoretic 
mobility shift assays (EMSA) can be performed using purified recombinant proteins 
to enable the characterization of putative ITAFS and their RNA target interaction, 
and helping in validating the identified protein (Alves and Cunha 2012). 
Future experiments to identify vFLIP IRES ITAFs would perhaps benefit from 
combining two or more of these methods identify and characterise the vFLIP IRES 
interacting proteins. Also, including a known control IRES that interacts with ITAFs 
should be utmost importance for forthcoming experiments as this would provide 
better comparison with KSHV vFLIP IRES. Perhaps the EV71 IRES that has been 
shown to interact with ITAFs such as PTB and (PCBP1 can be used as a positive 
control. 
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General discussion 
Eukaryotic translation initiation is a complex and stepwise process that depends on 
the cap structure at the 5’ end of the mRNA and a set of protein factors known as 
eukaryotic initiation factors (eIFs). The pathway is characterised by the formation of 
a preinitiation complex recruited to the 5’end of the mRNA, scanning along it in the 
5’-3’ direction in order to locate the appropriate start codon. Alternatively, translation 
initiation can be tethered internally without requiring the cap structure by elements 
known as internal ribosome entry sites (IRES). These elements are used by some 
viruses and cellular mRNAs to synthesise their proteins when the host translation 
machinery is impaired. 
Bearing in mind that studies in the Locker laboratory have previously defined the 
sufficient sequence required for vFLIP IRES activity in vitro; the broad aims of this 
thesis were to verify the sufficient sequence required for the vFLIP IRES activity in 
cellulo,  determine the secondary RNA structure of the IRES and characterise the 
functioning boundaries of the vFLIP IRES. Prior to this thesis, three studies had 
shown that the expression of vFLIP a major tumorigenesis factor is mediated by an 
IRES element during latency (Bieleski and Talbot, 2001; Grundhoff and Ganem, 
2001; Low et al. 2001). However, all three studies defined three different domains as 
the sufficient sequence required for vFLIP IRES activity. 
Chapter 3 described the study set out to analyse the sufficient domain required for 
the vFLIP IRES activity in cellulo. It also aimed to characterise the vFLIP IRES 
requirement for eukaryotic initiation factors (eIFs). Grundhoff and Ganem (2001) 
used a bicistronic luciferase reporter construct in SLK cells and identified a sufficient 
IRES within the 232-nt located upstream of ORF71. Bieleski and Talbot (2001) on 
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the other hand showed that a minimum fragment of 233 bp within the coding region 
of vCyclin was found to direct efficient expression of the downstream cistron (firefly 
luciferase) in BCP-1 cells while Low et al. (2001) identified 363-nt as the sufficient 
IRES sequence. In order to reconcile previous studies, the Locker group, and the 
work initiated by a previous PhD student, generated different plasmids containing 
decreasing length of the terminal vCyclin coding region (Othman et al. 2014). This 
study defined a sufficient 252-nt vFLIP IRES using an in vitro translation assay in 
RRL. Although the 252-nt differs from the previously identified locations, the results 
do not seem to far apart. For instance, the 252-nt identified in this study lies within 
the 363-nt identified by Bieleski and Talbot (2001). Also, the 232-nt identified by Low  
et al. (2001) lies within the 252-nt identified presently. Therefore, it is safe to 
conclude that all the locations identified so far are sufficient for vFLIP IRES activity. 
The ability of this domain to direct translation was then tested in HEK293 and SLK 
cells in this thesis. The result supports the data that a fragment of 252-nt is the 
sufficient domain required for the vFLIP IRES activity. The fragment 252-nt was 
thereon used in subsequent experiments to define the function boundaries of the 
vFLIP IRES.  
As determining the initiation factor requirements of an IRES emerges to be a reliable 
approach to classify which IRES class it belongs to (Kieft, 2008),  the requirement of 
the vFLIP IRES initiation factors was analyzed. The requirement for eIFs was 
dissected using specific inhibitors of translation. The IRES activity is sensitive to the 
addition of hippuristanol and as such it was concluded that eIF4A is required for the 
vFLIP IRES activity. The eIF4A is important for unwinding secondary structure in 
advance of the scanning pre-initiation complex (PIC) to facilitate attachment of the 
40S ribosomal subunit (Sonenberg and Hinnebusch 2009). The functional 
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requirement for the eIF4A could be reminiscent of type I and type II IRES such as PV 
or EMCV IRES respectively (Bordeleau et al., 2006; Kolupaeva et al., 2003; 
Sweeney et al., 2014). Kolupaeva and colleagues (2003) showed that eIF4A is 
recruited to the EMCV IRES by eIF4G and the bound eIF4G/eIF4A complex induces 
conformational changes in the IRES. This actively prepares the IRES for ribosomal 
attachment. Bordeleau et al. (2006) demonstrated that inhibition of eIF4A activity 
impeded poliovirus replication and suggested that PV IRES has a high dependency 
on eIF4A compared to cellular mRNAs in vivo. The functional requirement for eIF4A 
is also shared by the HIV-2 gag IRES as demonstrated by Locker et al. (Locker et 
al., 2011). As the case of the EMCV and FMDV IRES eIF4A in combination with 
eIF4GI is required to bring about conformational changes in the RNA near the 
ribosome binding site, it is therefore possible that these eIF4A functions in a similar 
manner on the vFLIP IRES.  
The vFLIP IRES requirement for the eIF4E:eIF4G was also analyzed and the result 
shows that the IRES is sensitive to the inhibitor 4E2Rcat, an inhibitor of the 
eIF4E:eIF4G interaction. This implies that the presence of eIF4E and the eIF4E-
binding domain of eIF4G are essential for internal entry of ribosomes mediated by 
the KSHV vFLIP IRES. This is echoed by Othman et al. (2014) in in vivo studies that 
showed that the vFLIP IRES activity is dependent on the eIF4E:eIF4G interaction by 
using 4E1RCat, another compound identified by high-throughput screening for 
inhibitors of the eIF4E:eIF4G interaction. They went a step further to examine the 
significance of the vFLIP IRES-eIF4E interaction for the vFLIP IRES activity. They 
examined translation efficiency in RRL treated with the cap analog m7GpppG to 
impair eIF4E function. The results suggest that functional eIF4E and the eIF4E 
binding domain of eIF4G are required for the internal entry of ribosomes mediated by 
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the vFLIP IRES. Overall indicating that the vFLIP IRES requires the whole-eIF4F 
complex for its activity, including eIF4E. The requirement for eIF4E is unprecedented 
for IRESs characterised so far. Although it was previously reported that hepatitis A 
virus (HAV) IRES requires eIF4E for its activity since cleavage of eIF4G by PV 2Apro 
or FMDV Lpro abrogated translation of mRNAs containing HAV IRES (Ali et al., 2001; 
Borman et al. 2001) which is in contrast to PV and EMCV IRESs that are able to 
function in the presence of a cleaved eIF4G (Yu et al. 2011; Sweeney et al. 2014). 
The HAV IRES activity was shown to be inhibited by addition of 4E-BP1, an inhibitor 
that binds to and sequesters eIF4E, preventing the interaction of eIF4E with eIF4G to 
constitute the eIF4F holoenzyme complex (Ali et al., 2001). It was then proposed that 
HAV IRES activity could require an interaction between the eIF4E cap-binding 
pocket and the IRES or that the eIF4E–eIF4G interaction was essential for eIF4G to 
adopt a conformation promoting IRES activity, independently from RNA binding by 
the cap-binding pocket (Ali et al. 2001; Borman et al. 2001). These findings were 
disputed in a recent study that demonstrated that HAV IRES translation can occur 
when eIF4G is cleaved by FMDV Lpro and hence HAV IRES does not represent an 
exception to the rest of picornavirus IRES functioning in regards to their requirement 
for eIF4E (Redondo et al. 2012)  
Although it has been generally assumed that eIF4E is not required for translation by 
IRES elements since it functions as a cap-binding protein but its direct role in cap-
independent translation cannot not be dismissed. The requirement for eIF4E in cap-
independent translation has been demonstrated in a number of positive-sense RNA 
plant viruses. Several of these viruses lack a 5′ cap structure and depend on cap-
independent translation elements (CITEs), located in 3′ UTRs, to mediate translation 
(Nicholson and White 2011). CITEs are highly folded RNA structures that recruit 
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initiation factors to the viral RNA and engage in long-range RNA–RNA base-pairing 
between the 3′ and 5′ UTR to direct translation (Nicholson and White 2011; Kraft et 
al. 2013). For instance, the umbravirus Pea enation mosaic virus RNA 2 (PEMV2), 
contains a 3′ CITE termed the Panicum mosaic virus-like translational enhancer 
(PTE ) which binds eIF4E with high affinity via its pseudoknot even in the absence of 
eIF4G to recruit eIF4F (Wang et al. 2009). The ORF of histone H4 mRNA contains a 
regulatory RNA element that enhances translation by recruiting eIF4E, and eIF4F, 
internally and independently from the cap (Martin et al. 2011). 
Overall, these results suggest that viral IRES may display a much larger functional 
requirement than those used to define the four groups of IRES elements. 
Chapter 4 described the study set out to determine the RNA structure of the vFLIP 
IRES and assess its role in the translation mediated by vFLIP IRES. To this end, we 
determined the structure of the KSHV IRES by chemically and enzymatically probing 
the sufficient sequence (252-nt) in solution combined with SHAPE analysis. Most 
viral IRESs adopt complex RNA structure that coordinate the requirement of the 
ribosome and initiation factors (Kieft 2008). Up until now, only one other group has 
proposed a structure for the KSHV vFLIP IRES structure. In 2001, Bieleski and 
Talbot presented an RNA secondary model within the 233 nt of the vCyclin coding 
region but this structure was never experimentally validated. Probing of the vFLIP 
IRES in solution revealed a very compact structure, which is the hallmark of many 
viral IRESs, reflected in the overall poor reactivity toward the single strand specific 
probes. This finding is also in agreement with the presence of two stretches of 
nucleotides (82–95 and 223–233) in which strong reverse transcription stops were 
repeatedly observed reflecting the presence of a structure that the reverse 
transcriptase is unable to resolve. The vFLIP IRES structure scaffold is separated 
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into two domains, consisting of domain Ia to If and domain II to domain IV, 
respectively (Figure 4.8). The first and second domain corresponds to 1-154nt and 
155-252nt respectively. The first section of the IRES structure is formed by domain I 
which comprises of subdomains Ia to If arranged into two consecutive junctions: a 
four-helix junction made up of Ia, Ib, Ie and If, followed-by a three-helix junction 
consisting of Ib, Ic and Id. Domains Ic and Id are capped by a UCGG and a GGCA 
tetraloop respectively whereas domains Ie and If are capped by CUACA and 
CCUAAC loops respectively. The second section of the IRES structure is made of 
three stem loop structures represented by domains II, III and IV. These domains 
present an appealing platform for protein recruitment as domains II and IV are 
capped by large loops consisting of 17 and 16-nt respectively whereas dIII is capped 
by a pyrimidine-rich (U4C2) loop. The data strongly suggest that elements of the 
modular structures could be involved in direct interaction with the ribosome, initiation 
factors or ITAFs. The proposed structure also highlighted a “kissing complex” by 
paring of dII 5’-171GCUUGUG177-3’ with dIV 5’-239UACAAGC245-3’ which have the 
potential to form Pseudoknot-like structures. Although the interruption of this 
structure did not have an effect on the activity of the vFLIP IRES, pseudoknots have 
been identified and well documented in numerous IRES elements and their function 
is best illustrated in HCV and Cricket paralysis virus (CrPV). The HCV forms a 
secondary structure that consists two major hairpins (domain II and III) and an 
essential pseudoknot structure at the base of domain III (Wang et al. 1995). This 
pseudoknot structure has been shown to play a role in the initial binding of 40S 
subunit to the basal region of domain III (Kieft et al. 2001; Otto and Puglisi 2004). 
In order to characterize the structure–function relationship of the vFLIP IRES, 
validate and decipher which region of the structure are important for the IRES-
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mediated translation of the vFLIP IRES, deletion of specific domains of the predicted 
structure was carried out. This revealed that the domain If in part or as a whole is 
required for the vFLIP IRES to function as the deletion of this domain completely 
abolished the activity of the vFLIP IRES. The domain If requires to be studied further 
in order to establish which part of the stem-loop is required for the vFLIP IRES to 
function. In several IRES elements, mutational analysis of their domains has shown 
the importance of those domains for the IRES function. For example, 
mutation/deletion studies of the HCV IRES has revealed that the integrity of domain 
III is of importance for the IRES function (Wang et al 1994). Tang et al. (1999) 
demonstrated that single point mutations in domain IIIc of the HCV IRES led to the 
dramatic loss of IRES function and suggested that the stem-loops IIIa and IIIc of the 
HCV IRES is critical for IRES function. Angulo et al. (2016) also showed that an 
interaction between loop IIId of HCV IRES and 18S rRNA triggers a structural 
rearrangement the locks the 40S ribosomal subunit in a conformation competent for 
translation. Given that the vFLIP IRES directly binds 40S ribosomal subunit as 
shown by Othman et al. (2014), further mutations to investigate whether deletion of 
domain If impairs ribosome binding is necessary. Also, the effects of point mutations 
on the IRES activity would be useful to further define the structure/function 
relationships of the vFLIP IRES. 
Chapter 5 described the study set out to identify ITAFs that potentially interact with 
the vFLIP IRES. To this end, affinity-based chromatography methods to isolate 
potential binding partners in HEK293 lysate was used. Previous studies have 
highlighted the significance of ITAFs for the activity of several IRES elements.  
The ITAF PTB has been shown to regulate the EMCV IRES by acting as a RNA 
chaperone, therefore stabilising the three dimensional structure of the EMCV IRES 
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(Kafasla et al. 2009). In HAV, La autoantigen was shown to suppress translation 
mediated by HAV IRES (Cordes et al. 2008). In the cellular IRES apoptotic 
peptidase-activating factor 1 (Apaf-1), Unr and PTB proteins remodel its structure in 
order to attain the correct conformation for interaction with the 40S ribosomal 
(Mitchell et al. 2003). However, in the present study we are yet to identify any ITAF 
interacting with vFLIP IRES. Although, there is a potential protein band (Figure 5.7) 
that is still awaiting further analysis and it could possibly be the first break through in 
identifying interacting partners of the vFLIP IRES. 
In conclusion, we have defined a new sufficient domain for the vFLIP IRES and to 
some extent defined the mode action of the vFLIP IRES for the first time. It has been 
shown that the vFLIP IRES requires eIF4A and the eIF4E/eIF4G interaction to 
efficiently initiate translation internally in cells. In addition, we have predicted a 
secondary structure of KSHV IRES by using chemical and enzymatic modifications 
and have begun to characterize structure/function relationship by carrying out 
mutation/deletion studies. So far we have shown that the subdomain If in part or as a 
whole is crucial for the activity of the vFLIP IRES. We also attempted to identify 
interacting partners (ITAFs) of the vFLIP IRES but have yet to successfully do so. 
Figure 6.1 summarises the vFLIP IRES structure and its requirement for eukaryotic 
initiation factors. 
In addition, the overall impact of impaired vFLIP IRES activity on viral replication, 
expression of the vFLIP and other markers of tumorigenesis such as LANA and 
vCyclin needs to be analyzed. This can be done by introducing mutations that 
impede the vFLIP IRES activity into the full length viral genome by engineering a 
recombinant KSHV. Recombinant KSHV has been a useful tool to study the 
replication of KSHV. For instance, a recombinant KSHV with the deletion of the 
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LANA genome was used to analyze the effect of LANA on the KSHV lytic 
transcriptional programme (Li et al. 2008). 
 
 
 
 
 
 
 
Figure 6.1 Schematic representation of the vFLIP IRES proposed structure 
with the eIFs required shown. The structure is divided into two major segments 
consisting of domains I to IV and subdomains Ia to If. The domain If shown in red is 
essential for the vFLIP IRES activity as demonstrated in chapter 4. The vFLIP IRES 
requires eIF4A, eIF4G, eIF4A and potentially an ITAF for its activity. It aslso binds 
40S directly as shown by Othman et al. (2014). Although, how these factors interact 
with the structure is yet to be known. 
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Appendix I  
Solutions 
10X TBE running buffer 
121g Tris 
62g Boric acid 
18.6g EDTA  
Make up to 1 L with ddH2O  
 
Bead binding buffer (BBB) 
100mM kcl 
10mM Tris (pH7.5) 
2mM MgCl2 
 
SSC buffer 
0.22g Nacl 
0.11g Na nitrate 
In 50 ml H2O 
 
RIPA buffer  
Tris 50mM  
NaCl 150 mM  
SDS 0.1 %  
Na.Deoxycholate 0.5 %  
Triton X 100 or NP40 1%   
Roche Complete Protease inhibitor tablet 
IP buffer recipe  
100 mM Tris pH 8.0  
150 mM NaCl  
1 mM EDTA  
5% glycerol  
1 mM DTT  
0.1 mg/ml tRNA  
Complete mini EDTA free tablets (ROCHE) 
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2XYT medium 
16 g Bacto-Tryptone (Difco 0123-01-1)  
10 g Bacto-yeast extract (Difco 0127-05-3)  
10 g NaCl  
ddH2O to 1 L  
Then autoclave to sterilise  
 
RNA structure probing 
  
DMS stock conc = 7.9 M  
CMCT stock conc=40 mg/ml in H2O just before use  
RNase V1 stock conc= 0.1 U/μl  
tRNA 2 mg/ml  
AMV RT: conc 10 U/μl)  
2x DMS buffer  
40 mM Tris pH 7.5  
200 mM K Acetate  
400 mM KCl  
5 mM MgCl2  
2 mM DTT  
5x CMCT buffer (for CMCT reactions)  
250 mM Borate-NaOH pH 8.0  
5 mM EDTA  
10x NTP-A10, C10, G10, T10  
A10 = 10 μl 10 mM dGTP  
10 μl 10 mM dCTP  
10 μl 10 mM dTTP  
2.5 μl 10 mM dATP  
H2O to 100 μl  
ddATP, ddCTP, ddGTP & ddTTP (all at 50 μM)  
2.5 mM dNTP mix  
10 μl each of 10 mM dATP, dCTP, dGTP and dTTP  
Formamide – XC Loading Buffer:  
975 μl Formamide  
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25 μl 1% xylene cyanol 
Sequencing gel 
  
Urea 20g  
10x TBE 5 ml  
40% (19:1) Acrylamide/Bis 10 ml (for 8% gel) 12.5 ml (for 10% gel)  
Water to 50 ml, dissolve, when ready add  
30% APS 55 μl  
Temed 55 μl 
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Appendix II 
Publication arising from thesis 
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